

ANTONIO MARION GOTTO, Jr, M.D., D.Phil.

CURRICULUM VITAE

Personal Information

Born October 10, 1935, Nashville, Tennessee
Married Anita Safford Gotto, 1959; Daughters Jennifer, Gillian, Teresa

Education

1957 Bachelor of Arts, Vanderbilt University (Biochemistry)
1961 Doctor of Philosophy, University of Oxford (Biochemistry)
1965 Doctor of Medicine, Vanderbilt University School of Medicine

Military Service

1967–1969 Surgeon, U.S. Public Health Service

Board Certification

1980 National Board of Medical Examiners, American Board of Internal Medicine

Medical Licensure

New York
Texas

Research Interests

Structure, metabolism, and function of the plasma lipoproteins and apolipoproteins and their relation to atherosclerosis

Clinical disorders of lipid transport, including hyperlipoproteinemias and hypolipidemias

Pathophysiology of atherosclerosis and coronary heart disease

Chronology of Employment

- 1957 Summer Research Assistant in Biochemistry, Vanderbilt University
- 1958–1961 Graduate Assistant in Biochemistry, University of Oxford
- 1959–1961 Predoctoral Fellow, National Science Foundation
- 1961–1965 Research Associate, Departments of Biochemistry and Molecular Biology, Vanderbilt University School of Medicine
- 1963–1965 Postdoctoral Research Scholar, American Cancer Society
- 1965–1966 Intern, Massachusetts General Hospital
- 1966–1967 Assistant Resident in Medicine, Massachusetts General Hospital
- 1967–1969 Staff Associate, Molecular Disease Branch, National Institutes of Health
- 1969–1971 Head, Section on Molecular Disease, Molecular Disease Branch, National Heart and Lung Institute
- 1969–1971 Clinical Instructor in Medicine, George Washington School of Medicine
- 1971–1984 Director and Principal Investigator (1971-1977), and Co-Director (1977-1984), Lipid Research Clinic of the National Heart, Lung, and Blood Institute
- 1971–1996 Professor of Medicine and Biochemistry, Baylor College of Medicine
- 1971–1996 Chief, Section on Atherosclerosis and Lipoprotein Research, Baylor College of Medicine and The Methodist Hospital
- 1971–1996 Director and Principal Investigator, Specialized Center of Research in Arteriosclerosis, National Heart, Lung, and Blood Institute
- 1973–1974 Scientific Director, Cardiovascular Research and Training Center, Baylor College of Medicine and The Methodist Hospital
- 1974-1983, 1987, 1990 Co-Principal Investigator and Scientific Director, National Heart and Blood Vessel Research and Demonstration Center, Baylor College of Medicine and The Methodist Hospital
- 1976–1996 J. S. Abercrombie Chair for Atherosclerosis and Lipoprotein Research, Baylor College of Medicine and The Methodist Hospital

- 1977–1996 The Bob and Vivian Smith Professor and Chairman, Department of Medicine, Baylor College of Medicine, and Chief, Internal Medicine Service, The Methodist Hospital
- 1985–1996 Distinguished Service Professor of Medicine, Baylor College of Medicine
- 1985–1996 Scientific Director, The Michael E. DeBakey Heart Center, Baylor College of Medicine and The Methodist Hospital
- 1997–2011 The Stephen and Suzanne Weiss Dean, Joan and Sanford I. Weill Medical College of Cornell University
- 1997–2011 Professor of Medicine, Joan and Sanford I. Weill Medical College of Cornell University
- 1997–2011 Provost for Medical Affairs, Cornell University
- 2012–present Dean Emeritus, Joan and Sanford I. Weill Medical College of Cornell University
- 2012–present Lewis Thomas University Professor, Joan and Sanford I. Weill Medical College of Cornell University
- 2012–present Vice President and Provost for Medical Affairs Emeritus, Cornell University

Hospital Appointments

- 1967–1969 Attending Physician, National Heart and Lung Institute, Bethesda Maryland
- 1969–1971 Attending Physician, George Washington University School of Medicine, Washington, D.C.
- 1971–1977 Attending Physician, The Methodist Hospital, Houston
- 1971–1977 Attending Physician, The Ben Taub General Hospital, Houston
- 1971–1996 Consulting Physician, The Veterans Administration Hospital (now Veterans Administration Medical Center), Houston
- 1977–1996 Physician-in-Chief, Internal Medicine Service, The Methodist Hospital, Houston
- 1977–1996 Physician-in-Chief, Internal Medicine Service, The Ben Taub General Hospital, Houston

1997–present Attending Physician, NewYork-Presbyterian Hospital, New York

Research Grants

- 1971–1975 Principal Investigator HL Grant 14194 for Specialized Center of Research (SCOR) in Arteriosclerosis
- 1971–1975 Principal Investigator Grant from John A. Hartford Foundation, Inc.
- 1971–1977 Principal Investigator HL Contract 71-2156 for a Lipid Research Clinic
1977–1996 Associate Director
- 1975–1983 Scientific Director and HL Grant 17269 for National Research and Co-Principal Investigator Demonstration Center
- 1981–1986 Principal Investigator HL Grant 27341 for Specialized Center of
1990–1996 Research (SCOR) in Arteriosclerosis
- 1986–1990 Principal Investigator HL Grant for National Research and Demonstration Center

Clinical Trials

- 1971–1988 Principal Investigator (1971–1977) and Associate Director (1977–1988), Lipid Research Clinics Coronary Primary Prevention Trial (LRC-CPPT)
- 1990–1997 Principal Investigator, Lipoprotein and Coronary Atherosclerosis Study (LCAS)
- 1991–1995 Co-Chairman, HDL Intervention Trial (HIT), Veterans Administration
- 1978–1990 Chairman, National Institutes of Health Committee on the Program on the Surgical Control of the Hyperlipidemias (POSCH) trial
- 1989–1996 Chairman, Data and Safety Monitoring Committee, Cholesterol and Recurrent Events (CARE) Study
- 1990–1998 Chairman, Steering Committee, Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS)
- 1993–1995 Chairman, Data and Safety Monitoring Committee, Peripheral Arterial Disease Pilot Study, National Heart, Lung, and Blood Institute
- 1998–2005 Member, Steering Committee, Treating to New Targets (TNT) trial
- 2000–2004 Member, Data Safety Monitoring Board, Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE-IT TIMI 22) trial

- 2003–2010 Member, Data Safety Monitoring Board, Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial
- 2003–2008 Member, Steering Committee, Justification for the Use of statins in Primary prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)
- 2004–2010 Chairman, Steering Committee, Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial
- 2008–present Member, Steering Committee, Determining the Efficacy and Tolerability of CETP Inhibition with Anacetrapib (DEFINE) trial

Institutional Activities

- 1969–1971 Faculty on Tutorial Seminars, National Institutes of Health
- 1971–1986 Member (1971–1974) and Chairman (1974–1986), Faculty Appointments and Promotions Committee, Baylor College of Medicine
- 1972–1976 Member, Neurosciences Executive Planning Committee, Baylor College of Medicine
- 1974–1981 Member, Ad Hoc Committee on Medical Ethics, Baylor College of Medicine
- 1975–1978 Member, Planning and Policy Committee, Baylor College of Medicine
- 1976–1984 Member, Physiology Search Committee, Baylor College of Medicine
- 1977–1996 Member, Executive Faculty Committee, Baylor College of Medicine
- 1977–1996 Member, Executive Committee, The Methodist Hospital
- 1977–1996 Member, Veterans Administration Dean's Committee, Veterans Administration Medical Center, Houston
- 1978–1979 Member, Committee on Succession, Baylor College of Medicine
- 1978–1996 Member, President's Council, Baylor College of Medicine
- 1981–1982 Member, Director for Center for Ethics, Medicine, and Public Issues Search Committee, Baylor College of Medicine
- 1986–1992 Chairman, Curriculum Committee, Baylor College of Medicine
- 1990 Member, Anesthesiology Search Committee, Baylor College of Medicine

- 1990 Chairman, Dean of Graduate School Search Committee, Baylor College of Medicine
- 1992–1996 Member, Chair's Advisory Committee, Baylor College of Medicine
- 1993 Member, Chairman of Surgery Search Committee, Baylor College of Medicine
- 1994 Member, Howard Hughes Medical Institute Liaison, Baylor College of Medicine
- 1994 Member, Rice Baylor Joint Programs Committee, Baylor College of Medicine
- 1994–1995 Executive Committee, Clinical Affairs Advisory Committee (CAAC), Baylor College of Medicine
- 1994–1997 The Methodist Hospital Board of Directors Planning Group
- 1995 Executive Committee, Baylor MedCare (was CAAC), Baylor College of Medicine
- 1995 Co-Director, Multi-Organ Transplant Center, The Methodist Hospital
- 1996-present Member, Board of Overseers, Weill Cornell Medical College
- 1996-2011 Co-Chair, Physicians Organization Policy Board, Weill Cornell Medical College
- 2001-present Co-Chair, Joint Advisory Board, Weill Cornell Medical College in Qatar
- 2001-present Member, Board of Governors, Sidra Medical and Research Center
- 2004-present Member, The Methodist Hospital Board Quality Committee
- 2011–present Senior Member, Houston Methodist Hospital Research Institute
- 2012-present Co-Chair, Board of Overseers, Weill Cornell Medical College

Government Committees and Study Section Activities

- 1971–1975 Co-Chairman, Committee on Definitions and Forms Design, Lipid Research Clinics, National Heart and Lung Institute
- 1972 Member, Technical Review Panel for Selection of Lipid Research Clinics, National Heart and Lung Institute

- 1972 Consultant, Hypolipidemic Drugs, Endocrinology and Metabolism Study Section, U.S. Food and Drug Administration
- 1972–1975 Member, Metabolism Study Section, National Institutes of Health
- 1975–1976 Member, Committee to Review Specialized Centers of Research in Arteriosclerosis, National Heart, Lung, and Blood Institute
- 1977–1984 Member, National Diabetes Advisory Board, Department of Health, Education, and Welfare
- 1978–1996 Member and Co-Chairman (1986–1991), Italian American Committee on Cardiovascular Disease, National Heart, Lung, and Blood Institute
- 1980–1990 Chairman, Policy and Data Monitoring Committee for the Program on the Surgical Control of the Hyperlipidemias, National Heart, Lung, and Blood Institute
- 1985–1996 Member, US Russia Cardiovascular Workgroup
- 1987–1991 Member, Advisory Council, National Heart, Lung, and Blood Institute
- 1989–1996 Chairman, Data and Safety Monitoring Committee, Coronary Artery Regression Evaluation (CARE) Study
- 1990–1998 Chairman, Data and Safety Monitoring Committee, Air Force Coronary Atherosclerosis Prevention Study (AFCAPS)
- 1993–1995 Chairman, Data and Safety Monitoring Committee, Peripheral Arterial Disease Pilot Study, National Heart, Lung, and Blood Institute
- 1995 Member, Lipidology Working Group, National Heart, Lung, and Blood Institute
- 2003–2010 Member, Data Safety Monitoring Board, Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial

Academy for Medical Development and Collaboration

- 2000–2011 Vice-Chair, Board of Directors
2012–present Member, Board of Directors

American Academy of Arts and Sciences

- 2001 Fellow

American Association of Rhodes Scholars

State Rhodes Scholar Selection Committee

1963 Mississippi
1964 Tennessee
1966 Vermont
1971–1996 Texas
1993–1995 Secretary, State and District Committees

American Board of Clinical Lipidology

2004–present Member, Board of Directors

American Board of Internal Medicine

1985–1991 Member, Subspecialty Board on Endocrinology, Metabolism, and
Nutrition

American Clinical and Climatological Society

1987–present Member

American College of Cardiology

1977–present Fellow
1977–1983 Member, Committee on Government Policy
1980–1983 Subcommittee on Long-Range Planning

American College of Physicians

1971–present Fellow

American Diabetes Association Texas Affiliate

1980–1981 National Grant Review Panel, American Diabetes Board
1994 Honorary Chairman

American Federation for Clinical Research

1978 Member

American Heart Association

1968–present Fellow, Council on Arteriosclerosis
1972 Delegate, Council on Arteriosclerosis

- 1972–present Fellow, Council on Thrombosis
- 1973 Member, Ad Hoc Committee to Revise Bylaws, Council on Arteriosclerosis
- 1973–1974 Member, Council on Arteriosclerosis
- 1974–1976 Member, Study Section on Immunology and Microbiology
- 1977–1986 Chairman, Committee on Step One Diet Treatment of Hyperlipidemia, Council on Arteriosclerosis
- 1980–1996 Steering Committee for Medical and Community Programs
- 1982 President Elect
- 1983 President
- 1984 Immediate Past President
- 1984–1996 Medical Advisor, Pharmaceutical Roundtable
- 1986–1993 Member, Task Force on Cholesterol
- 1989–1993 Chairman, International Program Committee
- 1995 Member, Secondary Prevention Panel

American Heart Association State or State Affiliate Level

- 1972–1974 Member, Central Research Committee, Texas
- 1974–1977 Member, Nutrition Committee (Subcommittee of Central Research Committee)
- 1975–1977 Chairman, Nutrition Task Force
- 1975–1978 Member, Executive Committee, Council on Arteriosclerosis
- 1975–1996 Member, Long-Range Planning Committee, Council on Arteriosclerosis
- 1975–1996 Member, Board of Directors
- 1978–1996 Member, Medical and Scientific Committee
- 1979–1996 Member of Corporate Cabinet

1980–1981 Vice Chairman, Medical and Scientific Committee

American Heart Association Houston Chapter

1973–1996 Member, Board of Directors

1974–1975 Chairman, High School Heart Careers Day

1975–1976 Vice President

1976–1996 Member, Executive Planning Committee

1979–1980 President

1980–1981 Chairman, Nominating Committee

1986–1996 Solicitations Committee, Heart Ball

1994 Major Gifts Committee, Heart Ball

1994–1995 Advisory Director, AHA Guild

American Lipid Information Board

1989-1993 Chairman

American Longevity Association

1982 Honorary Member of the Scientific Advisory Board

American Medical Association

1981–present Member

American Society for Biochemistry and Molecular Biology

1971–present Member

American Society for Clinical Investigation

1971–present Member

1980–1981 Vice President

American Society of Biological Chemists

1971–present Member

1972–1973, Chairman, Session on Lipoproteins: Federation of American

1976 Societies for Experimental Biology (FASEB) meetings

American Society of Internal Medicine

1986–present Member

Associated Medical Schools of New York

1997–present Member, Board of Trustees

2010-2011 Chair, Board of Trustees

2004–2009 President

Association of Academic Health Centers

2006-2009 Member, Board of Directors

Association of American Physicians

1977 Active Member

Association of American Medical Colleges

1997–2011 Member, Council of Deans

2001-2008 Member, Administrative Board, Council of Deans

Association of Professors of Medicine

1977-1996 Member

Central Society for Clinical Research

1995 Member

Citizens for Public Action on Blood Pressure and Cholesterol

1986 Chairman, Medical Advisory Committee

1988–2000 President

Foundation for Biomedical Research

1980–present Board of Directors

German Society for Internal Medicine

1995 Foreign Member

Interdisciplinary Council on Lipids and Cardiovascular Risk Intervention

1992–present Chairman

International Atherosclerosis Society

1973–present Program Committee

1979–1985 Vice President

1985–1997 President

The International Committee for the Evaluation of Hypertriglyceridemia as a Vascular Risk Factor

1989–1991 Co-Chairman

International Lipid Information Bureau

1988–2004 Chairman

International Olympic Committee

1994–2002 Selection Committee for Olympic Prize

International Society for Pharmacoeconomics and Outcomes Research

1997 Lipid Advisory Board

International Task Force for Prevention of Coronary Heart Disease Foundation

1993–present Member, Board of Directors

Institute of Medicine

1991–present Member

Juvenile Diabetes Foundation

1976–1996 Medical Advisory Board, Houston Chapter

1977–1980 Advisory Committee, Jack Benny Arena Tennis Tournament

1980 Co-Chairman, Workshop on Diabetes and Cardiovascular Diseases, co-sponsored by the National Heart, Lung, and Blood Institute

1984 Keynote speaker

1986 Chairman, Walk-A-Thon, Houston

1994 Honoree, Initiative on Atherosclerosis Kick-off, National Heart, Lung, and
Blood Institute

National Institutes of Health

1989 Member, Alumni Association

National Kidney Foundation

1982–1996 Medical Advisory Board, Southeast Texas Chapter

National Lipid Association

2004-2006 Member, Board of Directors
2013-present

2005–2011 Member, Board of Directors (Northeast Lipid Association)

New York Academy of Medicine

1997-2010 Trustee

New York Stem Cell Foundation

2005–present Medical Advisory Board

Research to Prevent Blindness

2013-present Trustee

Southern Medical Association

1987–present Member

1993–1995 Member, Advisory Committee on Scientific Activities

Southern Society for Clinical Investigation

1979–1980 Chairman, Nominating Committee

1980 Distinguished Lecturer

1981–1984 Councilor

Texas Hadassah Medical Research Foundation

1991–1996 Board Member

- 1992–1996 U.S. head of international research project to examine long-term effects of 1986 nuclear disaster at Chernobyl
- 1992–1996 Co-Chair of Public Policy Committee to study the effects of low-dose radiation therapy

Italian American Activities

- 1976 Annual Lecture, Società Italiana per lo Studio dell'Arteriosclerosi, Milan
- 1979 Paper read at Symposium on the Training of Italian Physicians in the U.S.A., Milan
- 1979 Host and American Co-Chairman, Symposium on Prostaglandins, Houston
- 1980 American Co-Chairman, Conference on Diet and Cardiovascular Disease, Rome
- 1980 Paper delivered at the Hearing on Hypolipidemic Drugs, sponsored by the Italian Ministry of Health
- 1986 Co-Chairman, American Italian Cardiovascular Work Group, National Heart, Lung, and Blood Institute
- 1992 2nd International Symposium on Serotonin, Giovanni Lorenzini Medical Foundation, Houston
- 1994 American Italian Joint Symposium on The Molecular Biology of the Arterial Wall

Consultant to Private Foundations

- 1976–1982 Advisory Committee, Giovanni Lorenzini Medical Foundation, Milan
- 1976–1990 Medical Advisory Board, Fritz Thyssen Stiftung, Cologne
- 1976–1992 Lasker Award Selection Jury, Albert and Mary Lasker Foundation
- 1976–present Scientific Advisory Board, Fondation Cardiologique Princesse Liliane, Brussels
- 1982–present Board of Trustees, Giovanni Lorenzini Medical Foundation, Milan
- 1988–present Chairman, Giovanni Lorenzini Medical Foundation Prize Committee, Milan
- 1997-1998 Chairman, Search Committee for Executive Director, Picower Institute for Medical Research

Selected Honors

- 1957 Rhodes Scholarship, University of Oxford
- 1957 Graduated magna cum laude, Phi Beta Kappa, Omicron Delta Kappa, Vanderbilt University
- 1957 Alpha Omega Alpha, Vanderbilt University
- 1959 Predoctoral Fellow, National Science Foundation
- 1965 Borden Medical Student Research Award
- 1965 Albert Weinstein Award for Proficiency in Internal Medicine
- 1975 American Heart Association Service Award (shared with Anita Gotto)
- 1979 Honorary Doctor of Laws, Abilene Christian University
- 1993 American Heart Association Outstanding Leadership Award
- 1982 Honorary Degree, Doctor of Letters, University of Bologna
- 1982 Calvarie Order of Merit of the Republic of Italy
- 1982 American Diabetes Association Citation for Distinguished Service
- 1982 Achievement and Science Award, Alexander Humboldt Foundation, presented by the International Atherosclerosis Society
- 1983 Knight of the Order of Merit of the Republic of Italy, presented by the President of the Republic of Italy
- 1983 International Honorary Citizen, New Orleans
- 1985 Distinguished Service Professor, Baylor College of Medicine
- 1985 Honorary Professorship, University of Buenos Aires
- 1985 Honorary Member, Argentina Cardiologic Society
- 1985 American Heart Association Medical Honoree, Annual Heart Ball, Houston
- 1986 Paul Ledbetter Award for Distinguished Service, Houston Division of the American Heart Association

- 1986 Paul Dudley White Award for Outstanding Contributions, Texas Affiliate of the American Heart Association
- 1987 Honorary Member, Japanese Atherosclerosis Society
- 1987 Distinguished Citizens Award, American Friends of Turkey
- 1987 International Executive of the Year Award, Houston Economic Development Council and Houston Kiwanis Club for contributions to international medicine
- 1989 Gold Heart Award, American Heart Association
- 1989 Award for Distinguished Achievement, Modern Medicine
- 1991 Elected to membership, National Academy of Sciences, Institute of Medicine
- 1991 Myrtle Wreath Award, Hadassah Organization
- 1992 Cancer Research Foundation (Houston) Pacesetters Award (shared with Anita Gotto)
- 1992 William A. "Tex" and Deborah Moncrief, Jr, Chair in Medicine endowed in honor of Antonio M. Gotto, Jr.
- 1992 Order of the Lion, Republic of Finland
- 1992 James Beard Foundation Award of Excellence in the Category of Healthier Living for The Chez Eddy Living Heart Cookbook
- 1992 American Heart Association Distinguished Service Award, Council on Arteriosclerosis
- 1993 American Diabetes Association Generosity to Mankind Award
- 1995 Southern Medical Association Seale Harris Award
- 1996 Alumni of Baylor College of Medicine Distinguished Faculty Award
- 1997 Vanderbilt University Distinguished Alumni of the Medical School
- 2000 Vanderbilt University Distinguished Alumni Award
- 2004 International Okamoto Award
- 2007 Antonio M. Gotto, Jr., MD, Center for Cardiology and Cardiovascular Diseases dedicated at the American Hospital, Istanbul

- 2008 Nashville Public Schools Hall of Fame
- 2008 Austrian Cross of Honor for Science and Art, First Class
- 2010 Maurice R. Greenberg Distinguished Service Award, New York-Presbyterian Hospital/Weill Cornell Medical Center
- 2011 Distinguished Achievement Award, National Lipid Association
- 2012 Robert J. and Claire Pasarow Foundation Award in Cardiovascular Research
- 2012 New York Leadership Award, Citizens Union
- 2012 John Stearns Medal for Distinguished Contributions in Medicine, New York Academy of Medicine
- 2013 Texas Chapter Laureate Award, American College of Physicians

Selected Lectureships

- 1970, 1972, 1976 Gordon Conference on Lipid Metabolism
- 1970, 1974 Deuel Conference on Lipids
- 1972 National Meeting of the American Diabetes Association
- 1972 Health Care and Aging Public Meeting on Aging, sponsored by the City of Houston
- 1972, 1978 Distinguished Lecturer, Shell Oil Company, Houston
- 1973 Third International Symposium on Atherosclerosis, Berlin
- 1974 Fourth International Conference on Drugs Affecting Lipid Metabolism, Milan
- 1974 Gordon Conference on Proteins
- 1975 International Symposium on Atherosclerosis, London, Ontario
- 1975 Conference on Lipoprotein Metabolism, Heidelberg
- 1975 International Conference on Biology of Lipids, Graz
- 1975 Conference on Familial Hyperlipidemia, London
- 1975, 1988 Annual Lecture, Japanese Atherosclerosis Society, Tokyo

- 1976 Symposium on the Arterial Wall, Fondation Cardiologique Princesse Liliane, Brussels
- 1976 International Congress of Biochemistry, Hamburg
- 1976 Fourth International Symposium on Atherosclerosis, Tokyo
- 1976 Annual Lecture, Società Italiana per lo Studio dell'Arteriosclerosi, Third Theoretical and Practical Course on Hyperlipoproteinemia, Giovanni Lorenzini Medical Foundation, Carlo Erba Institute, Milan
- 1977 Symposium on High Density Lipoproteins, Fondation Cardiologique Princesse Liliane, Brussels
- 1977 Simon Steven Institute, Brugge
- 1977 Kronberg Symposium
- 1978 International Society and Federation of Cardiology (Scientific Council on Arteriosclerosis), Berlin
- 1979 International Symposium on Thrombosis, London
- 1979 International Conference on Biology of Lipids, Cologne
- 1979 Chinese Academy of Medical Sciences, Peking
- 1980 Distinguished Lecturer, Southern Society for Clinical Investigation
- 1980 French Group for the Study of Lipids, Dijon
- 1980 Annual Clinical Day Lecturer, The Montreal Jewish General Hospital, McGill University, Montreal
- 1980 Lecture at Fortieth Anniversary Celebration, Institute of Experimental Medicine, Caracas
- 1980 Matteu Sandoz Lectureship, Rutgers University, New Brunswick, New Jersey
- 1980 Annual Clinical Lecture, American Society of Gerontology
- 1980 Bosworth Visiting Professorship in Internal Medicine, Denver
- 1980 Overseas Lecturer, Annual Meeting, Australian Atherosclerosis Society
- 1981 US USSR Cardiovascular Workgroup Symposium on HDL, Leningrad

- 1981 Distinguished Lecturer, Louisiana State University School of Medicine, Shreveport
- 1981 Carlo Erba Institute, Milan
- 1981 Istanbul Cardiology Society, American Bristol Hospital, Istanbul
- 1982 Sixth International Symposium on Atherosclerosis, Berlin
- 1983 International Satellite Telesymposium on Atherosclerosis
- 1984 Third Symposium on Medical Biochemistry, Moscow
- 1984 Ninth European Congress of Cardiology
- 1985 Cardiology Congress, Buenos Aires
- 1985 Seventh International Symposium on Atherosclerosis, Melbourne
- 1985 National Academy of Medicine, Argentina
- 1986 US USSR Lipoprotein Symposium, Washington, D.C.
- 1986 US Italy Lipoprotein Symposium
- 1986 Distinguished Riker 3-M Lectureship, International Symposium of Intern Medicine, Bogota, Colombia
- 1987 Physician-in-Chief Pro Tem, Harvard Medical School, Boston Grand Rounds, Brigham and Women's Hospital, Boston Grand Rounds, Beth Israel Hospital, Boston
- 1988 Eighth International Symposium on Atherosclerosis, Rome
- 1989 Seventh International Meeting on Atherosclerosis, Bologna
- 1989 American Clinical and Climatological Association, Bermuda
- 1989 Tenth International Symposium on Drugs Affecting Lipid Metabolism, Houston
- 1989 John G. Reinhold Lecture, University of Pennsylvania Department of Pathology and Laboratory Medicine
- 1989 Isadore Rosenfeld Visiting Professor, New York Hospital and Cornell Medical Center, New York
- 1989 Dedication of Rene Favoloro Institute, Buenos Aires

- 1990 Perlman Lecture, New York Cardiological Society
- 1990 Grollman Lecture, University of Virginia Health Sciences Center
- 1990 Co-Chairman, International Symposium on Multiple Risk Factors in Cardiovascular Disease, Washington, D.C.
- 1992 Co-Chairman, International Symposium on Multiple Risk Factors in Cardiovascular Disease, Osaka
- 1992 Shapiro Chair Symposium, Vanderbilt University Medical Center, Nashville
- 1992 11th International Conference on Drugs Affecting Lipid Metabolism, Florence
- 1994 Controversies in Cardiology Lecture, Distinguished Lectures Series, Mt. Sinai Hospital, Visiting Professor, New York
- 1993 Visiting Professor Ground Rounds, Distinguished Lectures Series, Cleveland Clinic, Heart Center, Cleveland
- 1994 Tenth International Symposium on Atherosclerosis, (IAS), Montréal
- 1994 Co-Chairman, International Symposium on Multiple Risk Factors in Cardiovascular Disease, Milan
- 1995 Myant Lecture, British Hyperlipidemia Association, Birmingham, England
- 1995 20th Giovanni Lorenzini Medical Foundation Meeting, Milan
- 1997 Lewis O'Connor Memorial Lecture, Los Angeles
- 1998 DeWitt S. Goodman Fellowship and Lecture in Nutrition and Preventive Medicine, Columbia University College of Physicians & Surgeons, New York, New York
- 2001 Stockton Kimball Memorial Lecture, State University at Buffalo, Buffalo, New York
- 2001 Robert I. Levy Endowed Lecture in Lipid Metabolism, Anaheim, California
- 2001 Peter T. Kuo, M.D. Lecture in Cardiology, Robert Wood Johnson Medical School, New Brunswick, New Jersey

- 2003 Symposium on The Hippocratic Oath and its Role in Modern Medicine, Alexander S. Onassis Public Benefit Foundation (USA), in collaboration with the Hellenic Medical Society of New York, New York
- 2003 Opening Lecture, First International Symposium on Triglycerides, Metabolic Disorders, and Cardiovascular Disease, New York, New York
- 2003 Plenary Lecture, XIII International Symposium on Atherosclerosis, Kyoto, Japan
- 2004 Borden Lecture in Cardiology, Northwestern University Hospital, Chicago, Illinois
- 2005 Louis F. Bishop Lecture, American College of Cardiology, New Orleans, Louisiana
- 2006 Alpha Omega Alpha Lecture, Vanderbilt University School of Medicine, Nashville, Tennessee
- 2007 Co-Chair, XVI International Symposium on Drugs Affecting Lipid Metabolism, New York, New York
- 2007 Wilbert J. Keon Endowed Lecture, Ottawa Heart Institute, Ottawa, Canada
- 2007 Rose Weiss Visiting Professor Grand Rounds, Lahey Clinic, Burlington, Massachusetts
- 2007 The Methodist Hospital Inaugural Lecture Grand Rounds, Houston, Texas
- 2008 Keynote Lecture, 77th European Atherosclerosis Society Congress, Istanbul, Turkey
- 2009 Association of Academic Health Centers Inaugural Asia-Pacific Meeting, Singapore
- 2009 Co-President, XV International Symposium on Atherosclerosis, Boston, Massachusetts
- 2010 Jeremiah Metzger Lecture, American Clinical and Climatological Association, San Antonio, Texas
- 2012 Gerald T. Gau Lecture in Preventive Cardiology, Mayo Clinic, Rochester, Minnesota
- 2012 Alpha Omega Alpha Ed Holloran Memorial Lecture, Vanderbilt University School of Medicine, Nashville, Tennessee
- 2013 Guller Family Lecture, Washington University School of Medicine in St. Louis, St. Louis, Missouri

Community Activities

- 1981–1996 Member, External Review Board, Rice University, Houston
- 1983–1991 Trustee, St. John's School, Houston
- 1985 Member, European Mission of Houston Economic Development Council
- 1991–1996 Honorary Co-Chairman, Community Development Committee, Friends of Hermann Park

Corporate Boards

- 1992–2007 Medtronic
- 1994–1995 The Upjohn Company
- 2001–2004 Esperion Therapeutics
2014–present
- 2005–present Aegerion Pharmaceuticals
- 2005–present Arisaph Pharmaceuticals

Editorial Activities

Journals

- 1972–1996 Member, Editorial Board, The Cardiovascular Research Center Bulletin
- 1973–1978 Member, Editorial Board, Advances in Lipid Research
- 1974–1979 Member, Editorial Board, Circulation Research
- 1976–1981 Member, Editorial Board, The Journal of Biological Chemistry
- 1976–1992 Co-Editor (with Rodolfo Paoletti), Atherosclerosis Reviews
- 1981–1989 Member, Editorial Board, Arteriosclerosis
- 1981–1996 Member, Editorial Board, American Heart Journal
- 1981–1996 Associate Editor, Journal of Protein Chemistry
- 1981–1996 Member, Editorial Board, Endocrinologia Clinica y Metabolismo

- 1982–1983 Member, Editorial Board, International Journal of Cardiology
- 1982–2013 Member, Editorial Board, American Journal of Cardiology
- 1983–1990 Associate Editor, Perspectives in Lipid Disorders
- 1983–1997 Member, Editorial Board, Experimental and Molecular Pathology
- 1986–2003 Member, Editorial Board, Atherosclerosis
- 2001–2004 Member, Editorial Board, Circulation
- 1990–1991 Member, Editorial Board, New England Journal of Medicine
- 1990–1996 Member, Editorial Board, American Journal of Hypertension
- 1991–present Member, Editorial Board, Current Opinion In Cardiology
- 1991–present Member, Editorial Board and Section Editor, Current Opinion In Lipidology
- 1991–1996 Member, Editorial Board, Nutrition, Metabolism and Cardiovascular Diseases
- 1992–2000 Member, Editorial Board, Southern Medical Journal
- 1993–2002 Co-Editor (with Peter Sleight), Journal of Cardiovascular Risk
- 1996–2007 Member, Editorial Board, Journal of Cardiovascular Pharmacology and Therapeutics
- 1998–2002 Editor, Best Practice of Medicine
- 1998–present Editor, Current Atherosclerosis Reports
- 1998–2001 Editor, Mediguide to Heart Diseases
- 2000–2002 Member, World Medical Leaders.com
- 2000–present Member, Editorial Board, Lipids Online
- 2003–present Member, Editorial Advisory Board, Cardiology News
- 2006–2010 Member, Editorial Board, Journal of the CardioMetabolic Syndrome
- 2007–present Member, Editorial Board, Obesity
- 2009–present Senior Editor, The Medical Roundtable—Cardiovascular Edition

2010–present Senior Editor, Journal of Clinical Hypertension

2013–present Member, Editorial Board, Journal of Clinical Lipidology

Television Series

1987–present Co-Editor, Milestones in Medicine

PUBLICATIONS

Original Articles

1. Kornberg HL, Gotto AM Jr, Lund P. Effect of growth substrates on isocitratase formation by *Pseudomonas ovalis* Chester. *Nature* 1958;182(4647):1430-1.
2. Kornberg HL, Gotto AM Jr. Formation of malate from glycollate by *Pseudomonas ovalis* Chester. *Nature* 1959;183:1791-3.
3. Kornberg HL, Gotto AM Jr. The metabolism of C₂ compounds in micro-organisms. 6. Synthesis of cell constituents from glycollate by *Pseudomonas* sp. *Biochem J* 1961;78:69-82.
4. Gotto AM Jr, Kornberg HL. Crystalline tartronic semialdehyde reductase from *Pseudomonas ovalis* Chester. *Biochim Biophys Acta* 1961;48:604-605.
5. Gotto AM Jr, Kornberg HL. The metabolism of C₂ compounds in micro-organisms. 7. Preparation and properties of crystalline tartronic semialdehyde reductase. *Biochem J* 1961;81:273-84.
6. Zelitch I, Gotto AM Jr. Properties of a new glyoxylate reductase from leaves. *Biochem J* 1962;84:541-6.
7. Gotto AM Jr, Pogell BM. Induction of fructose-1,6-diphosphatase activity in *Escherichia coli*. *Biochem Biophys Res Commun* 1962;9:381-7.
8. Gotto AM Jr, Meikle AW, Touster O. Nucleoside metabolism in Ehrlich ascites tumor cells: Phosphorolysis of purine nucleosides. *Biochim Biophys Acta* 1964;80:552-61.
9. Gotto AM Jr, Hutson RM, Meikle AW, Touster O. Spectrophotometric and manometric studies of NADPH and NADH oxidase activities of rat liver microsomes: Effects of drugs and adenine nucleotides. *Biochem Pharmacol* 1965;14(6):989-1002.
10. Burr RE, Gotto AM Jr, Beaver DL. Isolation and analysis of renal bismuth inclusions. *Toxic Appl Pharmacol* 1965;7(4):588-91.
11. Meikle AW, Gotto AM Jr, Touster O. The metabolism of purine compounds in Ehrlich ascites tumor cells: Evidence for a salvage pathway of inosine metabolism. *Biochim Biophys Acta* 1967;138(3):445-51.
12. Belkhome ML, Gotto AM Jr, Touster O. On the mechanism of the nucleoside stimulation of amino acid incorporation into protein of Ehrlich ascites tumor cells in vitro. *Cancer Res* 1967;27(6):1073-83.
13. Gotto AM Jr, Levy RI, Fredrickson DS. Human serum beta-lipoprotein: preparation and properties of a delipidated, soluble derivative. *Biochem Biophys Res Commun* 1968;31(2):151-7.
14. Gotto AM Jr, Levy RI, Fredrickson DS. Preparation and properties of an apoprotein derivative of human serum beta-lipoprotein. *Lipids* 1968;3:463-470.

15. Gotto AM Jr, Levy RI, Rosenthal AS, Birnbaumer ME, Fredrickson DS. The structure and properties of human beta-lipoprotein and beta-apoprotein. *Biochem Biophys Res Commun* 1968;31(5):699-705.
16. Gotto AM Jr, Levy RI, Fredrickson DS. Observations on the conformation of human beta-lipoprotein: Evidence for the occurrence of beta-structure. *Proc Natl Acad Sci USA* 1968;60(4):1436-41.
17. Gotto AM Jr, Levy RI, Rosenthal AS, Fredrickson DS. Human serum beta-lipoprotein. *Nature* 1968;219(5159):1157-9.
18. Gotto AM Jr, Belkhole ML, Touster O. Stimulatory effects of inosine and deoxyinosine on the incorporation of uracil-2-14C, 5-fluorouracil-2-14C and 5-bromouracil-2-14C into nucleic acids by Ehrlich ascites tumor cells in vitro. *Cancer Res* 1969;29(4):807-11.
19. Gotto AM Jr, Kon H. Application of electron spin resonance to the study of the structure of human serum lipoproteins. *Biochem Biophys Res Commun* 1969;37(3):444-50.
20. Gotto AM Jr, Levy RI, Lindgren FT, Fredrickson DS. Partial delipidation of human serum beta-lipoprotein by sodium decyl sulfate. *Biochim Biophys Acta* 1969;176(3):667-9.
21. Gotto AM Jr, Levy RI, Birnbaumer ME, Fredrickson DS. Human serum beta lipoprotein and beta apoprotein. *Nature* 1969;223(5208):835-7.
22. Gotto AM Jr, Shore B. Conformation of human serum high density lipoprotein and its peptide components. *Nature* 1969;224(5214):69-70.
23. Gotto AM Jr, Kon H, Birnbaumer ME. Electron spin resonance studies of lipid-protein interaction in human serum lipoproteins. *Proc Natl Acad Sci U S A* 1970;65(1):145-51.
24. Gotto AM Jr, Kon H. Observations on the conformation of human serum high-density lipoproteins using infrared spectroscopy, circular dichroism, and electron spin resonance. *Biochemistry* 1970;9(22):4276-83.
25. Gotto AM Jr, Levy RI, John K, Fredrickson DS. On the protein defect in abetalipoproteinemia. *N Engl J Med* 1971;284(15):813-8.
26. Gotto AM Jr, Brown WV, Levy RI, Birnbaumer ME, Fredrickson DS. Evidence for the identity of the major apoprotein in low density and very low density lipoproteins in normal subjects and patients with familial hyperlipoproteinemia. *J Clin Invest* 1972;51(6):1486-94.
27. Gotto AM Jr, Lux SE, Goodman DS. Circular dichroic studies of human plasma retinol-binding protein and prealbumin. *Biochim Biophys Acta* 1972;271(2):429-35.
28. Jackson RL, Gotto AM Jr. A study of the cystine-containing apolipoprotein of human plasma high density lipoproteins: characterization of cyanogen bromide and tryptic fragments. *Biochim Biophys Acta* 1972;285(1):36-47.

29. Jackson RL, Baker HN, David JS, Gotto AM Jr. Isolation of a helical, lipid-binding fragment from the human plasma high density lipoprotein, apoLP-GLN-I. *Biochem Biophys Res Commun* 1972;49(6):1444-51.
30. Lux SE, Hirz R, Shrager RI, Gotto AM Jr. The influence of lipid on the conformation of human plasma high density apolipoproteins. *J Biol Chem* 1972;247(8):2598-606.
31. Lux SE, Levy RI, Gotto AM Jr, Fredrickson DS. Studies on the protein defect in Tangier disease. Isolation and characterization of an abnormal high density lipoprotein. *J Clin Invest* 1972;51(10):2505-19.
32. Lux SE, John KM, Fleischer S, Jackson RL, Gotto AM Jr. Identification of the lipid-binding cyanogen bromide fragment from the cystine-containing high density apolipoprotein, APOLP-GLN-II. *Biochem Biophys Res Commun* 1972;49(1):23-9.
33. Gotto AM Jr, Levy RI, Lux SE, Birnbaumer ME, Fredrickson DS. A comparative study of the effects of chemical modification on the immunochemical and optical properties of human plasma low-density lipoprotein(s) and apoproteins. *Biochem J* 1973;133(2):369-82.
34. Baker HN, Jackson RL, Gotto AM Jr. Isolation and characterization of the cyanogen bromide fragments from the high-density apolipoprotein glutamine I. *Biochemistry* 1973;12(20):3866-71.
35. DeBlois RW, Uzgiris EE, Devi SK, Gotto AM Jr. Application of laser self-beat spectroscopic technique to the study of solutions of human plasma low-density lipoproteins. *Biochemistry* 1973;12:2645-2649.
36. Hoff HF, Jackson RL, Titus JL, DeBakey ME, Gotto AM Jr. Plasma lipoproteins and atherosclerosis in man: An immunohistochemical study. *Cardiovasc Res Cent Bull* 1973;12(2):29-39.
37. Hoff HF, Morrisett JD, Gotto AM Jr. Interaction of phosphatidylcholine and apolipoprotein-alanine: electron microscopic studies. *Biochim Biophys Acta* 1973;296(3):653- 60.
38. Jackson RL, Baker HN, Taunton OD, Smith LC, Garner CW, Gotto AM Jr. A comparison of the major apolipoprotein from pig and human high density lipoproteins. *J Biol Chem* 1973;248(8):2639-44.
39. Jackson RL, Gotto AM Jr, Lux SE, John KM, Fleischer S. Human plasma high density lipoprotein. Interaction of the cyanogen bromide fragments from apolipoprotein glutamine II (A-II) with phosphatidylcholine. *J Biol Chem* 1973;248(24):8449-56.
40. Jackson RL, Morrisett JD, Pownall HJ, Gotto AM Jr. Human high density lipoprotein, apolipoprotein glutamine II. The immunochemical and lipid-binding properties of apolipoprotein glutamine II derivatives. *J Biol Chem* 1973;248(15):5218-24.
41. Levy RI, Fredrickson DS, Stone NJ, Bilheimer DW, Brown WV, Glueck CJ, Gotto AM Jr, Herbert PN, Kwiterovich PO, Langer T, LaRosa J, Lux SE, Rider AK, Shulman RS, Sloan HR.

Cholestyramine in type II hyperlipoproteinemia. A double-blind trial. *Ann Intern Med* 1973;79(1):51-8.

42. Morrisett JD, David JS, Pownall HJ, Gotto AM Jr. Interaction of an apolipoprotein (apoLP-alanine) with phosphatidylcholine. *Biochemistry* 1973;12(7):1290-9.

43. Morrisett JD, Sparrow JT, Hoff HF, Gotto AM Jr. Methods for studying lipid-protein interactions. *Cardiovasc Res Cent Bull* 1973;12(2):39-51.

44. Sparrow JT, Gotto AM Jr, Morrisett JD. Chemical synthesis and biochemical properties of peptide fragments of apolipoprotein-alanine. *Proc Natl Acad Sci U S A* 1973;70(7):2124-8.

45. Baker HN, Delahunty T, Gotto AM Jr, Jackson RL. The primary structure of high density apolipoprotein-glutamine-I. *Proc Natl Acad Sci U S A* 1974;71(9):3631-4.

46. Hoff HF, Jackson RL, Mao SJ, Gotto AM Jr. Localization of low density lipoproteins in atherosclerotic lesions from human normolipemics employing a purified fluorescent-labeled antibody. *Biochim Biophys Acta* 1974;351(2):407-15.

47. Jackson RL, Mao SJ, Gotto AM Jr. Effects of maleylation on the lipid-binding and immunochemical properties of human plasma high density apolipoprotein-A-II. *Biochem Biophys Res Commun* 1974;61(4):1317-1324.

48. Jackson RL, Morrisett JD, Sparrow JT, Segrest JP, Pownall HJ, Smith LC, Hoff HF, Gotto AM Jr. The interaction of apolipoprotein-serine with phosphatidylcholine. *J Biol Chem* 1974;249(16):5314-20.

49. Jackson RL, Sparrow JT, Baker HN, Morrisett JD, Taunton OD, Gotto AM Jr. The primary structure of apolipoprotein-serine. *J Biol Chem* 1974;249(16):5308-13.

50. Morganroth J, Levy RI, McMahon AE, Gotto AM Jr. Pseudohomozygous type II hyperlipoproteinemia. *J Pediatr* 1974; 85(5):639-43.

51. Morrisett JD, Gallagher JG, Aune KC, Gotto AM Jr. Structure of the major complex formed by interaction of phosphatidylcholine bilamellar vesicles and apolipoprotein-alanine (APO-C-III). *Biochemistry* 1974;13:4765-4771.

52. Pownall HJ, Morrisett JD, Sparrow JT, Gotto AM Jr. The requirement for lipid fluidity in the formation and structure of lipoproteins: thermotropic analysis of apolipoprotein-alanine binding to dimyristoyl phosphatidylcholine. *Biochem Biophys Res Commun* 1974;60(2):779-86.

53. Segrest JP, Jackson RL, Morrisett JD, Gotto AM Jr. A molecular theory of lipid-protein interactions in the plasma lipoproteins. *FEBS Lett* 1974;38(3):247-58.

54. Segura R, Gotto AM Jr. A new fluorimetric procedure for the detection and quantitation of organic compounds in thin-layer chromatography. *J Chromatogr* 1974;99:643-57.

55. David JS, Thompson GR, Gotto AM Jr, Morrisett JD. Interaction of human plasma apolipoproteins and phospholipids. Semi-quantitative studies using polyacrylamide gel electrophoresis. *Biochim Biophys Acta* 1975;398(1):72-83.
56. Delahunty T, Baker HN, Gotto AM Jr, Jackson RL. The primary structure of human plasma high density apolipoprotein glutamine I (ApoA-I). I. The amino acid sequence of cyanogen bromide fragment II. *J Biol Chem* 1975;250(7):2718-24.
57. Baker HN, Gotto AM Jr, Jackson RL. The primary structure of human plasma high density apolipoprotein glutamine I (ApoA-I). II. The amino acid sequence and alignment of cyanogen bromide fragments IV, III and I. *J Biol Chem* 1975;250(7):2725-38.
58. Fujita Y, Gotto AM Jr, Unger RH. Basal and postprotein insulin and glucagon levels during a high and low carbohydrate intake and their relationships to plasma triglycerides. *Diabetes* 1975;24:552-8.
59. Hoff HF, Heideman CL, Jackson RL, Bajardo RJ, Kim HS, Gotto AM Jr. Localization patterns of plasma apolipoproteins in human atherosclerotic lesions. *Circ Res* 1975;37(1):72-9.
60. Hoff HF, Titus JL, Bajardo RJ, Jackson RL, Gotto AM Jr., DeBakey ME, Lie JT. Lipoproteins in atherosclerotic lesions. Localization by immunofluorescence of apo-low density lipoproteins in human atherosclerotic arteries from normal and hyperlipoproteinemics. *Arch Pathol* 1975;99(5):253-8.
61. Jackson RL, Gotto AM Jr, Stein O, Stein Y. A comparative study on the removal of cellular lipids from Landschutz ascites cells by human plasma apolipoproteins. *J Biol Chem* 1975;250(18):7204-9.
62. Jackson RL, Morrisett JD, Gotto AM Jr, Segrest JP. The mechanism of lipid-binding by plasma lipoproteins. *Mol Cell Biochem* 1975;6(1):43-50.
63. Mao SJ, Gotto AM Jr, Jackson RL. Immunochemistry of human plasma high density lipoproteins. Radioimmunoassay of apolipoprotein A-II. *Biochemistry* 1975;14:4127- 31.
64. Meikle AW, Gotto AM Jr. Bovine serum albumin: Study of the fatty acid and steroid binding sites using spin-labeled lipids. *J Biol Chem* 1975;250:2487-2494.
65. Morrisett JD, Pownall HJ, Gotto AM Jr. Bovine serum albumin. Study of the fatty acid and steroid binding sites using spin-labeled lipids. *J Biol Chem* 1975;250(7):2487-94.
66. Morrisett JD, Pownall HJ, Sparrow JT, Jackson RL, Gotto AM Jr. The interaction of apolipoprotein-alanine (apoC-III) with lipids: Study of structural features required for binding. *Adv Exp Med Biol* 1975;63:1-35.
67. Soutar KA, Garner CW, Baker HN, Sparrow JT, Jackson RL, Gotto AM Jr, Smith LC. Effect of human plasma apolipoproteins and phosphatidylcholine acyl donor on the activity of lecithin: cholesterol acyltransferase. *Biochemistry* 1975;14(14):3057-64.

68. Thompson GR, Segura R, Hoff H, Gotto AM Jr. Contrasting effects on plasma lipoproteins of intravenous versus oral administration of a triglyceride-phospholipid emulsion. *Eur J Clin Invest* 1975;5(5):373-84.
69. Gotto AM Jr. Introduction to the volume on dedication of the National Heart and Blood Vessel Research and Demonstration Center. *Cardiovasc Res Cent Bull* 1976;15(1):3-4.
70. Hoff HF, Jackson RL, Gotto AM Jr. Apolipoprotein localization in human atherosclerotic arteries. *Adv Exp Med Biol* 1976;67(00):109-20.
71. Jackson RL, Taunton OD, Segura R, Gallagher JG, Hoff HF, Gotto AM Jr. Comparative studies on plasma low density lipoproteins from pig and man. *Comp Biochem Physiol* 1976;53(2):245-53.
72. Jackson RL, Stein O, Glangeaud MC, Fainaru M, Gotto AM Jr, Stein Y. The removal of cellular lipids from Landschutz ascites cells and smooth muscle cells in culture. *Adv Exp Med Biol* 1976;67(00):453-61.
73. Novosad Z, Knapp RD, Gotto AM Jr, Pownall HJ, Morrisett JD. Structure of an apolipoprotein-phospholipid complex: apoC-III induced changes in the physical properties of dimyristoylphosphatidylcholine. *Biochemistry* 1976;15(15):3176-83.
74. Sigler GF, Soutar AK, Smith LC, Gotto AM Jr, Sparrow JT. The solid phase synthesis of a protein activator for lecithin-cholesterol acyltransferase corresponding to human plasma apoC-I. *Proc Natl Acad Sci U S A* 1976;73(5):1422-6.
75. Thompson GR, Birnbaumer ME, Levy RI, Gotto AM Jr. Solid phase radioimmunoassay of apolipoprotein B (apo B) in normal human plasma. *Atherosclerosis* 1976;24(1-2):107-18.
76. Thompson GR, Jadhav A, Nava M, Gotto AM Jr. Effects of intravenous phospholipid on low density lipoprotein turnover in man. *Eur J Clin Invest* 1976;6(3):241-8.
77. Gotto AM Jr, DeBakey ME, Foreyt JP, Scott LW, Thornby JJ. Dietary treatment of type IV hyperlipoproteinemia. *JAMA* 1977; 237(12):1212-5.
78. Gotto AM Jr, Gorry GA, Thompson JR, Cole JS, Trost R, Yeshurun D, DeBakey ME. Relationship between plasma lipid concentrations and coronary artery disease in 496 patients. *Circulation* 1977;56(5):875-83.
79. Aune KC, Gallagher JG, Gotto AM Jr, Morrisett JD. Physical properties of the dimyristoyl-phosphatidylcholine vesicle and of complexes formed by its interaction with apolipoprotein C-III. *Biochemistry* 1977;16(10):2151-6.
80. Blaton V, Vercaemst R, Rosseneu M, Mortelmans J, Jackson RL, Gotto AM Jr, Peeters H. Characterization of baboon plasma high-density lipoproteins and of their major apoproteins. *Biochemistry* 1977;16(10):2157-63.
81. Hoff HF, Heideman CL, Gotto AM Jr, Gaubatz JW. Apolipoprotein B retention in the grossly normal and atherosclerotic human aorta. *Circ Res* 1977;41(5):684-90.

82. Jackson RL, Baker HN, Gilliam EB, Gotto AM Jr. Primary structure of very low density apolipoprotein C-II of human plasma. *Proc Natl Acad Sci U S A* 1977;74(5):1942-5.
83. Jackson RL, Morrisett JD, Pownall HJ, Gotto AM Jr, Kamio A, Imai H, Tracy R, Kummerow FA. Influence of dietary trans-fatty acids on swine lipoprotein composition and structure. *J Lipid Res* 1977;18(2):182-90.
84. Kinnunen PK, Jackson RL, Smith LC, Gotto AM Jr, Sparrow JT. Activation of lipoprotein lipase by native and synthetic fragments of human plasma apolipoprotein C-II. *Proc Natl Acad Sci U S A* 1977;74(11):4848-51.
85. Gotto AM Jr. Biomedical research priorities in the 1970's. *Cardiovasc Res Cent Bull* 1977;16(2):35-43.
86. Mao SJ, Sparrow JT, Gilliam EB, Gotto AM Jr, Jackson RL. Mechanism of lipid-protein interaction in the plasma lipoproteins: lipid-binding properties of synthetic fragments of apolipoprotein A-II. *Biochemistry* 1977;16(19):4150-6.
87. Morrisett JD, Pownall HJ, Gotto AM Jr. Interaction of apolipoprotein C-III with phosphatidylcholine vesicles. Dependence of apoprotein-phospholipid complex formation on vesicle structure. *Biochim Biophys Acta* 1977;486(1):36-46.
88. Patsch JR, Aune KC, Gotto AM Jr, Morrisett JD. Isolation, chemical characterization, and biophysical properties of three different abnormal lipoproteins: LP-X1, LP-X2, and LP-X3. *J Biol Chem* 1977;252(6):2113-20.
89. Patsch JR, Jackson RL, Gotto AM Jr. Evaluation of the classical methods for the diagnosis of type III hyperlipoproteinemia. *Klin Wochenschr* 1977;55(21):1025-30.
90. Patsch JR, Soutar AK, Morrisett JD, Gotto AM Jr, Smith LC. Lipoprotein-X: A substrate for lecithin:cholesterol acyltransferase. *Eur J Clin Invest* 1977;7(3):213-217.
91. Patsch JR, Yeshurun D, Jackson RL, Gotto AM Jr. Effects of clofibrate, nicotinic acid and diet on the properties of the plasma lipoproteins in a subject with type III hyperlipoproteinemia. *Am J Med* 1977;63(6):1001-9.
92. Pownall HJ, Hsu FJ, Rosseneu M, Peeters H, Gotto AM Jr, Jackson RL. Thermodynamics of lipid protein associations. Thermodynamics of helix formation in the association of high density apolipoprotein A-I (apoA-I) to dimyristoyl phosphatidylcholine. *Biochim Biophys Acta* 1977;488(2):190-7.
93. Pownall HJ, Morrisett JD, Gotto AM Jr. Composition-structure-function correlations in the binding of an apolipoprotein to phosphatidylcholine bilayer mixtures. *J Lipid Res* 1977;18(1):14-23.
94. Ramirez AG, Weaver FJ, Raizner AE, Dorfman SB, Herrick KL, Gotto AM Jr. The efficacy of lay CPR instruction: An evaluation. *Am J Public Health* 1977;67(11):1093-5.

95. Roth RI, Jackson RL, Pownall HJ, Gotto AM Jr. Interaction of plasma "arginine-rich" apolipoprotein with dimyristoylphosphatidylcholine. *Biochemistry* 1977;16(23):5030-6.
96. Shepherd J, Gotto AM Jr, Taunton OD, Caslake MJ, Farish E. The in vitro interaction of human apolipoprotein A-I and high density lipoproteins. *Biochim Biophys Acta* 1977;489(3):486-501.
97. Sparrow JT, Pownall HJ, Hsu FJ, Blumenthal LD, Culwell AR, Gotto AM Jr. Lipid binding by fragments of apolipoprotein C-III-1 obtained by thrombin cleavage. *Biochemistry* 1977;16(25):5427-31.
98. Yeshurun D, Chung BH, Gotto AM Jr, Taunton OD. Primary type V hyperlipoproteinemia in childhood. *JAMA* 1977;238(23):2518-20.
99. Bradley WA, Rohde MF, Gotto AM Jr, Jackson RL. The cyanogen bromide peptides of the apoprotein of low density lipoprotein (ApoB): Its molecular weight from a chemical view. *Biochem Biophys Res Commun* 1978;81(3):928-35.
100. Catapano AL, Jackson RL, Gilliam EB, Gotto AM Jr, Smith LC. Quantification of apoC-II and apoC-III of human very low density lipoproteins by analytical isoelectric focusing. *J Lipid Res* 1978;19(8):1047-52.
101. Di Ferrante N, Donnelly PV, Di Ferrante DT, Toma S, Gotto AM Jr. Release of low density lipoprotein receptors from human fibroblasts or HeLa cells by tryptic digestion. *Biochem Biophys Res Commun* 1978;84(2):366-73.
102. Gianturco SH, Gotto AM Jr, Jackson RL, Patsch JR, Sybers HD, Taunton OD, Yeshurun DL, Smith LC. Control of 3-hydroxy-3-methylglutaryl-CoA reductase activity in cultured human fibroblasts by very low density lipoproteins of subjects with hypertriglyceridemia. *J Clin Invest* 1978;61(2):320-8.
103. Gorry GA, Chamberlain RM, Price BS, DeBakey ME, Gotto AM Jr. Communication patterns in a biomedical research center. *J Med Educ* 1978;53(3):206-7.
104. Herrick KL, Scott LW, Weaver FJ, Foreyt JP, Gotto AM Jr. Developing and evaluating audiovisual media for dietary education. *J Am Diet Assoc* 1978;73(6):660-2.
105. Hoff HF, Gaubatz JW, Gotto AM Jr. Apo B concentration in the normal human aorta. *Biochem Biophys Res Commun* 1978;85(4):1424-30.
106. Hoff HF, Heideman CL, Gaubatz JW, Scott DW, Titus JL, Gotto AM Jr. Correlation of apolipoprotein B retention with the structure of atherosclerotic plaques from human aortas. *Lab Invest* 1978;38(5):560-7.
107. Hoff HF, Heideman CL, Gaubatz JW, Scott DW, Gotto AM Jr. Detergent extraction of tightly-bound apoB from extracts of normal aortic intima and plaques. *Exp Mol Pathol* 1978;28(3):290-300.

108. Hoff HF, Heideman CL, Gaubatz JW, Titus JL, Gotto AM Jr. Quantitation of apo B in human aortic fatty streaks: A comparison with grossly normal intima and fibrous plaques. *Atherosclerosis* 1978;30(4):263-72.
109. Patsch JR, Gotto AM Jr, Olivecrona T, Eisenberg S. Formation of high density lipoprotein2-like particles during lipolysis of very low density lipoproteins in vitro. *Proc Natl Acad Sci U S A* 1978;75(9):4519-23.
110. Pownall HJ, Massey JB, Kusserow SK, Gotto AM Jr. Kinetics of lipid-protein interactions: interaction of apolipoprotein A-I from human plasma high density lipoproteins with phosphatidylcholines. *Biochemistry* 1978;17(7):1183-8.
111. Pownall HJ, Pao Q, Rohde M, Gotto AM Jr. Lipoprotein-apoprotein exchange in aqueous systems: relevance to the occurrence of apoA-I and apoC proteins in a common particle. *Biochem Biophys Res Commun* 1978;85(1):408-14.
112. Scott DW, Gotto AM Jr, Cole JS, Gorry GA. Plasma lipids as collateral risk factors in coronary artery disease -- a study of 371 males with chest pain. *J Chronic Dis* 1978;31(5):337-45.
113. Shepherd J, Packard CJ, Patsch JR, Gotto AM Jr, Taunton OD. Effects of dietary polyunsaturated and saturated fat on the properties of high density lipoproteins and the metabolism of apolipoprotein A-I. *J Clin Invest* 1978;61(6):1582-92.
114. Shepherd J, Packard CJ, Patsch JR, Gotto AM Jr, Taunton OD. Metabolism of apolipoproteins A-I and A-II and its influence on the high density lipoprotein subfraction distribution in males and females. *Eur J Clin Invest* 1978;8(3):115-120.
115. Shepherd J, Packard CJ, Gotto AM Jr, Taunton OD. Effects of dietary saturated and polyunsaturated fat on the metabolism of apolipoproteins A-I and B. Study of a patient with type IIb hyperlipoproteinaemia. *Clin Chim Acta* 1978;87(3):395-404.
116. Shepherd J, Packard CJ, Gotto AM Jr, Taunton OD. A comparison of two methods to investigate the metabolism of human apolipoproteins A-I and A-II. *J Lipid Res* 1978;19(5):656-61.
117. Shepherd J, Packard CJ, Patsch JR, Morgan G, Gotto AM Jr. Apoprotein exchange between human high-density-lipoprotein subfractions (high-density-lipoprotein subfractions 2 and 3). *Biochem Soc Trans* 1978;6(1):106-8.
118. Shepherd J, Packard C, Morgan G, Taunton D, Gotto AM Jr. The influence of dietary-fat saturation on the metabolism of apolipoproteins A-I, B and C in a type-IIb hyperlipoproteinaemic subject. *Biochem Soc Trans* 1978;6:592-596.
119. Shepherd J, Patsch JR, Packard CJ, Gotto AM Jr, Taunton OD. Dynamic properties of human high density lipoprotein apoproteins. *J Lipid Res* 1978;19(3):383-9.
120. Soutar AK, Sigler GF, Smith LC, Gotto AM Jr, Sparrow JT. Lecithin:cholesterol acyltransferase activation and lipid binding by synthetic fragments of apolipoprotein C-I. *Scand J Clin Lab Invest Suppl* 1978;150:53-8.

121. Yeshurun D, Taunton OD, Gotto AM Jr. [Familial hypobetalipoproteinemia.] *Harefuah* 1978;94(11):368-70.
122. Gotto AM Jr. Dedication of the Alkek Tower, Houston, Texas: Opening and closing remarks at the scientific lectures. *Cardiovasc Res Cent Bull* 1979;17(3):52-5.
123. Catapano AL, Gianturco SH, Kinnunen PK, Eisenberg S, Gotto AM Jr, Smith LC. Suppression of 3-hydroxy-3-methylglutaryl-CoA reductase by low density lipoproteins produced in vitro by lipoprotein lipase action on nonsuppressive very low density lipoproteins. *J Biol Chem* 1979;254(4):1007-9.
124. Catapano AL, Kinnunen PK, Breckenridge WC, Gotto AM Jr, Jackson RL, Little JA, Smith LC, Sparrow JT. Lipolysis of apoC-II deficient very low density lipoproteins: Enhancement of lipoprotein lipase action by synthetic fragments of apoC-II. *Biochem Biophys Res Commun* 1979;89(3):951-7.
125. Chen TC, Bradley WA, Gotto AM Jr, Morrisett JD. Binding of the chemical carcinogen, p-dimethylaminoazobenzene, by human plasma low density lipoproteins. *FEBS Lett* 1979;104(2):236-40.
126. Chen TC, Sparrow JT, Gotto AM Jr, Morrisett JD. Apolipoprotein A-II: Chemical synthesis and biophysical properties of three peptides corresponding to fragments in the amino-terminal half. *Biochemistry* 1979;18(8):1617-22.
127. Eisenberg S, Patsch JR, Sparrow JT, Gotto AM Jr, Olivecrona T. Very low density lipoprotein. Removal of apolipoproteins C-II and C-III-1 during lipolysis in vitro. *J Biol Chem* 1979;254(24):12603-8.
128. Foreyt JP, Scott LW, Mitchell RE, Gotto AM Jr. Plasma lipid changes in the normal population following behavioral treatment. *J Consult Clin Psychol* 1979;47(3):440-52.
129. Gianturco SH, Hong KY, Steiner MR, Taunton OD, Jackson RL, Gotto AM Jr, Smith LC. A laser spectrofluorimeter for studies of cultured cells on the growth surface. *Anal Biochem* 1979;92(1):74-81.
130. Hoff HF, Bradley WA, Heideman CL, Gaubatz JW, Karagas MD, Gotto AM Jr. Characterization of low density lipoprotein-like particle in the human aorta from grossly normal and atherosclerotic regions. *Biochim Biophys Acta* 1979;573(2):361-74.
131. Hoff HF, Karagas M, Heideman CL, Gaubatz JW, Gotto AM Jr. Correlation in the human aorta of APO B fractions with tissue cholesterol and collagen content. *Atherosclerosis* 1979;32(3):259-68.
132. Jensen RG, Clark RM, Gerrior SA, Fey MB, Gotto AM Jr. Cholesteryl ester and triacylglycerol fatty acids in type V hyperlipidemia. *Lipids* 1979;14(7):691-4.

133. Krieger M, Smith LC, Anderson RG, Goldstein JL, Kao YJ, Pownall HJ, Gotto AM Jr, Brown MS. Reconstituted low density lipoprotein: a vehicle for the delivery of hydrophobic fluorescent probes to cells. *J Supramol Struct* 1979;10(4):467-78.
134. Laggner P, Gotto AM Jr, Morrisett JD. Structure of the dimyristoylphosphatidylcholine vesicle and the complex formed by its interaction with apolipoprotein C-III: X-ray small-angle scattering studies. *Biochemistry* 1979;18(1):164-71.
135. Mao SJ, Sparrow JT, Gotto AM Jr, Jackson RL. Mechanism of lipid-protein interaction in the plasma lipoproteins: relationship of lipid-binding sites to antigenic sites in apolipoprotein A-II. *Biochemistry* 1979;18(18):3984-8.
136. Massey JB, Gotto AM Jr, Pownall HJ. Contribution of alpha helix formation in human plasma apolipoproteins to their enthalpy of association with phospholipids. *J Biol Chem* 1979;254(19):9359-61.
137. Packard CJ, Shepherd J, Joerns S, Gotto AM Jr, Taunton OD. Very low density and low density lipoprotein subfractions in type III and type IV hyperlipoproteinemia. Chemical and physical properties. *Biochim Biophys Acta* 1979;572(2):269-82.
138. Pownall HJ, Massey JB, Kusserow SK, Gotto AM Jr. Kinetics of lipid-protein interactions: effect of cholesterol on the association of human plasma high-density apolipoprotein A-I with L-alpha-dimyristoylphosphatidylcholine. *Biochemistry* 1979;18(4):574-9.
139. Scott LW, Foreyt JP, Manis E, O'Malley MP, Gotto AM Jr. A low-cholesterol menu in a steak restaurant. *J Am Diet Assoc* 1979;74(1):54-6.
140. Scott LW, Foreyt JP, Young J, Reeves RS, O'Malley MP, Gotto AM Jr. Are low-cholesterol diets expensive? *J Am Diet Assoc* 1979; 74:558-561.
141. Shepherd J, Packard CJ, Patsch JR, Gotto AM Jr, Taunton OD. Effects of nicotinic acid therapy on plasma high density lipoprotein subfraction distribution and composition and on apolipoprotein A metabolism. *J Clin Invest* 1979;63(5):858-67.
142. Gotto AM Jr, Butler WT. The DeBakey Center. *Cardiovasc Res Cent Bull* 1980;19(1):1- 4.
143. Bradley WA, Rohde MF, Gotto AM Jr. Studies on the primary structure of apolipoprotein B. *Ann N Y Acad Sci* 1980;348:87-103.
144. Brainard JR, Cordes EH, Gotto AM Jr, Patsch JR, Morrisett JD. Lipoprotein-X: proton and phosphorus-31 nuclear magnetic resonance studies of native, reconstituted, and model systems. *Biochemistry* 1980;19(18):4273-79.
145. Brainard JR, Hamilton JA, Cordes EH, Patsch JR, Gotto AM Jr, Morrisett JD. Lipoprotein-X: carbon-13 nuclear magnetic resonance studies on native, reconstituted, and model systems. *Biochemistry* 1980;19(18):4266-73.

146. Brainard JR, Knapp RD, Patsch JR, Gotto AM Jr, Morrisett JD. Dynamics of lipid motions in high density lipoprotein subfractions HDL2 and HDL3: magnetic resonance studies. *Ann N Y Acad Sci* 1980;348:299-317.
147. Chen TC, Knapp RD, Rohde MF, Brainard JR, Gotto AM Jr, Sparrow JT, Morrisett JD. Magnetic resonance studies of apolipoprotein C-I nitroxide labeled or [¹³C]methyl enriched at methionine-38. *Biochemistry* 1980;19(22):5140-6.
148. Daerr WH, Gianturco SH, Patsch JR, Smith LC, Gotto AM Jr. Effects of HDL subclasses on 3-hydroxy-3-methylglutaryl coenzyme A reductase in human fibroblasts. *Nutr Metab* 1980;24 Suppl 1:26-33.
149. Daerr WH, Gianturco SH, Patsch JR, Smith LC, Gotto AM Jr. Stimulation and suppression of 3-hydroxy-3-methylglutaryl coenzyme A reductase in normal human fibroblasts by high density lipoprotein subclasses. *Biochim Biophys Acta* 1980;619(2):287- 301.
150. Eskin SG, Sybers HD, Navarro LT, Gotto AM Jr, DeBakey ME. Tissue-cultured smooth muscle cells from normal and atherosclerotic arteries. *Cardiovasc Res Cent Bull* 1980;18(4):85-9.
151. Foreyt JP, Scott LW, Gotto AM Jr. Weight control and nutrition education programs in occupational settings. *Public Health Rep* 1980;95(2):127-36.
152. Gianturco SH, Eskin SG, Navarro LT, Lahart CJ, Smith LC, Gotto AM Jr. Abnormal effects of hypertriacylglycerolemic very low-density lipoproteins on 3-hydroxy-3-methylglutaryl-CoA reductase activity and viability of cultured bovine aortic endothelial cells. *Biochim Biophys Acta* 1980;618(1):143-52.
153. Gianturco SH, Packard CJ, Shepherd J, Smith LC, Catapano AL, Sybers HD, Gotto AM Jr. Abnormal suppression of 3-hydroxy-3-methylglutaryl-CoA reductase activity in cultured human fibroblasts by hypertriglyceridemic very low density lipoprotein subclasses. *Lipids* 1980;15(6):456-63.
154. Hartung GH, Foreyt JP, Mitchell RE, Vlasek I, Gotto AM Jr. Relation of diet to high-density-lipoprotein cholesterol in middle-aged marathon runners, joggers, and inactive men. *N Engl J Med* 1980;302(7):357-61.
155. Mantulin WW, Rohde MF, Gotto AM Jr, Pownall HJ. The conformational properties of human plasma apolipoprotein C-II. A spectroscopic study. *J Biol Chem* 1980;255(17):8185- 91.
156. Mao SJ, Bhatnagar PK, Gotto AM Jr, Sparrow JT. Immunochemistry of human very low density lipoproteins: Apolipoprotein C-III. *Biochemistry* 1980;19(2):315-20.
157. Mao SJ, Sparrow JT, Gotto AM Jr, Jackson RL. The phospholipid-binding and immunochemical properties of amidinated, guanidinated and acetylated apolipoprotein A-II. *Biochim Biophys Acta* 1980;617(2):245-53.

158. Mao SJ, Miller JP, Gotto AM Jr, Sparrow JT. The antigenic structure of apolipoprotein A-I in human high density lipoproteins. Radioimmunoassay using surface-specific antibodies. *J Biol Chem* 1980;255(8):3448-53.
159. Massey JB, Gotto AM Jr, Pownall HJ. Dynamics of lipid-protein interactions. Interaction of apolipoprotein A-II from human plasma high density lipoproteins with dimyristoylphosphatidylcholine. *J Biol Chem* 1980;255(21):10167-73.
160. Miller JP, Mao SJ, Patsch JR, Gotto AM Jr. The measurement of apolipoprotein A-I in human plasma by electroimmunoassay. *J Lipid Res* 1980;21(6):775-80.
161. Morrisett JD, Patsch JR, Gotto AM Jr, Taunton OD. Effects of saturated and polyunsaturated fat diets on the chemical and physical properties of lipoproteins from type V hyperlipoproteinemic subjects. *Prog Food Nutr Sci* 1980;4(5):47-63.
162. Packard CJ, Shepherd J, Joerns S, Gotto AM Jr, Taunton OD. Apolipoprotein B metabolism in normal, type IV and type V hyperlipoproteinemic subjects. *Metabolism* 1980;29(3):213-222.
163. Patsch W, Schonfeld G, Gotto AM Jr, Patsch JR. Characterization of human high density lipoproteins by zonal ultracentrifugation. *J Biol Chem* 1980;255(7):3178-85.
164. Pownall HJ, Hu A, Gotto AM Jr, Albers JJ, Sparrow JT. Activation of lecithin:cholesterol acyltransferase by a synthetic model lipid-associating peptide. *Proc Natl Acad Sci U S A* 1980;77(6):3154-8.
165. Pownall HJ, Jackson RL, Roth RI, Gotto AM Jr, Patsch JR, Kummerow FA. Influence of anatherogenic diet on the structure of swine low density lipoproteins. *J Lipid Res* 1980;21(8):1108-15.
166. Pownall HJ, Shepherd J, Mantulin WW, Sklar LA, Gotto AM Jr. Effect of saturated and polyunsaturated fat diets on the composition and structure of human low density lipoproteins. *Atherosclerosis* 1980;36:299-314.
167. Scott DW, Gorry GA, Hoffman RG, Barboriak JJ, Gotto AM Jr. A new approach for evaluating risk factors in coronary artery disease: A study of lipid concentrations and severity of disease in 1847 males. *Circulation* 1980;62(3):477-84.
168. Shepherd J, Packard CJ, Grundy SM, Yeshurun D, Gotto AM Jr, Taunton OD. Effects of saturated and polyunsaturated fat diets on the chemical composition and metabolism of low density lipoproteins in man. *J Lipid Res* 1980;21(1):91-9.
169. Sklar LA, Doody MC, Gotto AM Jr, Pownall HJ. Serum lipoprotein structure: Resonance energy transfer localization of fluorescent lipid probes. *Biochemistry* 1980;19(7):1294-301.
170. Smith LC, Voyta JC, Catapano AL, Kinnunen PK, Gotto AM Jr, Sparrow JT. Activation of lipoprotein lipase by synthetic fragments of apolipoprotein C-II. *Ann N Y Acad Sci* 1980;348:213-23.

171. Christensen BL, Stallones RA, Insull W Jr, Gotto AM Jr, Taunton OD. Cardiovascular risk factors in a tri-ethnic population: Houston, Texas 1972-1975. *J Chronic Dis* 1981;34(4):105-18.
172. Craig IF, Via DP, Mantulin WW, Pownall HJ, Gotto AM Jr, Smith LC. Low density lipoproteins reconstituted with steroids containing the nitrobenzoxadiazole fluorophore. *J Lipid Res* 1981; 22(4):687-96.
173. Eskin SG, Sybers HD, Lester JW, Navarro LT, Gotto AM Jr, DeBakey ME. Human smooth muscle cells cultured from atherosclerotic plaques and uninvolved vessel wall. *In Vitro* 1981;17(8):713-8.
174. Hancock WS, Bishop CA, Gotto AM Jr, Harding DR, Lamplugh SM, Sparrow JT. Separation of the apoprotein components of human very low density lipoproteins by ion-paired, reversed-phase high performance liquid chromatography. *Lipids* 1981;16(4):250-9.
175. Hancock WS, Pownall HJ, Gotto AM Jr, Sparrow JT. Separation of apolipoproteins A-I and A-II by ion-paired reversed-phase high performance liquid chromatography. *J Chromatogr* 1981;216:285-293.
176. Hara T, Miller JP, Gotto AM Jr, Patsch JR. Oxandrolone and plasma triglyceride reduction: effect on triglyceride-rich and high density lipoproteins. *Artery* 1981;9(5):328-41.
177. Hartung GH, Squires WG, Gotto AM Jr. Effect of exercise training on plasma high-density lipoprotein cholesterol in coronary disease patients. *Am Heart J* 1981;101(2):181-4.
178. Lippel K, Tyroler H, Eder H, Gotto AM Jr, Vahouny G. Relationship of hypertriglyceridemia to atherosclerosis. *Arteriosclerosis* 1981;1(6):406-17.
179. Mao SJ, Jackson RL, Gotto AM Jr, Sparrow JT. Mechanism of lipid-protein interaction in the plasma lipoproteins: identification of a lipid-binding site in apolipoprotein A-II. *Biochemistry* 1981;20(6):1676-80.
180. Mantulin WW, Massey JB, Gotto AM Jr, Pownall HJ. Reassembled model lipoproteins. Lipid dynamics in recombinants of human apolipoprotein A-II and dimyristoylphosphatidylcholine. *J Biol Chem* 1981;256(21):10815-9.
181. Massey JB, Gotto AM Jr, Pownall HJ. Thermodynamics of lipid-protein interactions: interaction of apolipoprotein A-II from human plasma high-density lipoproteins with dimyristoylphosphatidylcholine. *Biochemistry* 1981;20(6):1575-84.
182. Massey JB, Gotto AM Jr, Pownall HJ. Human plasma high density apolipoprotein A-I: effect of protein-protein interactions on the spontaneous formation of a lipid-protein recombinant. *Biochem Biophys Res Commun* 1981;99(2):466-74.
183. Massey JB, Rohde MF, Van Winkle WB, Gotto AM Jr, Pownall HJ. Physical properties of lipid-protein complexes formed by the interaction of dimyristoylphosphatidylcholine and human high-density apolipoprotein A-II. *Biochemistry* 1981;20(6):1569-74.

184. Myher JJ, Kuksis A, Shepherd J, Packard CJ, Morrisett JD, Taunton OD, Gotto AM Jr. Effect of saturated and unsaturated fat diets on molecular species of phosphatidylcholine and sphingomyelin of human plasma lipoproteins. *Biochim Biophys Acta* 1981;666(1):110-9.
185. Pownall HJ, Hickson D, Gotto AM Jr. Thermodynamics of lipid-protein association. The free energy of association of lecithin with reduced and carboxymethylated apolipoprotein A-II from human plasma high density lipoprotein. *J Biol Chem* 1981; 256(19):9849-54.
186. Pownall HJ, Massey JB, Hsu FJ, Gotto AM Jr. Thermodynamics of lipid-protein associations: the enthalpy of binding of apo C-III to synthetic phosphatidylcholines. *Can J Biochem* 1981;59(8):700-8.
187. Bradley WA, Gilliam EB, Gotto AM Jr, Gianturco SH. Apolipoprotein-E degradation in human very low density lipoproteins by plasma protease(s): Chemical and biological consequences. *Biochem Biophys Res Commun* 1982;109(4):1360-7.
188. Craig IF, Via DP, Sherrill BC, Sklar LA, Mantulin WW, Gotto AM Jr, Smith LC. Incorporation of defined cholesteryl esters into lipoproteins using cholesteryl ester-rich microemulsion. *J Biol Chem* 1982;257(1):330-5.
189. Doody MC, Gotto AM Jr, Smith LC. 5-(Dimethylamino)naphthalene-1-sulfonic acid, a fluorescent probe of the medium chain fatty acid binding site of serum albumin. *Biochemistry* 1982;21(1):28-33.
190. Foreyt JP, Mitchell RE, Garner DT, Gee M, Scott LW, Gotto AM Jr. Behavioral treatment of obesity: Results and limitations. *Behav Ther* 1982;13:153-61.
191. Gianturco SH, Bradley WA, Gotto AM Jr, Morrisett JD, Peavy DL. Hypertriglyceridemic very low density lipoproteins induce triglyceride synthesis and accumulation in mouse peritoneal macrophages. *J Clin Invest* 1982;70(1):168-78.
192. Gianturco SH, Brown FB, Gotto AM Jr, Bradley WA. Receptor-mediated uptake of hypertriglyceridemic very low density lipoproteins by normal human fibroblasts. *J Lipid Res* 1982;23(7):984-93.
193. Kuksis A, Myher JJ, Geher K, Jones GJL, Shepherd J, Packard CJ, Morrisett JD, Taunton OD, Gotto AM Jr. Effect of saturated and unsaturated fat diets on lipid profiles of plasma lipoproteins. *Atherosclerosis* 1982;41(2-3):221-40.
194. Massey JB, Gotto AM Jr, Pownall HJ. Kinetics and mechanism of the spontaneous transfer of fluorescent phosphatidylcholines between apolipoprotein-phospholipid recombinants. *Biochemistry* 1982;21(15):3630-6.
195. Massey JB, Gotto AM Jr, Pownall HJ. Kinetics and mechanism of the spontaneous transfer of fluorescent phospholipids between apolipoprotein-phospholipid recombinants: effect of the polar headgroup. *J Biol Chem* 1982;257(10):5444-8.

196. Ogilvie JT, Mishkel NR, Mishkel MA, Welch VE, Insull W Jr, Probstfield JL, Gotto AM Jr. Occupational screenings: recruitment from private industry. *Circulation* 1982;66(6 Pt 2):IV40-3.
197. Pownall HJ, Hickson D, Gotto AM Jr, Massey JB. Kinetics of spontaneous and plasma-stimulated sphingomyelin transfer. *Biochim Biophys Acta* 1982;712(1):169-76.
198. Pownall HJ, Pao Q, Hickson D, Sparrow JT, Gotto AM Jr. Thermodynamics of lipid-protein association in human plasma lipoproteins. *Biophys J* 1982;37:175-177.
199. Pownall HJ, Van Winkle WB, Pao Q, Rohde M, Gotto AM Jr. Action of lecithin:cholesterol acyltransferase on model lipoproteins. Preparation and characterization of model nascent high density lipoprotein. *Biochim Biophys Acta* 1982;713(3):494-503.
200. Smith LC, Voyta JC, Kinnunen PK, Gotto AM Jr, Sparrow JT. Lipoprotein lipase interaction with synthetic N-dansyl fragments of apolipoprotein C-II. *Biophys J* 1982;37:174-175.
201. Via DP, Craig IF, Jacobs GW, Van Winkle WB, Charlton SC, Gotto AM Jr, Smith LC. Cholesteryl ester-rich microemulsions: stable protein-free analogs of low density lipoproteins. *J Lipid Res* 1982;23(4):570-6.
202. Via DP, Willingham MC, Pastan I, Gotto AM Jr, Smith LC. Co-clustering and internalization of low density lipoproteins and alpha2 macroglobulin in human skin fibroblasts. *Exp Cell Res* 1982;14(1):15-22.
203. Bhatnagar PK, Mao SJ, Gotto AM Jr, Sparrow JT. The application of an improved solid phase synthetic technique to the delineation of an antigenic site of apolipoprotein A-II. *Peptides* 1983;4(3):343-9.
204. Doody MC, Sklar LA, Pownall HJ, Sparrow JT, Gotto AM Jr, Smith LC. A simplified approach to resonance energy transfer in membranes, lipoproteins and spatially restricted systems. *Biophys Chem* 1983;17(2):139-52.
205. Gaubatz JW, Heideman C, Gotto AM Jr, Morrisett JD, Dahlen GH. Human plasma lipoprotein [a]. Structural properties. *J Biol Chem* 1983;258(7):4582-(3)9.
206. Ghiselli G, Bradley WA, Gotto AM Jr, Sherrill BC. Identification of proapoA-I in rat lymph and plasma: metabolic conversion to "mature" apoA-I. *Biochem Biophys Res Commun* 1983;116(2):704-11.
207. Gianturco SH, Gotto AM Jr, Hwang SL, Karlin JB, Lin AH, Prasad SC, Bradley WA. Apolipoprotein E mediates uptake of Sf 100-400 hypertriglyceridemic very low density lipoproteins by the low density lipoprotein receptor pathway in normal human fibroblasts. *J Biol Chem* 1983;258(7):4526-33.
208. Hartung GH, Foreyt JP, Mitchell RE, Mitchell JG, Reeves RS, Gotto AM Jr. Effect of alcohol intake on high-density lipoprotein cholesterol levels in runners and inactive men. *JAMA* 1983;249(6):747-750.

209. Lippel K, Tyroler HA, Gotto AM Jr, Brewer HB, Albers JJ, Scanu A, Alaupovic P. Workshop on apolipoprotein quantification. *Arteriosclerosis* 1983;3:452-464.
210. Ornish D, Scherwitz LW, Doody RS, Kesten D, McLanahan SM, Brown SE, DePuey EG, Sonnemaker R, Haynes C, Lester J, McAllister GK, Hall RJ, Burdine JA, Gotto AM Jr. Effects of stress management training and dietary changes in treating ischemic heart disease. *JAMA* 1983;249(1):54-9.
211. Patsch JR, Karlin JB, Scott LW, Smith LC, Gotto AM Jr. Inverse relationship between blood levels of high density lipoprotein subfraction 2 and magnitude of postprandial lipemia. *Proc Natl Acad Sci U S A* 1983;80(5):1449-53.
212. Pownall HJ, Knapp RD, Gotto AM Jr, Massey JB. Helical amphipathic moment: Application to plasma lipoproteins. *FEBS Lett* 1983;159(1-2):17-23.
213. Reeves RS, Foreyt JP, Scott LW, Mitchell RE, Wohlleb J, Gotto AM Jr. Effects of a low cholesterol eating plan on plasma lipids: Results of a three-year community study. *Am J Public Health* 1983;73(8):873-7.
214. Roth RI, Gaubatz JW, Gotto AM Jr, Patsch JR. Effect of cholesterol feeding on the distribution of plasma lipoproteins and on the metabolism of apolipoprotein E in the rabbit. *J Lipid Res* 1983;24(1):1-11.
215. Vainio P, Virtanen JA, Kinnunen PK, Gotto AM Jr, Sparrow JT, Pattus F, Bougis P, Verger R. Action of lipoprotein lipase on mixed triacylglycerol/phosphatidylcholine monolayers. Activation by apolipoprotein C-II. *J Biol Chem* 1983;258(9):5477-82.
216. Vainio P, Virtanen JA, Kinnunen PK, Voyta JC, Smith LC, Gotto AM Jr, Sparrow JT, Pattus F, Verger R. Action of lipoprotein lipase on phospholipid monolayers. Activation by apolipoprotein C-II. *Biochemistry* 1983;22(9):2270-5.
217. Vainio P, Virtanen JA, Sparrow JT, Gotto AM Jr, Kinnunen PK. Esterase-type of activity possessed by human plasma apolipoprotein C-II and its synthetic fragments. *Chem Phys Lipids* 1983;33(1):21-32.
218. Voyta JC, Vainio P, Kinnunen PK, Gotto AM Jr, Sparrow JT, Smith LC. Interaction of synthetic N-5-dimethylaminonaphthalene-1-sulfonyl-apolipoprotein C-II peptides with lipoprotein lipase. *J Biol Chem* 1983;258(5):2934-9.
219. Gotto AM Jr, Bierman EL, Connor WE, Ford CH, Frantz ID Jr, Glueck CJ, Grundy SM, Little JA. Recommendations for treatment of hyperlipidemia in adults. A joint statement of the Nutrition Committee and the Council on Arteriosclerosis. *Circulation* 1984;69(5):1065A-1090A.
220. Bradley WA, Hwang SL, Karlin JB, Lin AH, Prasad SC, Gotto AM Jr, Gianturco SH. Low-density lipoprotein receptor binding determinants switch from apolipoprotein E to apolipoprotein B during conversion of hypertriglyceridemic very-low-density lipoprotein to low-density lipoproteins. *J Biol Chem* 1984;259(23):14728-35.

221. Massey JB, Gotto AM Jr, Pownall HJ. Thermodynamics of lipid-protein association. Enthalpy of association of apolipoprotein A-II with dimyristoylphosphatidylcholine-cholesterol mixtures. *Biochim Biophys Acta* 1984;794(1):137-41.
222. Massey JB, Hickson D, She HS, Sparrow JT, Via DP, Gotto AM Jr, Pownall HJ. Measurement and prediction of the rates of spontaneous transfer of phospholipids between plasma lipoproteins. *Biochim Biophys Acta* 1984;794(2):274-80.
223. Packard CJ, Munro A, Lorimer AR, Gotto AM Jr, Shepherd J. Metabolism of apolipoprotein B in large triglyceride-rich very low density lipoproteins of normal and hypertriglyceridemic subjects. *J Clin Invest* 1984;74(6):2178-92.
224. Patsch JR, Prasad S, Gotto AM Jr, Bengtsson-Olivecrona G. Postprandial lipemia. A key for the conversion of high density lipoprotein₂ into high density lipoprotein₃ by hepatic lipase. *J Clin Invest* 1984;74(6):2017-23.
225. Ponsin G, Strong K, Gotto AM Jr, Sparrow JT, Pownall HJ. In vitro binding of synthetic acylated lipid-associating peptides to high-density lipoproteins: effect of hydrophobicity. *Biochemistry* 1984;23(22):5337-42.
226. Pownall HJ, Hickson DL, Gotto AM Jr, Massey JB. In vitro transfer of phosphatidylcholines and their ether analogs by a human and rat plasma exchange factor. *Biochem Biophys Res Commun* 1984;119(2):452-7.
227. Gotto AM Jr, et al. Lowering blood cholesterol to prevent heart disease. NIH Consensus Development Conference Statement. *Nutr Rev* 1985;43:283-91.
228. Benson DM, Bryan J, Plant AL, Gotto AM Jr, Smith LC. Digital imaging fluorescence microscopy: spatial heterogeneity of photobleaching rate constants in individual cells. *J Cell Biol* 1985;100(4):1309-23.
229. Bradley WA, Gotto AM Jr, Gianturco SH. Expression of LDL receptor binding determinants in very low density lipoproteins. *Ann N Y Acad Sci* 1985;454:239-47.
230. Chan L, Van Tuinen P, Ledbetter DH, Daiger SP, Gotto AM Jr, Chen SH. The human apolipoprotein B-100 gene: A highly polymorphic gene that maps to the short arm of chromosome 2. *Biochem Biophys Res Commun* 1985;133(1):248-55.
231. Chan L, Wei CF, Li WH, Yang CY, Ratner P, Pownall HJ, Gotto AM Jr, Smith LC. Human liver fatty acid binding protein cDNA and amino acid sequence. Functional and evolutionary implications. *J Biol Chem* 1985;260(5):2629-32.
232. Dvorin E, Mantulin WW, Rohde MF, Gotto AM Jr, Pownall HJ, Sherrill BC. Conformational properties of human and rat apolipoprotein A-IV. *J Lipid Res* 1985;26(1):38- 46.
233. Ghiselli G, Gotto AM Jr, Tanenbaum S, Sherrill BC. Proapolipoprotein A-I conversion kinetics in vivo in human and in rat. *Proc Natl Acad Sci U S A* 1985;82(3):874- 8.

234. Ghiselli G, Rohde MF, Tanenbaum S, Krishnan S, Gotto AM Jr. Origin of apolipoprotein A-I polymorphism in plasma. *J Biol Chem* 1985;260(29):15662-8.
235. Gianturco SH, Gotto AM Jr, Bradley WA. Hypertriglyceridemia: Lipoprotein receptors and atherosclerosis. *Adv Exp Med Biol* 1985;183:47-71.
236. Guyton JR, Dahlen GH, Patsch W, Kautz JA, Gotto AM Jr. Relationship of plasma lipoprotein Lp(a) levels to race and to apolipoprotein B. *Arteriosclerosis* 1985;5(3):265-72.
237. Massey JB, Hickson-Bick D, Via DP, Gotto AM Jr, Pownall HJ. Fluorescence assay of the specificity of human plasma and bovine liver phospholipid transfer proteins. *Biochim Biophys Acta* 1985;835(1):124-31.
238. Massey JB, She HS, Gotto AM Jr, Pownall HJ. Lateral distribution of phospholipid and cholesterol in apolipoprotein A-I recombinants. *Biochemistry* 1985;24(25):7110-6.
239. Ponsin G, Gotto AM Jr, Utermann G, Pownall HJ. Abnormal interaction of the human apolipoprotein A-I variant [Lys107----0] with high density lipoproteins. *Biochem Biophys Res Commun* 1985;133(3):856-62.
240. Pownall HJ, Gotto AM Jr. The role of hydrophobicity in the structure of human plasma lipoproteins. *Adv Exp Med Biol* 1985;183:85-97.
241. Reiser R, Probstfield JL, Silvers A, Scott LW, Shorney ML, Wood RD, O'Brien BC, Gotto AM Jr, Insull W Jr. Plasma lipid and lipoprotein response of humans to beef fat, coconut oil and safflower oil. *Am J Clin Nutr* 1985;42(2):190-7.
242. Sparrow JT, Sparrow DA, Culwell AR, Gotto AM Jr. Apolipoprotein E: Phospholipid binding studies with synthetic peptides containing the putative receptor binding region. *Biochemistry* 1985;24(24):6984-8.
243. Tsao YK, Wei CF, Robberson DL, Gotto AM Jr, Chan L. Isolation and characterization of the human apolipoprotein A-II gene. Electron microscopic analysis of RNA:DNA hybrids, nucleotide sequence, identification of a polymorphic MspI site, and general structural organization of apolipoprotein genes. *J Biol Chem* 1985;260(28):15222- 31.
244. Via DP, Dresel HA, Cheng SL, Gotto AM Jr. Murine macrophage tumors are a source of a 260,000-dalton acetyl-low density lipoprotein receptor. *J Biol Chem* 1985;260:7379-7386.
245. Via DP, Massey JB, Vignale S, Kundu SK, Marcus DM, Pownall HJ, Gotto AM Jr. Spontaneous and plasma factor-mediated transfer of pyrenyl cerebroside between model and native lipoproteins. *Biochim Biophys Acta* 1985;837(1):27-34.
246. Via DP, Plant AL, Craig IF, Gotto AM Jr, Smith LC. Metabolism of normal and modified low-density lipoproteins by macrophage cell lines of murine and human origin. *Biochim Biophys Acta* 1985;833(3):417-28.

247. Voyta JC, Via DP, Kinnunen PK, Sparrow JT, Gotto AM Jr, Smith LC. Monoclonal antibodies against bovine milk lipoprotein lipase. Characterization of an antibody specific for the apolipoprotein C-II binding site. *J Biol Chem* 1985;260(2):893-8.
248. Wei CF, Chen SH, Yang CY, Marcel YL, Milne RW, Wi WH, Sparrow JT, Gotto AM Jr, Chan L. Molecular cloning and expression of partial cDNAs and deduced amino acid sequence of a carboxyl-terminal fragment of human apolipoprotein B-100. *Proc Natl Acad Sci U S A* 1985;82(21):7265-9.
249. Wei CF, Tsao YK, Robberson DL, Gotto AM Jr, Brown K, Chan L. The structure of the human apolipoprotein C-II gene. Electron microscopic analysis of RNA:DNA hybrids, complete nucleotide sequence, and identification of 5 homologous sequences among apolipoprotein genes. *J Biol Chem* 1985;260(28):15211-21.
250. Yang CY, Pownall HJ, Gotto AM Jr. Identification of peptides containing tryptophan, tyrosine, and phenylalanine using photodiode-array spectrophotometry. *Anal Biochem* 1985;145(1):67-72.
251. Bernini F, Tanenbaum SR, Sherrill BC, Gotto AM Jr, Smith LC. Enhanced catabolism of low density lipoproteins in rat by lactosaminated Fab fragment. A new carrier of macromolecules to the liver. *J Biol Chem* 1986;261(20):9294-9.
252. Brown SA, Via DP, Gotto AM Jr, Bradley WA, Gianturco SH. Apolipoprotein E-mediated binding of hypertriglyceridemic very low density lipoproteins to isolated low density lipoprotein receptors detected by ligand blotting. *Biochem Biophys Res Commun* 1986;139(1):333-40.
253. Chen SH, Yang CY, Chen PF, Setzer D, Tanimura M, Li WH, Gotto AM Jr, Chan L. The complete cDNA and amino acid sequence of human apolipoprotein B-100. *J Biol Chem* 1986;261(28):12918-21.
254. Crump WL III, Sherrill BC, Gotto AM Jr, Ghiselli G. Radioimmunoassay of rat apolipoprotein A-IV. *Anal Biochem* 1986;159(1):96-100.
255. Dahlen GH, Guyton JR, Attar M, Farmer JA, Kautz JA, Gotto AM Jr. Association of levels of lipoprotein Lp(a), plasma lipids, and other lipoproteins with coronary artery disease documented by angiography. *Circulation* 1986;74(4):758-65.
256. Dvorin E, Gorder NL, Benson DM, Gotto AM Jr. Apolipoprotein A-IV. A determinant for binding and uptake of high density lipoproteins by rat hepatocytes. *J Biol Chem* 1986;261(33):15714-8.
257. Foreyt JP, Reeves RS, Darnell LS, Wohlleb JC, Gotto AM Jr. Soup consumption as a behavioral weight loss strategy. *J Am Diet Assoc* 1986;86(4):524-6.
258. Ghiselli G, Beigel Y, Soma M, Gotto AM Jr. Plasma catabolism of human apolipoprotein E isoforms: Lack of conversion of the doubly sialylated form to the asialo form in plasma. *Metabolism* 1986;35(5):399-403.
259. Ghiselli G, Crump WL III, Gotto AM Jr. Binding of apoA-IV-phospholipid complexes to plasma membranes of rat liver. *Biochem Biophys Res Commun* 1986;139(1):122-8.

260. Ghiselli G, Krishnan S, Beigel Y, Gotto AM Jr. Plasma metabolism of apolipoprotein A-IV in humans. *J Lipid Res* 1986;27(8):813-27.
261. Hartung GH, Reeves RS, Foreyt JP, Patsch W, Gotto AM Jr. Effect of alcohol intake and exercise on plasma high-density lipoprotein cholesterol subfractions and apolipoprotein A-I in women. *Am J Cardiol* 1986;58(1):148-51.
262. Patsch W, Gotto AM Jr, Patsch JR. Effects of insulin on lipoprotein secretion in rat hepatocyte cultures. The role of the insulin receptor. *J Biol Chem* 1986;261(21):9603-6.
263. Picardo M, Massey JB, Kuhn DE, Gotto AM Jr, Gianturco SH, Pownall HJ. Partially reassembled high density lipoproteins. Effects on cholesterol flux, synthesis and esterification in normal human skin fibroblasts. *Arteriosclerosis* 1986;6(4):434-41.
264. Ponsin G, Hester L, Gotto AM Jr, Pownall HJ, Sparrow JT. Lipid-peptide association and activation of lecithin:cholesterol acyltransferase. Effect of alpha-helicity. *J Biol Chem* 1986;261(20):9202-5.
265. Ponsin G, Sparrow JT, Gotto AM Jr, Pownall HJ. In vivo interaction of synthetic acylated apo-peptides with high density lipoproteins in rat. *J Clin Invest* 1986;77(2):559-67.
266. Pownall HJ, Gotto AM Jr, Knapp RD, Massey JB. The helical hydrophobic moment avoids prolines in phospholipid-binding proteins. *Biochem Biophys Res Commun* 1986;139(1):202-8.
267. Smith LC, Benson DM, Gotto AM Jr, Bryan J. Digital imaging fluorescence microscopy. *Methods Enzymol* 1986;129:857-73.
268. Via DP, Dresel HA, Gotto AM Jr. Isolation and assay of the Ac-LDL receptor. *Methods Enzymol* 1986;129:216-26.
269. Yang CY, Chen SH, Gianturco SH, Bradley WA, Sparrow JT, Tanimura M, Li WH, Sparrow DA, DeLoof H, Rosseneu M, Lee FS, Gu ZW, Gotto AM Jr, Chan L. Sequence, structure, receptor-binding domains and internal repeats of human apolipoprotein B-100. *Nature* 1986;323(6090):738-42.
270. Yang CY, Lee FS, Chan L, Sparrow DA, Sparrow JT, Gotto AM Jr. Determination of the molecular mass of apolipoprotein B-100. A chemical approach. *Biochem J* 1986;239(3):777-80.
271. Yang CY, Yang T, Pownall HJ, Gotto AM Jr. The primary structure of apolipoprotein A-I from rabbit high-density lipoprotein. *Eur J Biochem* 1986;160(2):427-31.
272. Ballantyne CM, Jones PH, Payton-Ross C, Patsch W, Short HD III, Noon GP, Gotto AM Jr, DeBakey ME, Young JB. Hyperlipidemia following heart transplantation: Natural history and intervention with mevinolin (lovastatin). *Transplant Proc* 1987;19(4 Suppl 5):60- 2.
273. Chen SW, Habib G, Yang CY, Gu ZW, Lee BR, Weng SA, Silberman SR, Cai SJ, Deslypere JP, Rosseneu M, Gotto AM Jr, Li WH, Chan L. Apolipoprotein B-48 is the product of a messenger RNA with an organ-specific in-frame stop codon. *Science* 1987;238(4825):363-6.

274. De Loof H, Rosseneu M, Yang CY, Li WH, Gotto AM Jr, Chan L. Human apolipoprotein B: Analysis of internal repeats and homology with other apolipoproteins. *J Lipid Res* 1987;28(12):1455-65.
275. Patsch JR, Prasad S, Gotto AM Jr, Patsch W. High density lipoprotein². Relationship of the plasma levels of this lipoprotein species to its composition, to the magnitude of postprandial lipemia, and to the activities of lipoprotein lipase and hepatic lipase. *J Clin Invest* 1987;80(2):341-7.
276. Silberman SR, Bernini F, Sparrow JT, Gotto AM Jr, Smith LC. Monoclonal antibodies as probes of high-density lipoprotein structure: identification and localization of a lipid-dependent epitope. *Biochemistry* 1987;26(18):5833-43.
277. Turturro F, Heibig J, Chan L, Gotto AM Jr, Ghiselli GC. A complex Hind III polymorphism in the human apolipoprotein-B gene (APOB). *Nucleic Acids Res* 1987;15(22):9618.
278. Yang CY, Manoogian D, Pao Q, Lee FS, Knapp RD, Gotto AM Jr, Pownall HJ. Lecithin:cholesterol acyltransferase. Functional regions and a structural model of the enzyme. *J Biol Chem* 1987;262(7):3086-91.
279. Bernini F, Via DP, Bocan TM, Gotto AM Jr, Smith LC. Lactosaminated Fab fragments specific for low density lipoproteins/hepatocyte targeting and hypolipoproteinemic activity. *Arteriosclerosis* 1988;8(6):825-31.
280. Brown SA, Rhodes CE, Dunn K, Gotto AM Jr, Patsch W. Effect of blood collection and processing on radioimmunoassay results for apolipoprotein A-I in plasma. *Clin Chem* 1988;34(5):920-924.
281. Chen PF, Marcel YL, Yang CY, Gotto AM Jr, Milne RW, Sparrow JT, Chan L. Primary sequence mapping of human apolipoprotein B-100 epitopes. Comparisons of trypsin accessibility and immunoreactivity and implication for apoB conformation. *Eur J Biochem* 1988;175(1):111-8.
282. Hickson-Bick D, Knapp RD, Sparrow JT, Sparrow DA, Gotto AM Jr, Massey JB, Pownall HJ. Kinetics and mechanism of transfer of synthetic model apolipoproteins. *Biochemistry* 1988;27(20):7881-7886.
283. Sikand G, Kondo A, Foreyt JP, Jones PH, Gotto AM Jr. Two-year follow-up of patients treated with a very-low-calorie diet and exercise training. *J Am Diet Assoc* 1988;88(4):487-488.
284. Williams RR, Hunt SC, Barlow GK, Chamberlain RM, Weinberg AD, Cooper HP, Carbonari JP, Gotto AM Jr. Healthy family trees: A tool for finding and helping young family members of coronary and cancer prone pedigrees in Texas and Utah. *Am J Public Health* 1988;78(10):1283-6.

285. Bachorik PS, Bradford RH, Cole T, Frantz I, Gotto AM Jr, Roberts K, Warnick GR, Williams OD. Accuracy and precision of analyses for total cholesterol as measured with the Reflotron cholesterol method. *Clin Chem* 1989;35(8):17349.
286. Ghiselli G, Crump WL, Musanti R, Sherrill BC, Gotto AM Jr. Metabolism of apolipoprotein A-IV in rat. *Biochim Biophys Acta* 1989;1006(1):26-34.
287. Ballantyne CM, Podet EJ, Patsch WP, Harati Y, Appel V, Gotto AM Jr, Young JB. Effects of cyclosporine therapy on plasma lipoprotein levels. *JAMA* 1989;262(1):53-6.
288. Massey JB, Hickson-Bick DL, Gotto AM Jr, Pownall HJ. Kinetics of tryptic hydrolysis as a probe of the structure of human plasma apolipoprotein A-II. *Biochim Biophys Acta* 1989;999(2):121-7.
289. Overturf ML, Smith SA, Hewett ED, Loose-Mitchell DS, Soma MR, Gotto AM Jr, Morrisett JD. Development and partial metabolic characterization of a dietary cholesterol-resistant colony of rabbits. *J Lipid Res* 1989;30(2):263-73.
290. Patsch W, Brown SA, Gotto AM Jr, Young RL. The effect of triphasic oral contraceptives on plasma lipids and lipoproteins. *Am J Obstet Gynecol* 1989;161(5):1396-401.
291. Patsch W, Brown SA, Morrisett JD, Gotto AM Jr, Patsch JR. A dual-precipitation method evaluated for measurement of cholesterol in high-density lipoprotein subfractions HDL2 and HDL3 in human plasma. *Clin Chem* 1989;35(2):265-70.
292. Soma MR, Gotto AM Jr, Ghiselli G. Rapid modulation of rat adipocyte lipoprotein lipase: Effect of calcium, A23187 ionophore, and thrombin. *Biochim Biophys Acta* 1989;1003(3):307-14.
293. Strobl W, Gorder NL, Fienup GA, Lin-Lee YC, Gotto AM Jr, Patsch W. Effect of sucrose diet on apolipoprotein biosynthesis in rat liver. Increase in apolipoprotein E gene transcription. *J Biol Chem* 1989;264(2):1190-4.
294. Yang CY, Gu ZW, Chong I, Xiong W, Rosseneu M, Yang HX, Lee BR, Gotto AM Jr, Chan L. The primary structure of human apolipoprotein A-IV. *Biochim Biophys Acta* 1989;1002(2):231-7.
295. Yang CY, Gu ZW, Yang HX, Rohde MF, Gotto AM Jr, Pownall HJ. Structure of bovine milk lipoprotein lipase. *J Biol Chem* 1989;264:16822-16827.
296. Yang CY, Gu ZW, Weng SA, Kim TW, Chen SH, Pownall HJ, Sharp PM, Liu SW, Li WH, Gotto AM Jr. et al Structure of apolipoprotein B-100 of human low density lipoproteins. *Arteriosclerosis* 1989;9(1):96-108.
297. Yang CY, Kim TW, Pao Q, Chan L, Knapp RD, Gotto AM Jr, Pownall HJ. Structure and conformational analysis of lipid-associating peptides of apolipoprotein B-100 produced by trypsinolysis. *J Protein Chem* 1989;8(6):689-99.

298. Zacca NM, Raizner AE, Noon GP, Short D III, Weilbaecher D, Gotto AM Jr, Roberts R. Treatment of symptomatic peripheral atherosclerotic disease with a rotational atherectomy device. *Am J Cardiol* 1989;63(1):77-80.
299. Ahmad TY, Morrisett JD, Pownall HJ, Gotto AM Jr, Brockman HL, Sable HZ, Lewis EO, Hancock AJ. Cyclopentanoid analogs of dipalmitoyl phosphatidic acid: effect of backbone geometry on thermotropic properties. *Chem Phys Lipids* 1990;55(3):231-43.
300. Bradford RH, Bachorik PS, Roberts K, Williams OD, Gotto AM Jr. Blood cholesterol screening in several environments using a portable, dry-chemistry analyzer and fingerstick blood samples. Lipid Research Clinics Cholesterol Screening Study Group. *Am J Cardiol* 1990;65(1):6-13.
301. Brown SA, Epps DF, Dunn JK, Sharrett AR, Patsch JR, Gotto AM Jr, Patsch W. Effect of blood collection and processing on radioimmunoassay results for apolipoprotein B in plasma. *Clin Chem* 1990;36(9):1662-6.
302. Brown SA, Rogers LK, Dunn JK, Gotto AM Jr, Patsch W. Development of cholesterol homeostatic memory in the rat is influenced by maternal diets. *Metabolism* 1990;39(5):468-73.
303. Coleman RD, Kim TW, Gotto AM Jr, Yang CY. Determination of cysteine on low-density lipoproteins using the fluorescent probe, 5-iodoacetamidofluoresceine. *Biochim Biophys Acta* 1990;1037(1):129-32.
304. Ghiselli G, Crump W III, Musanti R, Gotto AM Jr. Identification of a detergent-solubilized plasma membrane protein from rat liver recognizing apolipoprotein A-IV. *Biochim Biophys Acta* 1990;1044(1):173-5.
305. Hartung GH, Foreyt JP, Reeves RS, Krock LP, Patsch W, Patsch JR, Gotto AM Jr. Effect of alcohol dose on plasma lipoprotein subfractions and lipolytic enzyme activity in active and inactive men. *Metabolism* 1990;39(1):81-6.
306. Kang EY, Coleman RD, Pownall HJ, Gotto AM Jr, Yang CY. Analysis of the carbohydrate composition of glycoproteins by high performance liquid chromatography. *J Protein Chem* 1990;9(1):31-5.
307. Lenz ML, Hughes H, Mitchell JR, Via DP, Guyton JR, Taylor AA, Gotto AM Jr, Smith CV. Lipid hydroperoxy and hydroxy derivatives in copper-catalyzed oxidation of low density lipoprotein. *J Lipid Res* 1990;31(6):1043-50.
308. Lo WD, Sloan HR, Fahey BP, Donat JF, Strobl W, Patsch JR, Gotto AM Jr, Patsch W. Tangier disease in a black patient: an unusual clinical presentation. *Am J Med* 1990;89(1):105-8.
309. Overturf ML, Smith SA, Gotto AM Jr, Morrisett JD, Tewson T, Poorman J, Loose-Mitchell DS. Dietary cholesterol absorption, and sterol and bile acid excretion in hypercholesterolemia-resistant white rabbits. *J Lipid Res* 1990;31(11):2019-27.
310. Soma MR, Morrisett JD, Gotto AM Jr, Loose-Mitchell DS, Poorman JA, Smith SA, Overturf ML. Cholesterol metabolism in fibroblasts from rabbits resistant to diet-induced hypercholesterolemia. *J Lipid Res* 1990;31(6):985-94.

311. Strobl W, Gorder NL, Lin-Lee YC, Gotto AM Jr, Patsch W. Role of thyroid hormones in apolipoprotein A-1 gene expression in rat liver. *J Clin Invest* 1990;85(3):659- 67.
312. Wittels EH, Hay JW, Gotto AM Jr. Medical costs of coronary artery disease in the United States. *Am J Cardiol* 1990;65(7):432-40.
313. Yang CY, Kim TW, Weng SA, Lee B, Yang M, Gotto AM Jr. Isolation and characterization of sulfhydryl and disulfide peptides of human apolipoprotein B-100. *Proc Natl Acad Sci U S A* 1990;87(14):5523-7.
314. Gotto AM Jr. Rationale for treatment. *Am J Med* 1991;91(1B):31S-36S.
315. Bijsterbosch MK, Bernini F, Bakkeren HF, Gotto AM Jr, Smith LC, van Berkel TJ. Enhanced hepatic uptake and processing of cholesterol esters from low density lipoprotein by specific lactosaminated Fab fragments. *Arterioscler Thromb* 1991;11(6):1806-13.
316. Boerwinkle E, Brown SA, Rohrbach K, Gotto AM Jr, Patsch W. Role of apolipoprotein E and B gene variation in determining response of lipid, lipoprotein, and apolipoprotein levels to increased dietary cholesterol. *Am J Hum Genet* 1991;49(6):1145- 54.
317. Brown SA, Morrisett JD, Patsch JR, Reeves RS, Gotto AM Jr, Patsch W. Influence of short term dietary cholesterol and fat on human plasma Lp[a] and LDL levels. *J Lipid Res* 1991;32(8):1281-9.
318. Farmer JA, Ballantyne CM, Frazier OH, Radovancevic B, Payton-Ross C, Patsch W, Morrisett JD, Gotto AM Jr, Young JB. Lipoprotein(a) and apolipoprotein changes after cardiac transplantation. *J Am Coll Cardiol* 1991;18(4):926-30.
319. Hay JW, Wittels EH, Gotto AM Jr. An economic evaluation of lovastatin for cholesterol lowering and coronary artery disease reduction. *Am J Cardiol* 1991;67(9):789-96.
320. Loose-Mitchell DS, Poorman JA, Smith SA, Overturf ML, Morrisett JD, Gotto AM Jr. Soma MR. Cholesterol metabolism in hypercholesterolemia-resistant rabbits. *Atherosclerosis* 1991;87(2-3):169-81.
321. Mallette LE, Hollis BW, Dunn K, Stinson M, Dunn JK, Wittels E, Gotto AM Jr. Ten weeks of intermittent hypocalcemic stimulation does not produce functional parathyroid hyperplasia. *Am J Med Sci* 1991;302(3):138-41.
322. Morrisett JD, Northrup SR, Gotto AM Jr, Starzl TE, Venkataramanan R, Van Thiel D, Murase N. Effect of FK 506 and cyclosporine on plasma cholesterol levels in rabbits. *Transplant Proc* 1991;23(6):3185-7.
323. Scott LW, Kimball KT, Wittels EH, Dunn JK, Brauchi DJ, Pownall HJ, Herd JA, Smith BR, Savell JW, Papadopoulos LS, Collins SS, Cross HR, Gotto AM Jr. Effects of a lean beef diet and of a chicken and fish diet on lipoprotein profiles. *Nutr Metab Cardiovasc Dis* 1991;1:25-30.

324. Xiong W, Li WH, Posner I, Yamamura T, Yamamoto A, Gotto AM Jr, Chan L. No severe bottleneck during human evolution: Evidence from two apolipoprotein C-II deficiency alleles. *Am J Hum Genet* 1991;48(2):383-9.
325. Xiong WJ, Zsigmond E, Gotto AM Jr, Lei KY, Chan L. Locating a low density lipoprotein targeting domain of human apolipoprotein B-100 by expressing a minigene construct in transgenic mice. *J Biol Chem* 1991;266(31):20893-8.
326. Gotto AM Jr. Therapeutic intervention for hypercholesterolemia. *Clin Cardiol* 1992;15(11 Suppl 3):III18-21;discussion III22-4
327. Ballantyne CM, Radovancevic B, Farmer JA, Frazier OH, Chandler L, Payton-Ross C, Cocanougher B, Jones PH, Young JB, Gotto AM Jr. Hyperlipidemia after heart transplantation: Report of a 6-year experience, with treatment recommendations. *J Am Coll Cardiol* 1992;19(6):1315-21.
328. Brown SA, Chambless LE, Sharrett AR, Gotto AM Jr, Patsch W. Postprandial lipemia: Reliability in an epidemiologic field study. *Am J Epidemiol* 1992;136(5):538-45.
329. Farmer JA, Washington LC, Jones PH, Shapiro DR, Gotto AM Jr, Mantell G. Comparative effects of simvastatin and lovastatin in patients with hypercholesterolemia. The Simvastatin and Lovastatin Multicenter Study participants. *Clin Ther* 1992;14(5):708- 17.
330. Goff DC Jr, Shekelle RB, Katan MB, Gotto AM Jr, Stamler J. Does body fatness modify the association between dietary cholesterol and risk of coronary death? Results from the Chicago Western Electric Study. *Arterioscler Thromb* 1992;12(7):755-61.
331. Gordon BR, Kelsey SF, Bilheimer DW, Brown DC, Dau PC, Gotto AM Jr, Illingworth DR, Jones PH, Leitman SF, Prihoda JS, Stein EA, Stern TN, Zavoral JH, Zwiener RJ. Treatment of refractory familial hypercholesterolemia by low-density lipoprotein apheresis using an automated dextran sulfate cellulose adsorption system. *Am J Cardiol* 1992;70(11):1010-6.
332. Mowri HO, Patsch W, Smith LC, Gotto AM Jr, Patsch JR. Different reactivities of high density lipoprotein2 subfractions with hepatic lipase. *J Lipid Res* 1992;33(9):1269-79.
333. Orekhov AN, Tertov VV, Sobenin IA, Smirnov VN, Via DP, Guevara J Jr, Gotto AM Jr, Morrisett JD. Sialic acid content of human low density lipoproteins affects their interaction with cell receptors and intracellular lipid accumulation. *J Lipid Res* 1992;33(6):805-17.
334. Patsch JR, Miesenbîck G, Hopferwieser T, MÅhlberger V, Knapp E, Dunn JK, Gotto AM Jr, Patsch W. Relation of triglyceride metabolism and coronary artery disease. Studies in the postprandial state. *Arterioscler Thromb* 1992;12(11):1336-45.
345. Pownall HJ, Gotto AM Jr. Lipid metabolism and the plasma lipoproteins. *Heart Cardiovasc Sys* 1992;187-205.
336. Radosavljevic N, Lin-Lee YC, Soyol SM, Strobl W, Seelos C, Gotto AM Jr, Patsch W. Effect of sucrose diet on expression of apolipoprotein genes A-I, C-III and A-IV in rat liver. *Atherosclerosis* 1992;95(2-3):147-56.

337. Sparrow DA, Lee BR, Laplaud PM, Auboiron S, Bauchart D, Chapman MJ, Gotto AM Jr, Yang CY, Sparrow JT. Plasma lipid transport in the preruminant calf. *Bos spp*: Primary structure of bovine apolipoprotein A-I. *Biochim Biophys Acta* 1992;1123(2):145- 150.
338. Sparrow JT, Sparrow DA, Fernando G, Culwell AR, Kovar M, Gotto AM Jr. Apolipoprotein E: Phospholipid binding studies with synthetic peptides from the carboxyl terminus. *Biochemistry* 1992;31(4):1065-8.
339. Via DP, Kempner ES, Pons L, Fanslow AE, Vignale S, Smith LC, Gotto AM Jr, Dresel HA. Mouse macrophage receptor for acetylated low density lipoprotein: demonstration of a fully functional subunit in the membrane and with purified receptor. *Proc Natl Acad Sci U S A* 1992;89(15):6780-4.
340. Williams RR, Hunt SC, Barlow GK, Wu LL, Hopkins PN, Schumacher MC, Hassed SJ, Ware J, Chamberlain RM, Weinberg AD, Gotto AM Jr, et al. Prevention of familial cardiovascular-disease by screening for family history and lipids in youths. *Clin Chem* 1992;38:1555-1560.
341. Gotto AM Jr. Dyslipidemia and atherosclerosis: A forecast of pharmaceutical approaches. *Circulation* 1993;87(4 Suppl):III54-9.
342. Gotto AM Jr, Breen WJ, Corder CN, Dunn JK, Goldberg A, Knopp RH, Schrott H, Sprecher D. Once-daily, extended-release gemfibrozil in patients with dyslipidemia. The Lipid SR Work Group I. *Am J Cardiol* 1993;71(12):1057-63.
343. Gotto AM Jr, Jones PH, Farmer JA. Lovastatin 5-year safety and efficacy study. Lovastatin Study Groups I through IV. *Arch Intern Med* 1993;153:1079-1087.
344. Brown SA, Hutchinson R, Morrisett J, Boerwinkle E, Davis CE, Gotto AM Jr, Patsch W. Plasma lipid, lipoprotein cholesterol, and apoprotein distributions in selected US communities: The Atherosclerosis Risk in Communities (ARIC) Study. *Arterioscler Thromb* 1993;13(8):1139-58.
345. Dujovne CA, Eff J, Ferraro L, Goldstein RJ, Gotto AM Jr, Hall WD, Harris WS, Held SJ, Herd A, Hunninghake DB, Johnston BF, Sztern MI. Comparative effects of atenolol versus celiprolol on serum lipids and blood pressure in hyperlipidemic and hypertensive subjects. *Am J Cardiol* 1993;72(15):1131-6.
346. Foreyt JP, Jackson AS, Squires WG Jr, Hartung GH, Murray TD, Gotto AM Jr. Psychological profile of college students who use smokeless tobacco. *Addict Behav* 1993;18(2):107-16.
347. Foreyt JP, Goodrick GK, Reeves RS, Raynaud AS, Darnell L, Brown AH, Gotto AM Jr. Response of free-living adults to behavioral treatment of obesity: Attrition and compliance to exercise. *Behavior Therapy* 1993;24(4):659-69.

348. Goff DC Jr, Shekelle RB, Moye LA, Katan MB, Gotto AM Jr, Stamler J. Does body fatness modify the effect of dietary cholesterol on serum cholesterol? Results from the Chicago Western Electric Study. *Am J Epidemiol* 1993;137(2):171-7.
349. Gu ZW, Xie YH, Yang M, Sparrow JT, Wang K, Li Y, Li WH, Gotto AM Jr, Yang CY. Primary structure of Beijing duck apolipoprotein A-I. *J Protein Chem* 1993;12(5):585- 91.
350. Lin-Lee YC, Strobl W, Soyal S, Radosavljevic M, Song M, Gotto AM Jr, Patsch W. Role of thyroid hormone in the expression of apolipoprotein A-IV and C-III genes in rat liver. *J Lipid Res* 1993;34(2):249-59.
351. Ponsin G, Pulcini T, Sparrow JT, Gotto AM Jr, Pownall HJ. High density lipoprotein interconversions in rat and man as assessed with a novel nontransferable apolipoprotein. *J Biol Chem* 1993;268(5):3114-9.
352. Tertov VV, Orekhov AN, Sobenin IA, Morrisett JD, Gotto AM Jr, Guevara JG Jr. Carbohydrate composition of protein and lipid components in sialic acid-rich and -poor low density lipoproteins from subjects with and without coronary artery disease. *J Lipid Res* 1993;34:365-375.
353. Warnick GR, Boerma GJ, Assmann G, Endler AT, Gerique G, Gotto AM Jr, Graziani MS, Lippi U, Patsch W, Riesen WF, Leary ET, Hiller G, Zerback R, Leinberger R. Multicenter evaluation of Reflotron direct dry-chemistry assay of high-density lipoprotein cholesterol in venous and fingerstick specimens. *Clin Chem* 1993;39(2):271-7.
354. Yang CY, Gu ZW, Valentinova N, Pownall HJ, Lee B, Yang M, Xie YH, Guyton JR, Vlasik TN, Fruchart JC, Gotto AM Jr. Human very low density lipoprotein structure: Interaction of the C apolipoproteins with apolipoprotein B-100. *J Lipid Res* 1993;34(8):1311- 22.
355. Herd JA, West MS, Ballantyne C, Farmer J, Gotto AM Jr. Baseline characteristics of subjects in the Lipoprotein and Coronary Atherosclerosis Study (LCAS) with fluvastatin. *Am J Cardiol* 1994;73(14):D42-9.
356. Kumar AG, Dai XY, Kozak C, Mims M, Gotto AM Jr, Ballantyne CM. Murine VCAM-1: Molecular cloning, mapping, and analysis of a truncated form. *J Immunol* 1994;153(9):4088-98.
357. Lins L, Brasseur R, Rosseneu M, Yang CY, Sparrow DA, Sparrow JT, Gotto AM Jr, Ruyschaert JM. Structure and orientation of apo B-100 peptides into a lipid bilayer. *J Protein Chem* 1994;13(1):77-88.
358. Scott LW, Dunn JK, Pownall HJ, Brauchi DJ, McMann MC, Herd JA, Harris KB, Savell JW, Cross HR, Gotto AM Jr. Effects of beef and chicken consumption on plasma lipid levels in hypercholesterolemic men. *Arch Intern Med* 1994;154(11):1261-7.
359. Teng B, Blumenthal S, Forte T, Navaratnam N, Scott J, Gotto AM Jr, Chan L. Adenovirus-mediated gene transfer of rat apolipoprotein B mRNA-editing protein in mice virtually eliminates apolipoprotein B-100 and normal low density lipoprotein production. *J Biol Chem* 1994;269(47):29395-404.

360. Valentinova NV, Gu ZW, Yang M, Yanushevskaya E, Antonov I, Guyton J, Smith C, Gotto AM Jr, Yang C. Immunoreactivity of apolipoprotein B-100 in oxidatively modified low density lipoprotein. *Biol Chem Hoppe Seyler* 1994;375(10):651-8.
361. Xie Y-H, Yang M, Quion JA, Gotto AM Jr, Yang C-Y. Quantitative determination of lipoprotein particles containing apolipoprotein B and E in plasma by an enzyme-linked immunosorbent assay. *J Protein Chem* 1994;13(5):501-2.
362. Yang C-Y, Gu Z-W, Blanco-Vaca F, Gaskell SJ, Yang M, Massey JB, Gotto AM Jr, Pownall HJ. Structure of human apolipoprotein D: Locations of the intermolecular and intramolecular disulfide links. *Biochemistry* 1994;33(41):12451-5.
363. Yang C-Y, Gu Z-W, Yang M, Gotto AM Jr. Primary structure of apoB-100. *Chem Phys Lipids* 1994;67/68:99-104.
364. Yang C-Y, Valentinova NV, Yang M, Gu Z-W, Gotto AM Jr. Immunological approach to study the structure of oxidized low-density lipoproteins. *J Protein Chem* 1994;13:469-470.
365. Chen CH, Nguyen HH, Weilbaecher D, Luo S, Gotto AM Jr, Henry PD. Basic fibroblast growth factor reverses atherosclerotic impairment of human coronary angiogenesis-like responses in vitro. *Atherosclerosis* 1995;116(2):261-8.
366. de Andrade M; Thandi I; Brown S; Gotto A Jr.; Patsch W; Boerwinkle E. Relationship of the apolipoprotein E polymorphism with carotid artery atherosclerosis. *Am J Hum Genet* 1995 Jun;56(6):1379-90.
367. Patsch W, Gotto AM Jr. High-density lipoprotein cholesterol, plasma triglyceride, and coronary heart disease: pathophysiology and management. *Adv Pharmacol* 1995;32:375-426.
368. Soyol SM, Seelos C, Lin-Lee YC, Sanders S, Gotto AM Jr, Hachey DL, Patsch W. Thyroid hormone influences the maturation of apolipoprotein A-I messenger RNA in rat liver. *J Biol Chem* 1995;270(8):3996-4004.
369. Sparrow DA, Laplaud PM, Saboureau M, Zhou G, Dolphin PJ, Gotto AM Jr, Sparrow JT. Plasma lipid transport in the hedgehog: Partial characterization of structure and function of apolipoprotein A-I. *J Lipid Res* 1995;36(3):485-95.
370. Yang CY; Xie YH; Yang M; Quion JA; Gotto AM Jr. ELISA quantitation of apolipoproteins in plasma lipoprotein fractions: ApoE in ApoB-containing lipoproteins (Lp B:E) and ApoB in ApoE-containing lipoproteins (Lp E:B). *J Protein Chem* 1995 Oct;14(7):503-9.
371. Yeshurun D, Gotto AM Jr. Hyperlipidemia: perspectives in diagnosis and treatment. *South Med J* 1995;8(4):379-91.
372. Guevara J Jr.; Valentinova NV; Garcia O; Gotto AM; Yang CY; Legal S; Gaubatz J; Sparrow. Interaction of apolipoprotein[a] with apolipoproteinB-100 Cys3734 region in lipoprotein[a] is confirmed immunochemically. *J Protein Chem* 1996 Jan;15(1):17-25.

373. Hackman A, Abe Y, Insull W Jr, Pownall H, Smith L, Dunn K, Gotto AM Jr, Ballantyne CM. Levels of soluble cell adhesion molecules in patients with dyslipidemia. *Circulation* 1996;93(7):1334-8.
374. Jones PH, Pownall HJ, Patsch W, Herd JA, Farmer JA, Payton-Ross C, Kimball KT, Gotto AM, Morrisett JD. Effect of gemfibrozil on levels of lipoprotein[a] in type II hyperlipoproteinemic subjects. *Lipid Res* 1996 Jun;37(6):1298-308.
375. Lambert DA; Catapano AL; Smith LC; Sparrow JT; Gotto AM Jr. Effect of the apolipoprotein C-II/C-III ratio on the capacity of purified milk lipoprotein lipase to hydrolyse triglycerides in monolayer vesicles. *Atherosclerosis* 1996 Dec 20;127(2):205-12.
376. Mowri H-O, Patsch JR, Gotto AM Jr, Patsch W. Apolipoprotein A-II influences the substrate properties of human HDL2 and HDL3 for hepatic lipase. *Arterioscler Thromb Vasc Biol* 1996.;16(6):755-62.
377. Skender ML; Goodrick GK; Del Junco DJ; Reeves RS; Darnell L; Gotto AM; Foreyt. Comparison of 2-year weight loss trends in behavioral treatments of obesity: diet, exercise, and combination interventions. *J Am Diet Assoc* 1996 Apr;96(4):342-6.
378. West MS; Herd JA; Ballantyne CM; Pownall HJ; Simpson S; Gould L; Gotto AM Jr. The Lipoprotein and Coronary Atherosclerosis Study (LCAS): design, methods, and baseline data of a trial of fluvastatin in patients without severe hypercholesterolemia. *Control Clin Trials* 1996 Dec;17(6):550-83.
379. Teng BB; Ishida B; Forte TM; Blumenthal S; Song LZ; Gotto AM; Chan L. Effective lowering of plasma, LDL, and esterified cholesterol in LDL receptor-knockout mice by adenovirus-mediated gene delivery of ApoB mRNA editing enzyme (ApoBc1). *Arterioscler Thromb Vasc Biol* 1997 May;17(5):889-97.
380. Yang CY; Gu ZW; Yang HX; Yang M; Gotto AM; Smith CV. Oxidative modifications of apoB-100 by exposure of low density lipoproteins to HOCL in vitro. *Free Radic Biol Med* 1997;23(1):82-9.
381. Chen CH, Cartwright J Jr, Li Z, Luo S, Nguyen HH, Gotto AM Jr, Henry PD. Inhibitory effects of hypercholesterolemia and oxidized LDL on angiogenesis-like endothelial growth in rabbit aortic explants: essential role of basic fibroblast growth factor. *Arterioscler Thromb Vasc Biol* 1997;17(7):1303-12.
382. Herd JA, Ballantyne CM, Farmer JH, Ferguson JJ III, Jones PH, West MS, Gould KL, Gotto AM Jr. Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS]). *Am J Cardiol* 1997;80(3):278-86.
383. Downs JR, Beere PA, Whitney E, Clearfield M, Weis S, Rothen J, Stein EA, Shapiro DR, Langendorfer A, Gotto AM Jr. Design & rationale of the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). *Am J Cardiol* 1997;80(3):287-93.

384. Lambert DA, Catapano AL, Smith LC, Sparrow JT, Gotto AM Jr. A new fluorometric method for measuring the action of C apolipoproteins on milk lipoprotein lipase. *Clin Chim Acta* 1997;264(1):75-90.
385. Hwang SJ, Ballantyne CM, Sharrett AR, Smith LC, Davis CE, Gotto AM Jr, Boerwinkle E. Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk In Communities (ARIC) study. *Circulation* 1997;96(12):4219-25.
386. Gordon BR, Kelsey SF, Dau PC, Gotto AM Jr, Graham K, Illingworth DR, Isaacsohn J, Jones PH, Leitman SF, Saal SD, Stein EA, Stern TN, Troendle A, Zwiener RJ. Long-term effects of low-density lipoprotein apheresis using an automated dextran sulfate cellulose adsorption system. Liposorber Study Group. *Am J Cardiol* 1998;81(4):407-11.
387. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W, Gotto AM Jr. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. *JAMA* 1998;279(20):1615-22.
388. Ballantyne CM, Herd JA, Ferlic LL, Dunn JK, Farmer JA, Jones PH, Schein JR, Gotto AM Jr. Influence of low HDL on progression of coronary artery disease and response to fluvastatin therapy. *Circulation* 1999;99(6):736-43.
389. Pownall HJ, Brauchi D, Kilinc C, Osmundsen K, Pao Q, Payton-Ross C, Gotto AM Jr, Ballantyne CM. Correlation of serum triglyceride and its reduction by omega-3 fatty acids with lipid transfer activity and the neutral lipid compositions of high-density and low-density lipoproteins. *Atherosclerosis* 1999;143(2):285-97.
390. Pownall HJ, Ballantyne CM, Kimball KT, Simpson SL, Yeshurun D, Gotto AM Jr. Effect of moderate alcohol consumption on hypertriglyceridemia: a study in the fasting state. *Arch Intern Med* 1999;159(9):981-7.
391. Orlova EV, Sherman MB, Chiu W, Mowri H, Smith LC, Gotto AM Jr. Three-dimensional structure of low density lipoproteins by electron cryomicroscopy. *Proc Natl Acad Sci U S A* 1999;96(15):8420-5.
392. Gotto AM Jr, Whitney E, Stein EA, Shapiro DR, Clearfield M, Weis S, Jou JY, Langendorfer A, Beere PA, Watson DJ, Downs JR, de Cani JS. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). *Circulation* 2000;101(5):477-84.
393. Clearfield M, Whitney EJ, Weis S, Downs JR, Shapiro DR, Stein EA, Watson DJ, Langendorfer A, Beere PA, Stamler J, Gotto AM Jr. Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS): baseline characteristics and comparison with USA population. *J Cardiovasc Risk* 2000;7(2):125-33.
394. Gotto AM Jr, Whitney E, Stein EA, Shapiro DR, Clearfield M, Weis S, Jou JY, Langendorfer A, Beere PA, Watson DJ, Downs JR, de Cani JS. Application of National

Cholesterol Education Program and Joint European treatment criteria and clinical benefit in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). *Eur Heart J*. 2000 Oct;21(19):1627-33.

395. Gotto AM Jr, Boccuzzi SJ, Cook JR, Alexander CM, Roehm JB, Meyer GS, Clearfield M, Weis S, Whitney E, for the AFCAPS/TexCAPS Research Group. The effect of lovastatin on cardiovascular resource utilization and costs in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). AFCAPS/TexCAPS Research Group. *Am J Cardiol* 2000;86(11):1176-81.

396. Marian AJ, Safavi F, Ferlic L, Dunn JK, Gotto AM, Ballantyne CM. Interactions between angiotensin-I converting enzyme insertion/deletion polymorphism and response of plasma lipids and coronary atherosclerosis to treatment with fluvastatin: the lipoprotein and coronary atherosclerosis study. *J Am Coll Cardiol* 2000 Jan;35(1):89-95.

397. Han J, Hajjar DP, Tauras JM, Feng J, Gotto AM Jr, Nicholson AC. Transforming growth factor-beta1 (TGF-beta1) and TGF-beta2 decrease expression of CD36, the type B scavenger receptor, through mitogen-activated protein kinase phosphorylation of peroxisome proliferator-activated receptor-gamma. *J Biol Chem* 2000;275(2):1241-6.

398. Lambert DA, Smith LC, Pownall H, Sparrow JT, Nicolas JP, Gotto AM Jr. Hydrolysis of phospholipids by purified milk lipoprotein lipase. Effect of apoprotein CII, CIII, A and E, and synthetic fragments. *Clin Chim Acta* 2000;291(1):19-33.

399. Feng J, Han J, Pearce SF, Silverstein RL, Gotto AM Jr, Hajjar DP, Nicholson AC. Induction of CD36 expression by oxidized LDL and IL-4 by a common signaling pathway dependent on protein kinase C and PPAR-gamma. *J Lipid Res* 2000;41(5):688-96.

400. Ballantyne CM, Herd JA, Stein EA, Ferlic LL, Dunn JK, Gotto AM Jr, Marian AJ. Apolipoprotein E genotypes and response of plasma lipids and progression-regression of coronary atherosclerosis to lipid-lowering drug therapy. *J Am Coll Cardiol*. 2000 Nov 1;36(5):1572-8.

401. Elghannam H, Tavackoli S, Ferlic L, Gotto AM Jr, Ballantyne CM, Marian AJ. A prospective study of genetic markers of susceptibility to infection and inflammation, and the severity, progression, and regression of coronary atherosclerosis and its response to therapy. *J Mol Med* 2000;78(10):562-8.

402. Turban S, Fuentes F, Ferlic L, Brugada R, Gotto AM Jr, Ballantyne CM, Marian AJ. A prospective study of paraoxonase gene Q/R192 polymorphism and severity, progression and regression of coronary atherosclerosis, plasma lipid levels, clinical events and responses to fluvastatin. *Atherosclerosis* 2001;154(3):633-40.

403. Downs JR, Clearfield M, Tyroler HA, Whitney EJ, Kruyer W, Langendorfer A, Zagrebelsky V, Weis S, Shapiro DR, Beere PA, Gotto AM Jr. Air force/Texas coronary atherosclerosis prevention study (AFCAPS/TEXCAPS): additional perspectives on tolerability of long-term treatment with lovastatin. *Am J Cardiol* 2001;87(9):1074-9

404. Ridker PM, Rifai N, Clearfield M, Downs JR, Weis SE, Miles JS, Gotto AM Jr; Air Force/Texas Coronary Atherosclerosis Prevention Study Investigators. N Engl J Med 2001;344(26):1959-65.
405. Han J, Nicholson AC, Zhou X, Feng J, Gotto AM Jr, Hajjar DP. Oxidized low density lipoprotein decreases macrophage expression of scavenger receptor B-1 (SR-B-1). J Biol Chem 2001; 276(19):16567-72.
406. Lutucuta S, Ballantyne CM, Elghannam H, Gotto AM Jr, Marian AJ. Novel polymorphisms in promoter region of atp binding cassette transporter gene and plasma lipids, severity, progression and regression of coronary atherosclerosis and response to therapy. Circ Res 2001;88(9):969-73
407. Han J, Hajjar DP, Zhou X, Gotto AM Jr, Nicholson AC. Regulation of peroxisome proliferator-activated receptor-gamma-mediated gene expression. A new mechanism of action for high density lipoprotein. J Biol Chem 2002;277(26):23582-6.
408. Markle RA, Han J, Summers BD, Yokoyama T, Hajjar KA, Hajjar DP, Gotto AM Jr, Nicholson AC. Pitavastatin alters the expression of thrombotic and fibrinolytic proteins in human vascular cells. J Cell Biochem 2003;90(1):23-32.
409. Sun L, Nicholson AC, Hajjar DP, Gotto AM Jr, Han J. Adipogenic differentiating agents regulate expression of fatty acid binding protein and CD36 in the J744 macrophage cell line. J Lipid Res 2003;44(10):1877-86.
410. Chen S, Tsybouleva N, Ballantyne CM, Gotto AM Jr, Marian AJ. Effects of PPARalpha, gamma and delta haplotypes on plasma levels of lipids, severity and progression of coronary atherosclerosis and response to statin therapy in the lipoprotein coronary atherosclerosis study. Pharmacogenetics 2004;14(1):61-71.
411. Girman CJ, Rhodes T, Mercuri M, Pyorala K, Kjekshus J, Pedersen TR, Beere PA, Gotto AM, Clearfield M; 4S Group and the AFCAPS/TexCAPS Research Group. The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Am J Cardiol 2004;93(2):136-41.
412. Han J, Zhou X, Yokoyama T, Hajjar DP, Gotto AM Jr, Nicholson AC. Pitavastatin downregulates expression of the macrophage type B scavenger receptor, CD36. Circulation 2004;109(6):790-6.
413. Han J, Parsons M, Zhou X, Nicholson AC, Gotto AM Jr, Hajjar DP. Functional interplay between the macrophage scavenger receptor class B type I and pitavastatin (NK-104). Circulation 2004;110(22):3472-9.
414. Whitney EJ, Krasuski RA, Personius BE, Michalek JE, Maranian AM, Kolasa MW, Monick E, Brown BG, Gotto AM Jr. A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical events. Ann Intern Med 2005;142(2):95-104.

415. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, Gotto AM, Greten H, Kastelein JJ, Shepherd J, Wenger NK; Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. *N Engl J Med* 2005;352(14):1425-35.
416. Chen SN, Ballantyne CM, Gotto AM Jr, Tan Y, Willerson JT, Marian AJ. A common PCSK9 haplotype, encompassing the E670G coding single nucleotide polymorphism, is a novel genetic marker for plasma low-density lipoprotein cholesterol levels and severity of coronary atherosclerosis. *J Am Coll Cardiol* 2005;45(10):1611-9.
417. Clearfield M, Downs JR, Lee M, Langendorfer A, McConathy W, Gotto AM Jr. Implications from the Air Force/Texas Coronary Atherosclerosis Prevention Study for the Adult Treatment Panel III guidelines. *Am J Cardiol* 2005;96(12):1674-80.
418. Waters DD, LaRosa JC, Barter P, Fruchart JC, Gotto AM Jr, Carter R, Breazna A, Kastelein JJ, Grundy SM. Effects of high-dose atorvastatin on cerebrovascular events in patients with stable coronary disease in the TNT (Treating to New Targets) study. *J Am Coll Cardiol* 2006;48(9):1793-9.
419. Nicholson AC, Hajjar DP, Zhou X, He W, Gotto AM Jr, Han J. Anti-adipogenic action of pitavastatin occurs through the coordinate regulation of PPAR γ and Pref-1 expression. *Br J Pharmacol* 2007;151(6):807-15.
420. Barter P, Gotto AM Jr, LaRosa JC, Maroni J, Szarek M, Grundy SM, Kastelein JJ, Bittner V, Fruchart JC; Treating to New Targets Investigators. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. *N Engl J Med* 2007;357(13):1301-10.
421. Ridker PM, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Khurmi NS, Koenig W, Libby P, Lorenzatti AJ, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ; JUPITER Trial Study Group. Baseline characteristics of participants in the JUPITER trial, a randomized placebo-controlled primary prevention trial of statin therapy among individuals with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein. *Am J Cardiol* 2007;100(11):1659-64.
422. Zhou X, He W, Huang Z, Gotto AM Jr, Hajjar DP, Han J. Genetic deletion of low density lipoprotein receptor impairs sterol-induced mouse macrophage ABCA1 expression. A new SREBP1-dependent mechanism. *J Biol Chem* 2008;283(4):2129-38.
423. Huang Z, Zhou X, Nicholson AC, Gotto AM Jr, Hajjar DP, Han J. Activation of peroxisome proliferator-activated receptor- α in mice induces expression of the hepatic low-density lipoprotein receptor. *Br J Pharmacol* 2008;155(4):596-605.
424. Ridker PM, Danilson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ; JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. *N Engl J Med* 2008;359(21):2195-207.

425. Chen SN, Ballantyne CM, Gotto AM Jr, Marian AJ. The 9p21 susceptibility locus for coronary artery disease and the severity of coronary atherosclerosis. *BMC Cardiovasc Disord* 2009;9:3.
426. Lamon BD, Summers BD, Gotto AM Jr, Hajjar DP. Pitavastatin suppresses mitogen activated protein kinase-mediated Erg-1-induction in human vascular smooth muscle cells. *Eur J Pharmacol* 2009;606(1-3):72-76.
427. Glynn RJ, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, Mafadyen JG, Nordestgaard BG, Shepard J, Willerson JT, Ridker PM. A Randomized Trial of Rosuvastatin in the Prevention of Venous Thromboembolism. *N Engl J Med* 2009;360(18):1851-61.
428. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, Macfadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ, JUPITER Trial Study Group. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. *Lancet*. 2009;373(9670): 1175-82.
429. Nakaya H, Summers BD, Nicholson AC, Gotto AM Jr, Hajjar DP, Han J. Atherosclerosis in LDLR-knockout mice is inhibited, but not reversed, by the PPARgamma ligand pioglitazone. *Am J Pathol*. 2009;174(6):2007-14.
430. Cannon CP, Danksy HM, Davidson M, Gotto AM Jr, Brinton EA, Gould AL, et al. Design of the DEFINE trial: determining the Efficacy and tolerability of CETP INhibition with AnacEtrapib. *Am Heart J* 2009;158(4):513-519.
431. Chen SN, Cilingiroglu M, Todd J, Lombardi R, Willerson JT, Gotto AM Jr, Ballantyne CM, Marian AJ. Candidate genetic analysis of plasma high-density lipoprotein-cholesterol and severity of coronary atherosclerosis. *BMC Med Genet* 2009;10:111.
432. Ridker PM, MacFadyen JG, Fonseca FA, Genest J, Gotto AM, et al. Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER). *Circ Cardiovasc Qual Outcomes* 2009;2(6):616-23.
433. Brugts JJ, Yetgin T, Hoeks SE, Gotto AM, Shepherd J, Westendorp RG, de Craen AJ, Knopp RH, Nakamura H, Ridker P, van Domburg R, Deckers JW. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomized controlled trials. *BMJ* 2009;338(301):b2376.
434. Cui Y, Watson DJ, Girman CJ, Shapiro DR, Gotto AM, Hiserote P, Clearfield MB. Effects of increasing high-density lipoprotein cholesterol and decreasing low-density lipoprotein cholesterol on the incidence of first acute coronary events (from the Air Force/Texas Coronary Atherosclerosis Prevention Study). *Am J Cardiol* 2009;104(6):829-34.
435. Kizer JR, Madias C, Wilner B, Vaughan CJ, Mushlin AI, Trushin P, Gotto AM Jr, Pasternak RC. Relation of different measures of low-density lipoprotein cholesterol to risk of

coronary artery disease and death in a meta-regression analysis of large-scale trials of statin therapy. *Am J Cardiol* 2010;105(9):1289-96.

436. Sattar N, Preiss D, Murray HM, Welsh P, Buckley DM, de Craen AJ, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomized statin trials. *Lancet* 2010;375(9716):735-42.

437. Ridker PM, Genest J, Boekholdt SM, Libby P, Gotto AM, Nordestgaard BG, Mora S, MacFayden JG, Glynn RJ, Kastelein JJ; JUPITER Trial Study Group. HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial. *Lancet* 2010;376(9738):333-9.

438. Cannon CP, Shah S, Dansky HM, Davidson M, Brinton EA, Gotto AM, et al. Safety of anacetrapib in patients with or at high risk for coronary heart disease. *N Engl J Med* 2010.

439. Boekholdt SM, Arsenault BJ, Mora S, Pedersen TR, LaRosa JC, Nestel PJ, et al. Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis. *JAMA* 2012;307(12):1302-9.

440. Davidson M, Liu SX, Barter P, Brinton EA, Cannon CP, Gotto AM Jr, et al. Measurement of LDL-C after treatment with the CETP inhibitor anacetrapib. *J Lipid Res* 2013;54(2):467-72.

441. Ní Chróinín D, Asplund K, Asberg S, Callaly E, Cuadrado-Godia E, Díez-Tejedor E, Di Napoli M, Engelter ST, Furie KL, Giannopoulos S, Gotto AM Jr, et al. Statin therapy and outcome after ischemic stroke: systematic review and meta-analysis of observational studies and randomized trials. *Stroke* 2013;44(2):448-56.

171. Boekholdt SM, Arsenault BJ, Hovingh GK, Mora S, Pedersen TR, Larosa JC, Welch KM, Amarenco P, Demicco DA, Tonkin AM, Sullivan DR, Kirby A, Colhoun HM, Hitman GA, Betteridge DJ, Durrington PN, Clearfield MB, Downs JR, Gotto AM Jr, Ridker PM, Kastelein JJ. Levels and changes of HDL cholesterol and apolipoprotein A-I in relation to risk of cardiovascular events among statin-treated patients: a meta-analysis. *Circulation* 2013;128(14):1504-12.

172. Savarese G, Gotto AM Jr, Paolillo S, D'Amore C, Losco T, Musella F, Scala O, Marciano C, Ruggiero D, Marsico F, De Luca G, Trimarco B, Perrone-Filardi P. Benefits of statins in elderly subjects without established cardiovascular disease: a meta-analysis. *J Am Coll Cardiol* 2013;62(22):2090-9.

173. Gotto AM Jr, Cannon CP, Li XS, Vaidya S, Kher U, Brinton EA, Davidson M, Moon JE, Shah S, Dansky HM, Mitchel Y, Barter P; DEFINE Investigators. Evaluation of lipids, drug concentration, and safety parameters following cessation of treatment with the cholesteryl ester transfer protein inhibitor anacetrapib in patients with or at high risk for coronary heart disease. *Am J Cardiol* 2014;113(1):76-83.

174. Abou Ziki MD, Strulovici-Barel Y, Hackett NR, Rodriguez-Flores JL, Mezey JG, Salit J, Radisch S, Hollmann C, Chouchane L, Malek J, Zirie MA, Jayyousi A, Gotto AM Jr, Crystal

RG. Prevalence of the Apolipoprotein E Arg145Cys Dyslipidemia At-Risk Polymorphism in African-Derived Populations. *Am J Cardiol* 2014;113(2):302-8.

Review Articles

1. Gotto AM Jr. Recent studies on the structure of human serum low- and high-density lipoproteins. *Proc Natl Acad Sci U S A* 1969;64(3):1119-1127.
2. Gotto AM Jr. Recognition and management of the hyperlipoproteinemias. *Heart Lung* 1972;1:508-518.
3. Gotto AM Jr. Hyperlipoproteinemia-1972. *Cardiovasc Res Cent Bull* 1972;2:3-20.
4. Gotto AM Jr. Review of Treatment of the Hyperlipidemic States. *Am Rev Respir Dis* 1973;107:310-321.
5. Gotto AM Jr. Type V hyperlipoproteinemia. *Clin Endocrinol Metab* 1973;2(1):11-39.
6. Gotto AM Jr, Scott LW. Dietary aspects of hyperlipidemia. *J Am Diet Assoc* 1973;62(6):617-625.
7. Gotto AM Jr, Scott LW, Manis E. Prudent eating after 40. Relationship of diet to blood lipids and coronary heart disease. *Geriatrics* 1974;29:109-114.
8. Jackson RL, Gotto AM Jr. Phospholipids in biology and medicine. *N Engl J Med* 1974;290(1):24-29.
9. Jackson RL, Gotto AM Jr. The biochemistry of atherosclerosis. II *Progresso Medico* 1974;30:761-780.
10. Morrisett JD, Jackson RL, Gotto AM Jr. Lipoproteins: Structure and function. *Annu Rev Biochem* 1975;44:183-207.
11. Jackson RL, Gotto AM Jr. Hypothesis concerning membrane structure, cholesterol and atherosclerosis. *Atherosclerosis Reviews* 1976;1:1-21.
12. Jackson RL, Morrisett JD, Gotto AM Jr. Lipoprotein structure and metabolism. *Physiol Rev* 1976;56(2):259-316.
13. Segura R, Gotto AM Jr. Lipid and lipoprotein abnormalities in renal disease. *Perspect Nephrol Hypertens* 1976;3:159-200.
14. Yeshurun D, Gotto AM Jr. Drug treatment of hyperlipidemia. *Am J Med* 1976;60(3):379-96.
15. Gotto AM Jr. Lipid-binding studies in the human plasma lipoproteins: Potential clinical application for prevention of atherosclerosis. *J Japan Athero Soc* 1977;5:17-26.

16. Gotto AM Jr, Jackson RL. Plasma lipoproteins: Recent developments. *Adv Exp Med Biol* 1977;82:15-33.
17. Jackson RL, Smith LC, Taunton OD, Gotto AM Jr. Familial hypercholesterolemia: Diagnosis, metabolic defect and management. *Life Sci* 1977;21(10):1395-402.
18. Morrisett JD, Jackson RL, Gotto AM Jr. Lipid-protein interactions in the plasma lipoproteins. *Biochim Biophys Acta* 1977;472(2):93-133.
19. Gotto AM Jr. The plasma lipoproteins: Current concepts of metabolism and structure with clinical implications. *Adv Exp Med Biol* 1978;104:61-76.
20. Gotto AM Jr. Should hyperlipidemia be treated? Available agents and clinical results. *Cardiovasc Res Cent Bull* 1978;17(1):3-27.
21. Gotto AM Jr. Hyperlipidemia: Finding the patient at risk. *Mod Med* 1978;46:62-74.
22. Gotto AM Jr. Drug treatment of hyperlipidemias. *Mod Med* 1978;46:92-101.
23. Gotto AM Jr, Foreyt JP, Scott LW. Dietary and behavioral treatment of hyperlipidemia. *Compr Ther* 1978;4(10):40-8.
24. Gotto AM Jr, Jackson RL. Plasma lipoproteins and atherosclerosis. *Atherosclerosis Reviews* 1978;3:231-242.
25. Gotto AM Jr, Nichols BL, Scott LW, Foreyt JP, Jackson RL. Obesity: Risk factor no. 1. *Heart Lung* 1978;7:132-136.
26. Gotto AM Jr, O'Malley MP, Scott LW, Foreyt JP. Diet and heart disease. In: Baylor College of Medicine cardiology series. Northfield, Ill. Medical Communications, 1978.
27. Foreyt JP, O'Malley MP, Scott LW, Gotto AM Jr. Behavior modification for dietary change. *Health Values* 1978;2:316-8.
28. Jackson RL, Taunton OD, Morrisett JD, Gotto AM Jr. The role of dietary polyunsaturated fat in lowering blood cholesterol in man. *Circ Res* 1978;42(4):447-453.
29. O'Malley MP, Scott LW, Foreyt JP, Gotto AM Jr. Diet and heart disease: The basic concept. *Health Values* 1978;2:263-5.
30. Smith LC, Pownall HJ, Gotto AM Jr. The plasma lipoproteins: Structure and metabolism. *Annu Rev Biochem* 1978;47:751-7.
31. Gotto AM Jr. Is atherosclerosis reversible? *J Am Diet Assoc* 1979;74(5):551-7.
32. Gotto AM Jr. Status report: Plasma lipids, lipoproteins, and coronary artery disease. *Atherosclerosis Reviews* 1979;4:17-28.

33. Gotto AM Jr, Silvers A. Clinical studies of the genetic hypolipoproteinemias. *Prev Med* 1979;8:684-687.
34. Pownall HJ, Morrisett JD, Sparrow JT, Smith LC, Shepherd J, Jackson RL, Gotto AM Jr. A review of the unique features of HDL apoproteins. *Lipids* 1979;14(4):428-34.
35. Foreyt JP, Gotto AM Jr. Behavioral treatment of obesity. *Atherosclerosis Reviews* 1979;6:179-201.
36. Gotto AM Jr, Foreyt JP, Scott LW. Hyperlipidemia and nutrition: Ongoing work. *Atherosclerosis Reviews* 1980;7:169-201.
37. Gotto AM Jr, Wittels EH. What's new: Arguments for and against the treatment of hyperlipidemia. *Tex Med* 1980;76:38-42.
38. Catapano A, Gotto AM Jr. [Apo-C-II and lipoprotein lipase: Research methods, functions, and clinical significance.] *Clinica e Laboratorio* 1980;4:27-40.
39. Foreyt JP, Scott LW, O'Malley MP, Gotto AM Jr. Diet modification: An example of behavioral medicine. *Natl Forum* 1980;59:9-13.
40. Sparrow JT, Gotto AM Jr. Phospholipid binding studies with synthetic apolipoprotein fragments. *Ann N Y Acad Sci* 1980; 348:187-211.
41. Gotto AM Jr. Controlling cardiovascular risk factors: How to lower lipids with drugs and diet. *Mod Med* 1981:90-108.
42. Foreyt JP, Goodrick GK, Gotto AM Jr. Limitations of behavioral treatment of obesity: Review and analysis. *J Behav Med* 1981;4(2):159-74.
43. Patsch JR, Gotto AM Jr. The high density lipoproteins. *Expos Annu Biochim Med* 1982;35:1-12.
44. Sparrow JT, Gotto AM Jr. Apolipoprotein/lipid interactions: Studies with synthetic polypeptides. *CRC Crit Rev Biochem* 1982;13:87-107.
45. Gotto AM Jr. High-density lipoproteins: biochemical and metabolic factors. *Am J Cardiol* 1983;52(4):2B-4B
46. Gotto AM Jr. Clinical diagnosis of hyperlipoproteinemia. *Am J Med* 1983;74:5-9.
47. Gotto AM Jr, Doody MC. The transport of plasma lipids: basic and clinical research and relationship to coronary heart disease. *Cardiovasc Res Cent Bull* 1983;21(3):69-86.
48. Foreyt JP, Gotto AM Jr. Behavioral strategies for losing weight. *Consultant* 1983;23:200-15.
49. Gotto AM Jr. Lipids, lipoproteins, and apolipoproteins: Biological end points and means of intervention. *Atherosclerosis reviews* 1984;12:87-101.

50. Gotto AM Jr. Chelation therapy in 1984. *Tex Med* 1984;80(2):36-7.
51. Gotto AM Jr. Directions of atherosclerosis research in the 1980s and 1990s. *Circulation* 1984;70(5 Pt 2):III88-94.
52. Gotto AM Jr, Scott LW, Foreyt JP. Diet and health. *West J Med* 1984;141(6):872-7.
53. Jones P, Gotto AM Jr. Drug treatment of hyperlipidemia. *Modern Concepts of Cardiovascular Disease* 1984;53:53-8.
54. Ingersoll RW, Weinberg AD, Gotto AM Jr, DeBakey ME. Linking biomedical research to prevention in the community. *Health Values* 1984;8(3):3-6.
55. Gotto AM Jr. Classification and structure of lipoproteins. *Am J Cardiol* 1985;56(18):J2-J4.
56. Gotto AM Jr. Some reflections on arteriosclerosis: Past, present, and future. *Circulation* 1985;72(1):8-17.
57. Gotto AM Jr. Treatment of hyperlipidemia. *Am J Cardiol* 1986;57(14):11G-16G.
58. Gotto AM Jr. Interactions of the major risk factors for coronary heart disease. *Am J Med* 1986;80(2A):48-55.
59. Gotto AM Jr, Jones PH, Scott LW. The diagnosis and management of hyperlipidemia. *Dis Mon* 1986;32(5):245-311.
60. Gotto AM Jr, Pownall HJ, Havel RJ. Introduction to the plasma lipoproteins. *Methods Enzymol* 1986;128:3-41.
61. Gotto AM Jr. Hypercholesterolemia: An assessment of screening and diagnostic techniques. *Mod Med* 1987;55:28-32.
62. Gotto AM Jr. Hypercholesterolemia: Implications of drug and diet therapy. *Mod Med* 1987;55:38-44.
63. Gotto AM Jr, Wittels E. The family history in health care evaluation. *Health Values* 1987;11:25-9.
64. Bolli R, Gotto AM Jr. Coronary bypass surgery When should it be recommended? *Heartbeat* 1987;8-10.
65. DeBakey ME, Gotto AM Jr, Scott LW, Foreyt JP. Diet, nutrition and heart disease. *J Am Diet Assoc* 1987;86:729-731.
66. Gotto AM Jr. The lipid hypothesis. *Beitr Infusionsther* 1988;23:1-7.
67. Gotto AM Jr. Lipoprotein metabolism and the etiology of hyperlipidemia. *Hosp Pract (Off Ed)* 1988;23 Supp 1:4-13.

68. Assmann G, Davignon J, Fernandez-Cruz A, Gotto AM Jr, Jacotot B, Lewis B, Paoletti R. [Detection and treatment of lipid disorders]. *Rev Clin Esp* 1988;183(8):433-41.
69. Assmann G, Davignon J, Fernandez-Cruz A, Gotto AM Jr, Jacotot B, Lewis B, Paoletti R. [HDL cholesterol profile in 1988]. *Rev Clin Esp* 1989;184(8):421-30.
70. Assmann G, Davignon J, Fernandez CA, Gotto AM Jr, Jacotot B, Lewis B, Paoletti R. [Non-pharmacologic treatment of hyperlipidemia: diet and exercise]. *Rev Clin Esp* 1989;185(3):153-61.
71. Assmann G, Davignon J, Fernandez-Cruz A, Gotto AM, Jacotot B, Lewis B, Paoletti R. [Women and ischemic cardiopathy]. *Rev Clin Esp* 1989;185(6):308-15.
72. Patsch W, Patsch JR, Gotto AM Jr. The hyperlipoproteinemias. *Med Clin North Am* 1989;73(4):859-93.
73. Gotto AM Jr. Apolipoproteins and metabolism in atherosclerosis. *Trans Am Clin Climatol Assoc* 1990;101:46-58.
74. Gotto AM Jr. Interrelationship of triglycerides with lipoproteins and high-density lipoproteins. *Am J Cardiol* 1990;66(6):20A-23A.
75. Gotto AM Jr. Calcium channel blockers and the prevention of atherosclerosis. *Am J Hypertens* 1990;3(12 Pt 2):342S-346S.
76. Assmann G, Davignon J, Fernandez-Cruz A, Gotto AM Jr, Jacotot B, Lewis B, Paoletti R. [Children and dyslipemia]. *Rev Clin Esp* 1990;186(4):178-86.
77. LaRosa JC, Hunninghake D, Bush D, Criqui MH, Getz GS, Gotto AM Jr, Grundy SM, Rakita L, Robertson RM, Weisfeldt ML, et al. The cholesterol facts. A summary of the evidence relating dietary fats, serum cholesterol, and coronary heart disease. A joint statement by the AHA and the NHLBI. The Task Force on Cholesterol Issues, AHA. *Circulation* 1990;81(5):1721-33.
78. Gotto AM Jr, Patsch J, Yamamoto A. Postprandial hyperlipidemia. *Am J Cardiol* 1991;68(3):11A-12A.
79. Gotto AM Jr. Hypercholesterolemia: new findings and clinical applications. Introduction. *Am J Med* 1991;91(1B):1S-2S.
80. Gotto AM Jr. Regression in atherosclerosis. *Cardiovasc Risk Fact* 1992;2:215-17.
81. Gotto AM Jr. Primary and secondary prevention of coronary artery disease. *Curr Opin Cardiol* 1992;7(4):553-62.
82. Gotto AM Jr. Hypertriglyceridemia: risks and perspectives. *Am J Cardiol* 1992;70(19):19H-25H.
83. Rifkind BM, Gotto AM Jr. U.S.A. perspective. *Int J Cardiol* 1992;37(Suppl 1):S28 -S30.

84. Stein Y, Gotto AM Jr. A symposium: triglycerides as a vascular risk factor: a global forum. Introduction. *Am J Cardiol* 1992;70(19):1H-2H.
85. Gotto AM Jr. Overview of current issues in management of dyslipidemia. *Am J Cardiol* 1993;71(6):3B-8B.
86. Gotto AM Jr. Implications for the present and directions for the future. *Mod Med* 1993;61(Suppl 2):16-18.
87. Gotto AM Jr. A symposium: Antioxidants and lipid metabolism: Introduction. *Am J Cardiol* 1993;71(Suppl B):37-42.
88. Patsch W, Gotto AM Jr. The clinical importance and management of hypertriglyceridemia. *Contemporary Internal Medicine* 1993;25:37-53.
89. Gotto AM Jr. Heart disease in the assessment and treatment of hypercholesterolemia: coronary artery disease and other atherosclerotic disease, family history, and left ventricular hypertrophy. *Am J Med* 1994;96(6A):9S-18S.
90. Gotto AM Jr. The Second International Conference on Lipoprotein[a]: Preface. *Chem Phys Lipids* 1994;67-68:1-8.
91. Gotto AM Jr. Cholesterol levels in young adults: Screen and intervene? *Hosp Pract (Off Ed)* 1994;29(3):109-10, 115-6.
92. Gotto AM Jr, Ballantyne CM. Introduction to: Debate Dietary treatment of hyperlipidemia. *J Cardiovasc Risk* 1994;1:283.
93. Ballantyne CM, Chan L, Guevara J Jr, Morrisett JD, Mims MP, Gotto AM Jr. Recent advances in lipoprotein and atherosclerosis research at Baylor College of Medicine. Apolipoprotein B, lipoprotein[a], and transplantation arteriopathy. *Tex Heart Inst J* 1994;21(1):48-55.
94. Farmer JA, Gotto AM Jr. Antihyperlipidaemic agents: Drug interactions of clinical significance. *Drug Saf* 1994;11(5):301-9.
95. Jones PH, Gotto AM Jr. Prevention of coronary heart disease in 1994: evidence for intervention. *Heart Dis Stroke* 1994;3(6):290-6.
96. Leibovitch MD, Gotto AM Jr. Don't underestimate the significance of elevated triglyceride levels. *Mod Med* 1994;62:32-43.
97. Gotto AM Jr. Lipid risk factors and the regression of atherosclerosis. *Am J Cardiol* 1995;76(2):3A-7A.
98. Gotto AM Jr. Effects of pravastatin in heart transplant recipients: Implications of Kobashigawa et al. *Curr Opin Lipidol* 1995;6(6):341-3.

99. Gotto AM Jr. Reduction of coronary events: evidence from clinical trials. *Curr Opin Lipidol* 1995;6(6):345-7.
100. Gotto AM Jr. Lipid risk factors and the regression of atherosclerosis. *Am J Cardiol* 1995;76(2):3A-7A.
101. Gotto AM Jr. Lipid lowering, regression, and coronary events. A review of the Interdisciplinary Council on Lipids and Cardiovascular Risk Intervention, Seventh Council meeting. *Circulation* 1995;92(3):646-56.
102. Farmer JA; Gotto AM Jr. Currently available hypolipidaemic drugs and future therapeutic developments. *Baillieres Clin Endocrinol Metab* 1995;9(4):825-47.
103. Herd JA; Gotto AM Jr. Does post-menopausal hormone-replacement therapy increase risk for breast cancer? A perspective on the findings of the Nurses' Health Study. *Pharmacol Res* 1995;32(6):331-3.
104. Jones PH, Gotto AM Jr. Extending the benefit of lipid-regulating therapy to primary prevention. *Am J Cardiol* 1995;76(9):118C-121C.
105. Farmer JA; Gotto AM Jr. Clinical investigations of the arrest and reversal of coronary artery disease. *Coron Artery Dis* 1995;6(6):457-65.
106. Smith SC Jr, Blair SN, Criqui MH, Fletcher GF, Fuster V, Gersh BJ, Gotto AM Jr, Gould KL, Greenland P, Grundy SM, Hill MN, Hlatky MA, Houston-Miller N, Krauss RM, LaRosa J, Ockene IS, Oparil S, Pearson TA, Rapaport E, Starke RD; the Secondary Prevention Panel. Consensus Panel Statement. Preventing heart attack and death in patients with coronary disease. *Circulation* 1995;92(1):2-4 and *J Am Coll Cardiol* 1995;26(1):292-4 and *Cardiovasc Nurs* 1996;32(4):26-8.
107. Gotto AM Jr. Lipid-regulating and antiatherosclerotic therapy: current options and future approaches. *Cleve Clin J Med* 1996;63(1):31-41.
108. Gotto AM Jr. Lipid lowering and coronary risk. *Isr J Med Sci* 1996;32(6):355-9.
109. Gotto AM Jr. Lipid-lowering trials: what have they taught us about morbidity and mortality? *Cardiology* 1996;87(6):453-7.
110. Gotto AM Jr. HMG-CoA reductase inhibitors: issues in assessing their benefits in coronary heart disease. *Drug Saf* 1996 Jan;14(1):8-10.
111. Farmer JA; Gotto AM Jr. Choosing the right lipid-regulating agent. A guide to selection. *Drugs* 1996;52(5):649-61.
112. Farmer JA; Gotto AM Jr. Current and future therapeutic approaches to hyperlipidemia. *Adv Pharmacol* 1996;35:79-114.
113. Fuster V, Gotto AM Jr, Libby P, Loscalzo J, McGill HC Jr. Task Force 1. Pathogenesis of coronary disease: the biologic role of risk factors. *J Am Coll Cardiol* 1996;27(5):964-976.

114. Patsch W, Gotto AM Jr. Apolipoproteins: pathophysiology and clinical implications. *Methods Enzymol* 1996;263:3-32.
115. Gotto AM Jr. The case for aggressive lipid regulation. *Hosp Pract (Minneap)* 1997;32(2):145-9, 155-6.
116. Ballantyne CM, Herd JA, Dunn JK, Jones PH, Farmer JA, Gotto AM Jr. Effects of lipid lowering therapy on progression of coronary and carotid artery disease. *Curr Opin Lipidol* 1997;8(6):354-61.
117. Gotto AM Jr. Cholesterol management in theory and practice. *Circulation* 1997;96(12):4424-30.
118. Gotto AM Jr. Assessing the benefits of lipid-lowering therapy. *Am J Cardiol* 1998;82(6A):2M-4M.
119. Gotto AM Jr. Triglyceride as a risk factor for coronary artery disease. *Am J Cardiol* 1998;82(9A):22Q-25Q.
120. Gotto AM Jr, Grundy SM. Lowering LDL cholesterol: questions from recent meta-analyses and subset analyses of clinical trial DataIssues from the Interdisciplinary Council on Reducing the Risk for Coronary Heart Disease, ninth Council meeting. *Circulation* 1999;99(8):E1-7.
121. Gotto AM. Current Advances in Therapy with HMG-CoA Reductase Inhibitors. *The Economics of Neuroscience*. 1999;1(1):46-50.
122. Steinberg D, Gotto AM Jr. Preventing coronary artery disease by lowering cholesterol levels: fifty years from bench to bedside. *JAMA*. 1999;282(21):2043-50.
123. Vaughan CJ, Gotto AMG Jr, Basson CT. The evolving role of statins in the management of atherosclerosis. *J Am Coll Cardiol* 2000;35(1):1-10.
124. Fuster V, Gotto AM Jr. Risk reduction. *Circulation*. 2000;102(20 Suppl 4):IV94-IV102.
125. Hunninghake DB, McKenney JM, Gotto AM Jr, Mehta JL, Jone PH. Roundtable discussion. Achieving more aggressive low-density lipoprotein cholesterol lowering. *Am J Manag Care* 2000;6(19 Suppl):S1008-16.
126. Gotto AM Jr. Insights on treating an over-the-counter-type subgroup: data from the Air Force/Texas Coronary Atherosclerosis Prevention Study Population. *Am J Cardiol* 2000;85(12A):8E-14E.
127. Gotto AM Jr, Olsson AG. Introduction. *Am J Cardiol*. 2001;87(5 Suppl 1):1.
128. Gotto AM Jr. Statin therapy: where are we? Where do we go next? *Am J Cardiol* 2001;87(5A):13B-18B.

129. Gotto AM Jr. Primary prevention of coronary heart disease: where do we go from here? *Arch Intern Med* 2001;161(7):922-4.
130. Gotto AM Jr. Low high-density lipoprotein cholesterol as a risk factor in coronary heart disease: a working group report. *Circulation* 2001; 103(17):2213-8.
131. Gotto AM Jr. High-density lipoprotein cholesterol: an updated view. *Curr Opin Pharmacol* 2001;1(2):109-12.
132. Gotto AM Jr. Emerging perspectives on lipid management: international approaches and global challenges. *Am J Cardiol* 2001;88(8):876-81.
133. Gotto AM Jr. Ongoing clinical trials of statins. *Am J Cardiol* 2001;88(4A):36F-40F.
134. Gotto AM Jr. How do we achieve optimal cardiovascular risk reduction? *Clin Cardiol* 2001;24(8 Suppl):III8-12.
135. Hirsch AT, Gotto AM Jr. Undertreatment of dyslipidemia in peripheral arterial disease and other high-risk populations: an opportunity for cardiovascular disease reduction. *Vasc Med* 2002;7(4):323-31.
136. Gotto AM Jr. High-density lipoprotein cholesterol and triglycerides as therapeutic targets for preventing and treating coronary artery disease. *Am Heart J* 2002;144(6 Pt 2):S33-42.
137. Gotto AM Jr, Paoletti R. New options in lipid management – can we extend the benefits of current therapy? Introduction. *Am Heart J* 2002;144(6 Pt 2):S19-20.
138. Gotto AM Jr. Treating hypercholesterolemia: looking forward. *Clin Cardiol* 2003;26(1 Suppl 1):I21-8.
139. Gotto AM Jr. Antioxidants, statins, and atherosclerosis. *J Am Coll Cardiol* 2003;41(7):1205-10.
140. Gotto AM Jr. Risks and benefits of continued aggressive statin therapy. *Clin Cardiol* 2003;26(4 Suppl 3):III3-12.
141. Farmer JA, Gotto AM Jr. The Heart Protection Study: expanding the boundaries for high-risk coronary disease prevention. *Am J Cardiol* 2003;92(1A):3i-9i.
142. Hajjar DP, Gotto AM Jr. Targeting CD36: modulating inflammation and atherogenesis. *Curr Atheroscler Rep* 2003;5(3):155-6
143. Gotto AM Jr, Brinton EA. Assessing low levels of high-density lipoprotein cholesterol as a risk factor in coronary heart disease: a working group report and update. *J Am Coll Cardiol* 2004;43(5):717-24.
144. LaRosa JC, Gotto AM Jr. Past, present, and future standards for management of dyslipidemia. *Am J Med* 2004;116 Suppl 6A:3S-8S.

145. Paoletti R, Gotto AM Jr, Hajjar DP. Inflammation in atherosclerosis and implications for therapy. *Circulation* 2004;109(23 Suppl 1):III20-6.
146. Assmann G, Gotto AM Jr. HDL cholesterol and protective factors in atherosclerosis. *Circulation* 2004;109(23 Suppl 1):III8-14.
147. Vaughan CJ, Gotto AM Jr. Update on statins: 2003. *Circulation* 2004;110(7):886-92.
148. Gotto AM Jr. The case for over-the-counter statins. *Am J Cardiol* 2004;94(6):753-6.
149. Gotto AM Jr. Review of primary and secondary prevention trials with lovastatin, pravastatin, and simvastatin. *Am J Cardiol* 2005;96(5A):34F-38F.
150. Gotto AM Jr. Evolving concepts of dyslipidemia, atherosclerosis, and cardiovascular disease: the Louis F. Bishop Lecture. *J Am Coll Cardiol* 2005;46(7):1219-24.
151. Gotto AM Jr, LaRosa JC. The benefits of statin therapy—what questions remain? *Clin Cardiol* 2005;28(11):499-503.
152. Gotto AM Jr. Statins, cardiovascular disease, and drug safety. *Am J Cardiol* 2006;97(8A):3C-5C.
153. Gotto AM Jr, Farmer JA. Drug insight: the role of statins in combination with ezetimibe to lower LDL cholesterol. *Nat Clin Pract Cardiovasc Med* 2006;3(12):664-72.
154. Gotto AM Jr, Blackburn GL, Daily GE 3rd, Garber AJ, Grundy SM, Sobel BE, Weir MR. The metabolic syndrome: a call to action. *Coron Artery Dis* 2006;17(1):77-80.
155. Gotto AM Jr. Role of C-reactive protein in coronary risk reduction: focus on primary prevention. *Am J Cardiol* 2007;99:718-25. Erratum in: *Am J Cardiol* 2007;100(4):746.
156. Gotto AM Jr. Cardiologist's role in improving glucose control and global cardiovascular risk in patients with type 2 diabetes mellitus. *Am J Cardiol* 2007;99(4A):3B-5B.
157. Gotto, AM Jr. Establishing the benefit of statins in low-to-moderate—risk primary prevention: the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). *Atheroscler Suppl* 2007;8(2):3-8.
158. Matsuzawa Y, Kita T, Shepherd J, Gotto AM Jr, Nakamura H, Sacks FM, Oikawa S, Sasaki J. A trilogy of primary prevention statin trials. Panel discussion. *Atheroscler Suppl* 2007;8(2):19-24.
159. Metroka CE, Truong P, Gotto AM Jr. Treatment of HIV-associated dyslipidemia: a role for omega-3 fatty acids. *AIDS Read* 2007;17(7):362-4, 367-73.
160. Gotto AM, Moon J. Pitavastatin for the treatment of primary hyperlipidemia and mixed dyslipidemia. *Expert Rev Cardiovasc Ther* 2010;8(8):1079-90.

161. Roberts WC, Gotto AM Jr, Guyton J, LaRosa J, Viggiani R. The editor's roundtable: Closing the clinical practice gap—using evidence-based treatments for managing lipids. *Am J Cardiol* 2011;107(2):230-42.
162. Friedewald VE, Ballantyne CM, Davidson MH, Gotto AM Jr, Ridker PM, Roberts WC. The Editor's Roundtable: JUPITER Follow-Up. *Am J Cardiol* 2011;107(10):1549-57.
163. Gotto AM, Moon JE. Management of cardiovascular risk: the importance of meeting lipid targets. *Am J Cardiol* 2012;110(1 Suppl):3A-14A.
164. Gotto AM, Moon JE. Recent clinical studies of the effects of lipid-modifying therapies. *Am J Cardiol* 2012;110(1 Suppl):15A-26A.
165. Gotto AM Jr, Moon JE. Safety of inhibition of cholesteryl ester transfer protein with anacetrapib: the DEFINE study. *Expert Rev Cardiovasc Ther* 2012;10(8):955-63.
166. Gotto AM Jr. Suffering, medicine, and the book of Job. *J Relig Disabil Health* 2012;16(4):420-31.
167. Rosenson RS, Gotto AM Jr. When clinical trials fail to address treatment gaps: the failure of niacin-laropirant to reduce cardiovascular events. *Curr Atheroscler Rep* 2013;15(6):332.
168. Hajjar DP, Gotto AM Jr. Biological relevance of inflammation and oxidative stress in the pathogenesis of arterial diseases. *Am J Pathol* 2013;182(5):1474-81.
169. Savarese G, Gotto AM Jr, Paolillo S, D'Amore C, Losco T, Musella F, Scala O, Marciano C, Ruggiero D, Marsico F, De Luca G, Trimarco B, Perrone-Filardi P. Benefits of statins in elderly subjects without established cardiovascular disease. A meta-analysis. *J Am Coll Cardiol* 2013;62(22):2090-9.
170. Gotto AM Jr, Moon JE. Pharmacotherapies for lipid modification: beyond the statins. *Nat Rev Cardiol* 2013;10(10):560-70.

Editorials and Letters

1. Gotto AM Jr. Beta-apoprotein sufficiency and function. *N Engl J Med* 1969;280:1297- 1298.
2. Thompson GR, Gotto AM Jr. Ileal bypass in the treatment of hyperlipoproteinemia. *Lancet* 1973;2:35-36.
3. Gotto AM Jr, Yeshurun D, DeBakey ME. Atherosclerotic cardiovascular disease: Current prospectives. *J Chronic Dis* 1976;29(11):677-681.
4. Gotto AM Jr. apo-C-II deficiency: A new mutant. *N Engl J Med* 1978;298(23):1308-9.
5. Gotto AM Jr. U.S. World's leader in medical discovery and development. *Medical Digest* 1978;2:1-3.

6. DeBakey ME, Gotto AM Jr, Weinberg AD. Health values: Achieving high-level wellness. *Health Values* 1978;2:237.
7. Gotto AM Jr. Regression of atherosclerosis. *Am J Med* 1981;70(5):989-91.
8. Bonte F, Gotto AM Jr, Howell R, Bowen JM, McGuire WL. Debate: Funds for medical research. *Tex Med* 1981;17:41-4.
9. Scott LW, Gorry GA, Gotto AM Jr. Diet and coronary heart disease: The statistical analysis of risk. *Circulation* 1981;63(3):516-8.
10. Gotto AM Jr, Foreyt JP, Goodrick GK. Evaluating commercial weight-loss clinics. *Arch Intern Med* 1982;142(4):682-3.
11. Gotto AM Jr. Can the progression of atherosclerosis be halted? *Drug Therapy* 1984:37- 39.
12. Gotto AM Jr. Coronaries and diet. *Nature* 1984;309(5970):664.
13. Gotto AM Jr. Apolipoprotein CII deficiency revisited. *N Engl J Med* 1984;310(25):1664- 5.
14. Gotto AM Jr. Diet and cholesterol guidelines and coronary heart disease. *J Am Coll Cardiol* 1989;13(2):503-7.
15. Gotto AM Jr. Cholesterol intake and serum cholesterol level. *N Engl J Med* 1991;324(13):912-3.
16. Rubenstein JJ, Gotto AM Jr, Grundy SM. More on SI units. *N Engl J Med* 1992;327(1):51-2.
17. Rossouw JE, Gotto AM Jr. Does low cholesterol cause death? *Cardiovasc Drugs Therapy* 1993;7(5):789-93.
18. Stamler J, Stamler R, Brown WV, Gotto AM Jr, Greenland P, Grundy S, Hegsted M, Luepker RV, Neaton JD, Steinberg D, Stone N, Van Horn L, Wissler RW. Serum cholesterol. Doing the right thing. *Circulation* 1993;88(4 Pt 1):1954-60.
19. Gotto AM Jr. Postmenopausal hormone-replacement therapy, plasma lipoprotein[a], and risk for coronary heart disease. *J Lab Clin Med* 1994;123(6):800-3.
20. Gotto AM Jr. Reduction of coronary events: evidence from clinical trials. *Curr Opin Lipidol* 1995;6(6):345-7.
21. Gotto AM Jr, Hay JW. Cost of lipid-lowering statin drugs. *Am J Cardiol* 1996;77(2):225-6.
22. Gotto AM Jr. The Multiple Risk Factor Intervention Trial (MRFIT). A return to a landmark trial. *JAMA* 1997;277(7):595-7.
23. Gotto AM Jr. Statin therapy and reduced incidence of stroke. Implications of cholesterol-lowering therapy for cerebrovascular disease. *Arch Intern Med* 1997;157(12):1283-4.

24. Gotto AM Jr. Results of recent large cholesterol-lowering trials and implications for clinical management. *Am J Cardiol* 1997;79(12):1663-6.
25. Gotto AM Jr. The new cholesterol education imperative and some comments on niacin. *Am J Cardiol* 1998;81(4):492-4.
26. Gotto AM Jr. Risk factor modification: rationale for management of dyslipidemia. *Am J Med* 1998;104(2A):6S-8S.
27. Gotto AM Jr. Triglyceride: the forgotten risk factor. *Circulation* 1998;97(11):1027-8.
28. Gotto AM Jr. Preventing coronary disease in women: brief observations from the clinical data. *J Women's Health* 1998;7(2):195-7.
29. Gotto AM Jr. The Lipoprotein and Coronary Atherosclerosis Study (LCAS) in context: assessing the benefits of lipid-lowering therapy. Introduction. *Am J Cardiol* 1998;82(6A) :1M.
30. Gotto AM, Cooper GR. Citation classics in lipid measurement and applications. *Clin Chem* 1998;44(11):2234-7.
31. Gotto AM Jr. Impact of multiple risk factors on coronary artery disease: beyond total cholesterol. Introduction. *Am J Cardiol* 1998;82(9A):1Q-2Q.
32. Gotto AM Jr. Prognostic and therapeutic significance of low levels of high-density lipoprotein cholesterol: current perspectives. *Arch Intern Med* 1999;159(10):1038-40.
33. Gotto AM Jr. Lipid-lowering therapy for the primary prevention of coronary heart disease. *J Am Coll Cardiol* 1999;33(7):2078-82.
34. Friedewald VE Jr, Gotto AM Jr. Case 1: a patient with elevated low-density lipoprotein cholesterol. *Am J Cardiol* 2000;85(1):131
35. Friedewald VE Jr, Gotto AM Jr. Case 2: a patient with low levels of high-density lipoprotein cholesterol. *Am J Cardiol* 2000;85(3):403, A10.
36. Gotto AM Jr, Friedewald VE Jr. Case 3: Insulin-dependent diabetes mellitus. *Am J Cardiol* 2000;85(7):916, A10.
37. Gotto AM Jr. In memoriam : Robert I. Levy 1937-2000. *J Lipid Res* 2001;42(5):886-7.
38. Gotto AM Jr. Safety and statin therapy: reconsidering the risks and benefits. *Arch Intern Med* 2003;163(6):657-9.
39. Hajjar DP, Gotto AM. Targeting CD36: modulating inflammation and atherogenesis. *Curr Atheroscler Rep* 2003;5(3):155-6.
40. Gotto AM; NCEP ATP III. NCEP ATP III guidelines incorporate global risk assessment. *Am J Manag Care* 2003;Suppl:1, 3.

41. Foody JM, Gotto AM, Wenger N. C-reactive protein and coronary heart disease. *N Engl J Med* 2004;351(3):295-8.
42. Gotto AM Jr. Targeting high-risk young patients for statin therapy. *JAMA* 2004;292(3):377-8.
43. Gotto AM Jr. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. *N Engl J Med* 2004;351(7):714-7.
44. Gotto AM. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized controlled trial. *J Pediatr*. 2005;146(1):144-5.
45. Gotto AM Jr. Should patients with combined hyperlipidemia receive statin-fibrate combination therapy? *Nat Clin Pract Cardiovasc Med* 2005;2(6):284-5.
46. Gotto AM Jr. Over-the-counter statins and cardiovascular disease prevention: perspectives, challenges, and opportunities. *Clin Pharmacol Ther* 2005;78(3):213-7.
47. Sostman HD, Forese LL, Boom ML, Schroth L, Klein AA, Mushlin AI, Hagale JE, Pardes H, Girotto RG, Gotto AM Jr. Building a transcontinental affiliation: a new model for academic health centers. *Acad Med* 2005;80(11):1046-53.
48. Gotto AM Jr, Blackburn GL, Dailey GE 3rd, Garber AJ, Grundy SM, Sobel BE, Weir MR. The metabolic syndrome: a call to action. *Coron Artery Dis* 2006;17(1):77-80.
49. Gotto AM Jr. Is it appropriate to make statins available over the counter? Over-the-counter statins are worth considering in primary prevention of cardiovascular disease. *Circulation* 2006;114(12):1310-4.
50. Friedewald VE, Grundy S, Gotto AM Jr, Haffner S, Denke MA, Hollander P, Roberts WC. The Editor's Roundtable: the metabolic syndrome. *Am J Cardiol* 2007;99:382-9.
51. Gotto AM Jr. Statin therapy and the elderly: SAGE advice? *Circulation* 2007;115(6):681-3.
52. Gotto AM Jr. Does torcetrapib reduce the progression of atherosclerosis disease? *Nat Clin Pract Cardiovasc Med* 2007;4(9):478-9.
53. Fins JJ, Fein OT, Gotto AM Jr. Ethical issues and global health. *Acad Med* 2008;83(11):997.
54. Gotto AM Jr. Improving lipid goal attainment: is it enough? *Circulation* 2009;120(1):3-5.

General Readership Articles

1. Gotto AM Jr, Scott LW, McMann MC. A look at eating habits and heart disease around the world. (feature). In: *Encyclopædia Britannica 1993 Medical and Health Annual*. Chicago: Encyclopædia Britannica, 1992:42-71.

Book Chapters

1. Fredrickson DS, Gotto AM Jr. Genetically determined lipoprotein deficiencies with neuropathy. In: Goldensohn ES, Appel SH, eds. The cellular and molecular basis of neurologic disease. Philadelphia: Lea and Febiger, 1971.
2. Fredrickson DS, Gotto AM Jr, Levy RI. Familial lipoprotein deficiency (abetalipoproteinemia, hypobetalipoproteinemia, and Tangier disease). In: Stanbury JB, Wyngaarden JB, Fredrickson DS, eds. The metabolic basis of inherited disease, 3rd ed. New York: McGraw-Hill, 1972:493-524.
3. Gotto AM Jr. Hyperlipoproteinemia: Method of Antonio M. Gotto, Jr, M.D. In: Cohn HF, ed. Current therapy. Philadelphia: Saunders, 1974:418-427.
4. Gotto AM Jr, Foreyt JP, Scott LW. Cardiovascular risk factors. In: Williams BJ, Martin S, Foreyt JP, eds. Obesity: Behavioral approaches to dietary management. New York: Brunner/Mazel, 1976:109-120.
5. Foreyt JP, Scott LW, Gotto AM Jr. Diet modification in the community. In: Williams BJ, Martin S, Foreyt JP, eds. Obesity: Behavioral approaches to dietary management. New York: Brunner/Mazel, 1976:186-195.
6. Hoff HF, Meyer JS, Gotto AM Jr. Localization of low density lipoproteins in atherosclerotic extra and intracranial arteries from normo and hyperlipemics. In: Meyer JS, Lechner HS, Reivich M, Eichorn O, eds. Cerebral vascular disease. Stuttgart: George Thieme, 1976:170-173.
7. Scott LW, Foreyt JP, Gotto AM Jr. Nutrition during weight loss. In: Williams BJ, Martin S, Foreyt JP, eds. Obesity: Behavioral approaches to dietary management. New York: Brunner/Mazel, 1976:121-135.
8. Gotto AM Jr, Jackson RL, Morrisett JD, Pownall HJ, Sparrow JT. Molecular association of lipids and proteins in the plasma lipoproteins: A review. In: Greten H, ed. Lipoprotein metabolism. Berlin: Springer-Verlag, 1976:152-157.
9. Gotto AM Jr. Diagnosis and management of risk factors for atherosclerosis. In: Gross HL, ed. Atherosclerosis. Kalamazoo, Mich.: The Upjohn Company, 1977:9-35.
10. Morrisett JD, Pownall HJ, Jackson RL, Segura R, Gotto AM Jr, Taunton OD. Effects of polyunsaturated and saturated fat diets on the chemical composition and thermotropic properties of human plasma lipoproteins. In: Homan RT, Kunau WH, eds. The chemistry and biochemistry of polyunsaturated fatty acids. American Oil Chemists Society Monograph #4. Champaign, IL: AOCS Publishers, 1977:139-161.
11. Gotto AM Jr. Goal 6: Reduce cholesterol consumption to about 300 grams a day. In: Staff of the Select Committee on Nutrition and Human Needs United States Senate Dietary Goals for the United States, 2nd ed. Publication no. 98364 0. Washington, D.C.: U.S. Government Printing Office, 1977:42-48.

12. Herbert PN, Gotto AM Jr, Fredrickson DS. Familial lipoprotein deficiency (abetalipoproteinemia, hypobetalipoproteinemia and Tangier disease). In: Stanbury JB, Wyngaarden JB, Fredrickson DS, eds. The metabolic basis of inherited disease, 4th ed. New York: McGraw-Hill, 1977:544-588.
13. Jackson RL, Morrisett JD, Gotto AM Jr. Lipoproteins and lipid transport: Structural and functional concepts. In: Rifkind BM, Levy RI, eds. Hyperlipidemia: Diagnosis and therapy. New York: Grune and Stratton, 1977:1-16.
14. Levy RI, Gotto AM Jr. Diagnosis and management of lipid transport disorders. In: Tice DA, ed. Practice of medicine, Vol. 8. Hagerston, Md: Harper and Row, 1977:
15. Gotto AM Jr, Jackson RL. Plasma lipoproteins and atherosclerosis. In: Schettler G, Drews J, Greten H, eds. Changes in the medical panorama. Stuttgart: George Thieme, 1978:125-130.
16. Bradley WA, Gotto AM Jr. Structure of intact human plasma lipoproteins. In: Dietschy JM, Gotto AM Jr, Ontko JA, eds. Disturbances in lipid and lipoprotein metabolism. Bethesda: American Physiological Society, 1978:111-137.
17. Hartung GH, Smith LC, Foreyt JP, Gorry GA, Gotto AM Jr. Plasma lipid levels in middle-aged runners, joggers, and sedentary men. In: Sports cardiology. Bologna: Aulo Gagi, 1978:843-849.
18. Pownall HJ, Gotto AM Jr. Mechanisms of lipid transport by the human plasma proteins. In: Bing DH, ed. The chemistry and physiology of the human plasma proteins. New York: Pergamon, 1979:127-144.
19. Pownall HJ, Jackson RL, Morrisett JD, Gotto AM Jr. Structure and dynamics of reassembled plasma lipoproteins. In: Scanu AM, Wissler RW, Getz GS, eds. The biochemistry of atherosclerosis. New York: Marcel Dekker, 1979:123-143.
20. Patsch JR, Gotto AM Jr. Separation and analysis of HDL subclasses by zonal ultracentrifugation. In: Report of the High Density Lipoprotein Methodology Workshop, San Francisco. NIH Publication No.791661. Bethesda, Md, 1979:310-324.
21. Gotto AM Jr, Shepherd J, Scott LW, Manis E. Primary hyperlipoproteinemia and dietary management. In: Levy R, Rifkind B, Dennis B, Ernst N, eds. Nutrition, lipids and coronary heart disease. New York: Raven Press, 1979:247-283.
22. Gotto AM Jr. Relationship between diet and coronary artery disease. In: National Academy of Sciences. Report on healthful diets. Publication no. 66408. Washington DC: U.S. Government Printing Office, 1980:127-134.
23. Gotto AM Jr. The plasma apolipoproteins: Regulation of the structure and function of the plasma lipoproteins. In: Braunwald E, Levy RI, eds. Hyperlipoproteinemia and coronary artery disease. The atherogenic connection. New York: AV/MD Press, 1982:9- 12.

24. Bradley WA, Gotto AM Jr, Sparrow JT. The use of radially compressed reversed phase HPLC for the separation of tryptic peptides of apolipoproteins. In: Elzinga M, ed. Methods in protein sequence analysis. Clifton, NJ: Humana Press, Inc., 1982:479-488.
25. Foreyt JP, Scott LW, Gotto AM Jr. Weight control and nutrition education programs in occupational settings. In: Parkinson RS, ed. Managing health promotion in the workplace: Guidelines for implementation and evaluation. Palo Alto: Mayfield Publishing Company, 1982.
26. Miller JP, Gotto AM Jr. The plasma lipoproteins: Their formation and metabolism. In: Neuberger A, van Deenen LLM, eds. Comprehensive biochemistry. Amsterdam: Elsevier, 1982:419-506.
27. Probstfield JL, Gotto AM Jr. Lipoproteins in health and disease: Diagnosis and management. In: McIntosh HD, ed. Baylor College of Medicine Cardiology Series Vol. 5. Princeton: Cardiology Series Inc, 1982.
28. Gotto AM Jr, Wittels EH. Diet, serum cholesterol, lipoproteins, and coronary heart disease. In: Kaplan NM, Stamler J, eds. Prevention of coronary heart disease: Practical management of the risk factors. Philadelphia: Saunders, 1983:33-50.
29. Herbert PN, Assmann G, Gotto AM Jr, Fredrickson DS. Familial lipoprotein deficiency: Abetalipoproteinemia, hypobetalipoproteinemia and Tangier disease. In: Stanbury JB, Wyngaarden JB, Fredrickson DS, Goldstein JL, Brown MS, eds. The metabolic basis of inherited disease, 5th ed. New York: McGraw-Hill, 1983:589-621.
30. Pownall HJ, Gotto AM Jr. Structure and function of plasma lipoproteins. In: Avogaro P, Mancini M, Ricci G, Paoletti R, eds. Phospholipids and atherosclerosis. New York: Raven Press, 1983:99-114.
31. Probstfield JL, Gotto AM Jr. Disorders of lipids and lipoproteins. In: Stein HJ, ed. Internal medicine. New York: Little, Brown, 1983:1888-1895.
32. Scott LW, Foreyt JP, Gotto AM Jr. Variations on the prudent diet. In: Feldman EB, ed. Nutrition and heart disease. New York: Churchill-Livingstone, 1983:183-202.
33. Smith LC, Massey JB, Sparrow JT, Gotto AM Jr, Pownall HJ. Structure and dynamics of human plasma lipoproteins. In: Pifat G, Herak JN, eds. Supramolecular structure and function. New York: Plenum, 1983:205-244.
34. Gotto AM Jr. Lipoproteins. In: Jaffe ER, ed. Research needs in hematology. Bethesda, Md. U.S. Department of Health and Human services, Public Health Service, NIH Publication No.832630.1983:565-576.
35. Pownall HJ, Gotto AM Jr. Plasma apolipoproteins: Composition, structure and function. In: Miller NE, ed. Atherosclerosis: Mechanisms and approaches to therapy. New York: Raven Press, 1984:125-141.

36. Beigel Y, Gotto AM Jr, Lipoproteins in health and disease: Diagnosis and management. In: McIntosh HD, ed. Baylor College of Medicine Cardiology Series Vol. 9. Princeton: Cardiology Series, Inc., 1986:
37. Yang CY, Yang T, Pownall HJ, Gotto AM Jr. Primary structure of rabbit apolipoprotein AI high performance liquid chromatography, PTC amino acid analysis, and microsequencing. In: Wittman-Liebold B, ed. Advanced methods in protein microsequence analysis. Berlin: Springer-Verlag, 1986:320-339.
38. Morrisett JD, Guyton JR, Gaubatz JW, Gotto AM Jr. Lipoprotein[a]: Structure, metabolism, and epidemiology. In: Gotto AM Jr, ed. New comprehensive biochemistry, vol. 14. Amsterdam: Elsevier, 1987.
39. Patsch JR, Gotto AM Jr. Metabolism of high density lipoproteins. In: Gotto AM Jr, ed. New comprehensive biochemistry, vol. 14. Amsterdam: Elsevier, 1987:
40. Guyton JR, Gotto AM Jr. Drug therapy of dyslipoproteinemias. In: Fruchart JC, Shepherd J, eds. Human plasma lipoproteins. Clinical Biochemistry Series. Berlin: Walter deGruyter, 1989:335-361.
41. Gotto AM Jr. The role of lipids in coronary heart disease. In: Current concepts. Kalamazoo, Mich.: The Upjohn Company, 1991.
42. Gotto AM Jr, Farmer JA. Risk factors for coronary artery disease. In: Braunwald E, ed. Heart disease: A textbook of cardiovascular medicine, 3rd ed. Philadelphia: Saunders, 1992:1153-1190.
43. Gotto AM Jr. Triglycerides and the development of atherosclerosis: Emerging data. In: The Council on Hypertension and Atherosclerosis Education. Atherosclerosis beyond cholesterol. New York: The Council on Hypertension and Atherosclerosis Education, 1992:25-35.
44. Gotto AM Jr. Introduction. In: The Council on Hypertension and Atherosclerosis Education. Atherosclerosis beyond cholesterol. New York: The Council on Hypertension and Atherosclerosis Education, 1992:1-2.
45. Guyton JR, Gotto AM Jr. The pathogenesis of atherosclerosis: Lipid metabolism. In: Loscalzo J, Creager MA, Dzau VJ, eds. Vascular medicine: A Textbook of vascular biology and diseases. Boston: Little, Brown, 1992:345-369.
46. Jones PH, Gotto AM Jr. Hyperlipidemia. In: Hurst JW, ed. Medicine for the practicing physician, 3rd ed. Stoneham, Mass.: Butterworth-Heinemann, 1992:1029-1033.
47. Wittels EH, Gotto AM Jr. Clinical features of ischemic heart disease in diabetes mellitus. In: Alberti KGMM, DeFronzo RA, Keen H, Zinnet P, eds. International textbook of diabetes mellitus. New York: John Wiley, 1992.
48. Gotto AM Jr. Drug therapy in the prevention of coronary heart disease: Current agents and future directions. In: Born GVR, Schwartz CJ, eds. New horizons in coronary heart disease. London: Current Science, 1993:17.1-17.4.

49. Morrisett JD, Gaubatz JW, Nava MN, Guyton JR, Hoffman AS, Opekun AR, Hachey DL, Gotto AM Jr. Metabolism of apo[a] and apoB-100 in human lipoprotein[a]. In: Catapano AL, Gotto AM Jr, Smith LC, Paoletti R, eds. [Proceedings of the XI International Symposium on] Drugs affecting lipid metabolism. Dordrecht: Kluwer Academic Publishers, 1993:161-168.
50. Gotto AM Jr, Morrisett JD, guest eds. Second International Conference on Lipoprotein[a], DALM November 12-14, 1992: Special issue of reviewed papers contributed by invited speakers. Chem Phys Lipids 1994;67/68.
51. Jones PH, Patsch J, Gotto AM Jr. The biochemistry of blood lipid regulation and the assessment of lipid abnormalities. In: Schlant RC, Alexander RW, eds. The heart: arteries and veins, 8th ed. New York: McGraw-Hill, 1994:973-987.
52. Patsch W, Gotto AM Jr. Plasma lipid transport and the development of atherosclerosis. In: Singh BN, Dzau VJ, Vanhoutte PM, Woosley RL, eds. Cardiovascular pharmacology and therapeutics. New York: Churchill-Livingstone, 1994:1025-1041.
53. Quion JAV, Gotto AM. Dyslipidemia. In: Freed M, Grines C, eds, Essentials of Cardiovascular Medicine. Birmingham, MI: Physicians' Press, 1994: 34-53.
54. Gotto AM Jr, Farmer JA. Currently available hypolipidemic drugs and future therapeutic developments. In: Betteridge DJ, ed. Clinical endocrinology and metabolism. London: Balliäre, 1995;9:825-847.
55. Gotto AM Jr, Farmer JA. Dyslipidemia and other risk factors for coronary artery disease. In: Braunwald E, ed. Heart disease: A textbook of cardiovascular medicine, 5th ed. Philadelphia: Saunders, 1995.
56. Gotto AM Jr, Farmer JA. Primary and secondary prevention of coronary heart disease. In: Deedwania P, Kupersmith J, eds. Heart disease management: A pharmacologic approach. Baltimore: Williams & Wilkins, 1995.
57. Gotto AM Jr. Antilipidemic drug therapy: An overview. In: Messerli FH, ed. Cardiovascular drug therapy, 2nd ed. Philadelphia: Saunders, 1995:19-26.
58. Goff DC, Gotto AM Jr. Störungen des lipoproteinstoffwechsels und ihre auswirkungen auf das Herz-Kreislauf-System. In: Schwandt P, Richter WO, eds. Handbuch der Fettstoffwechselstörungen. Pathophysiologie, Diagnostik, Therapie und Prävention der Dyslipoproteinämien. Stuttgart: Schattauer, 1995:104-118.
59. Farmer JA, Gotto AM Jr. Atherosclerosis: Pathogenesis and risk factors. In: Willerson JT, Cohn JN, eds. Cardiovascular medicine. New York: Churchill-Livingstone, 1995:1101-1113.
60. Gotto AM, Farmer JA. Dyslipoproteinemias/Atherosclerosis: Introduction. In: TW Smith ed. Cardiovascular therapeutics. New York: W. B. Saunders Company, 1996.
61. Gotto AM, Farmer JA. Dyslipoproteinemias/Atherosclerosis: Pharmacologic therapy. In: TW Smith ed. Cardiovascular therapeutics. New York: W. B. Saunders Company, 1996.

62. Via DP, Gotto AM Jr. The pathogenesis of atherosclerosis and lipid metabolism. In: Loscalzo J, Creager MA, Dzau VJ, eds. Vascular medicine: A textbook of vascular biology and diseases. 2nd ed. Boston: Little, Brown, 1996.
63. Jones PH, Gotto AM Jr. Hyperlipidemia. In: Hurst JW, ed. Medicine for the Practicing Physician, ed. 4. Stamford, CT: Appleton & Lange, 1996, pp.1114-1120.
64. Jackson RL, Morrisett JD, Gotto AM Jr. Lipid-protein interactions in human plasma high density lipoproteins. In: Peters H, ed. Protides of the biological fluids Twenty-first Colloquium. New York: Pergamon, 1973:227-236.
65. Gotto AM Jr. Lipids and diabetes. In: Diabetology '74. Report from the Geigy Symposium: Diabetes reexamined. Albuquerque, 1974.
66. Gotto AM Jr. Hyperlipidemia as a diabetic complication. In: Diabetology '74. Report from the Geigy Symposium: Diabetes reexamined. Albuquerque, 1974.
67. Sparrow JT, Morrisett JD, Pownall HJ, Jackson RL, Gotto AM Jr. The mechanism of lipid binding by the plasma lipoproteins: Synthesis of model peptides. In: Walter R, Meienhofer J, eds. Peptides: Chemistry, structure, and biology. Ann Arbor: Ann Arbor Science, 1975:597-602.
68. Hoff HF, Jackson RL, Gotto AM Jr. Apolipoprotein localization in human atherosclerotic arteries. In: Day CE, ed. Atherosclerosis drug discovery. New York: Plenum, 1976:109-120.
69. Jackson RL, Stein O, Glangeaud MC, Fainaru M, Gotto AM Jr, Stein Y. The removal of cellular lipids from Landschutz ascites cells in culture. In: Day CE, ed. Atherosclerosis drug discovery. New York: Plenum, 1976:453-561.
70. Gotto AM Jr. Lipid constituents of plasma. In: Altman PL, Katz DD, eds. Human health and disease. Bethesda: FASEB, 1977:132-139.
71. Gotto AM Jr. Current concepts of hyperlipoproteinemia. In: Schettler G, Goto Y, Hata Y, Klose G, eds. Atherosclerosis IV. New York: Springer, 1977:209-219.
72. Gotto AM Jr, Jackson RL. Structure of the plasma lipoproteins A review. In: Schettler G, Goto Y, Hata Y, Klose G, eds. Atherosclerosis IV. New York: Springer, 1977:177- 188.
73. Gotto AM Jr, Jackson RL. Plasma lipoproteins: Recent developments. In: Manning GW, Haust MD, eds. Atherosclerosis. New York: Plenum, 1977:15-33.
74. Sparrow JT, Pownall HJ, Sigler GF, Smith LC, Soutar AK, Gotto AM Jr. The mechanism of phospholipid binding by the plasma apolipoproteins. In: Goodman M, Meienhofer J, eds. Peptides: Proceedings of the Fifth American Peptides Symposium. New York: John Wiley, 1977:149-152.
75. Gotto AM Jr. Chairman's summary: Do high density lipoproteins protect against atherosclerosis? In: Gotto AM Jr, Miller NE, Oliver MF, eds. High density lipoproteins and atherosclerosis. Amsterdam: Elsevier, 1978:

76. Gotto AM Jr, Jackson RL. Structure and metabolism of the plasma lipoproteins: Macheboeuf to 1977. In: Peeters H, ed. *Protides of the biological fluids. Proceedings of the Twenty-fifth Colloquium*. New York: Pergamon, 1978:15-24.
77. Catapano AL, Kinnunen PK, Packard CL, Gotto AM Jr, Smith LC. Action of lipoprotein lipase on very low density lipoprotein subclasses in vitro. In: Carlson LA, Paoletti R, Weber G, eds. *International Conference on Atherosclerosis*. New York: Raven, 1978:315-318.
78. Mantulin WW, Gotto AM Jr. Human plasma lipoproteins: Structure and metabolism. In: Carlson LA, Paoletti R, Weber G, eds. *International Conference on Atherosclerosis*. New York: Raven, 1978:57-69.
79. Pownall HJ, Gotto AM Jr. Physicochemical factors in the distribution of plasma lipoprotein subunits between the plasma lipoproteins and the arterial wall. In: Hauss WH, et al., eds. *International symposium: State of Prevention and Therapy in Human Arteriosclerosis and in Animal Models*. Opladen: Westdeutscher, 1978:457-462.
80. Pownall HJ, Massey JB, Sparrow JT, Gotto AM Jr. Kinetics and mechanism of lipid apolipoprotein association. In: Peeters H, ed. *Protides of the biological fluids. Proceedings of the Twenty-fifth Colloquium*. New York: Pergamon, 1978:115-119.
81. Pownall HJ, Sparrow JT, Gotto AM Jr. High density apolipoprotein structure and function. In: Gotto AM Jr, Miller NE, Oliver MF, eds. *High density lipoproteins and atherosclerosis*. Amsterdam: Elsevier, 1978:5-18.
82. Smith LC, Kinnunen PK, Jackson RL, Gotto AM Jr, Sparrow JT. Activation of lipoprotein lipase by native and synthetic peptide fragments of apolipoprotein CII. In: Carlson LA, Paoletti R, Weber G, eds. *International Conference on Atherosclerosis*. New York: Raven, 1978:269-273.
83. Pownall HJ, Morrisett JD, Sparrow JT, Smith LC, Shepherd J, Jackson RL, Gotto AM Jr. A review of the unique features of HDL apoproteins. In: *Report of the Symposium on High Density Lipoproteins (HDL)*. American Oil Chemists Society Press, 1979:13-19.
84. Bhatnagar P, Mao SJ, Gotto AM Jr, Sparrow JT. Delineation of an antigenic site of lipoprotein AII. In: Gross E, Meienhofer J, eds. *Peptides: Structure and biological function: Proceedings of the Sixth American Peptide Symposium*. Rockford: Pierce Chemical, 1979:953-956.
85. Sparrow JT, Warman AH, Gotto AM Jr. Lipid binding by apolipoprotein AI: Synthetic studies. In: Gross E, Meienhofer J, eds. *Peptides: Structure and biological function. Proceedings of the Sixth American Peptide Symposium*. Rockford: Pierce Chemical, 1979:523-526.
86. Patsch JR, Gotto AM Jr. [The role of high-density lipoprotein (HDL) in catabolism of triglyceride-rich lipoproteins.] In: Greten H, Lang PD, Schettler G, eds. *Lipoproteine und Herzinfarkt*. New York: Gerhard Witzstrock, 1979:17-22.

87. Pownall HJ, Sparrow JT, Smith LC, Gotto AM Jr. Structure and function of the human plasma apolipoproteins. In: Gotto AM Jr, Smith LC, Allen B, eds. Atherosclerosis V. New York: Springer, 1980:624-630.
88. Smith LC, Voyta JC, Catapano AL, Kinnunen PK, Gotto AM Jr, Sparrow JT. Activation of lipoprotein lipase by synthetic fragments of apo CII. In: Gotto AM, Smith LC, Allen B, eds. Atherosclerosis V. New York: Springer, 1980:397-400.
89. Jackson RL, Harmony JAK, Gotto AM Jr. The cell membrane and lipid metabolism. In: Proceedings of the International Symposium on Cell Membrane in Function and Dysfunction of Vascular Tissue. Brussels: Elsevier, 1980:
90. Gotto AM Jr. The plasma lipoproteins: Metabolism, structure-function relationships, and their relevance to atherosclerosis. In: Moskowitz J, ed. Diabetes and atherosclerosis connection. New York: Juvenile Diabetes Foundation, 1981:167-180.
91. Sparrow JT, Ferez CR, Gotto AM Jr, Pownall HJ. The thermodynamics of lipid-protein association and the activation of lecithin:cholesterol acyltransferase by synthetic lipopeptides. In: Rich DH, Gross E, eds. Peptides: Synthesis structure function. Proceedings of the Seventh American Peptide Symposium. Pierce Chemical Company, 1981:253-256.
92. Gotto AM Jr. Arguments for and against the treatment of hyperlipidemia. In: Ricci G, Paoletti R, Pochiari F, Polliolini D, eds. Therapeutic selectivity and risk/benefit assessment of hypolipidemic drugs. New York: Raven, 1982:19-27.
93. Gotto AM Jr. Atherosclerosis today. In: Lenzi S, Descovich GC, Eds. Atherosclerosis clinical evaluation and therapy: Proceedings of the Fourth International Meeting on Atherosclerosis. Boston: MTP, 1982:301-305.
94. Pownall HJ, Gotto AM Jr. Role of lipid-protein interactions in the structure and function of human plasma lipoproteins. In: Proceedings of the USA USSR First Lipoprotein Symposium, 1982. NIH Pub No.831966.
95. Pownall HJ, Massey JB, Gotto AM Jr. Thermodynamics and mechanism of the association of plasma apolipoproteins with synthetic phosphatidylcholines. In: Born GRV, Catapano AL, Paoletti R, eds. Factors in formation and regression of the atherosclerotic plaque. New York: Plenum, 1982:125-137.
96. Gotto AM Jr. Structure-function relationships in the plasma lipoproteins. In: Schettler FG, Gotto AM Jr, Middelhoff G, Habenicht AJR, Jurutka KR, eds. Atherosclerosis VI: Proceedings of the Sixth International Symposium. Berlin: Springer, 1983:469-479.
97. Gotto AM Jr, Bradley WA, Gianturco SH. The plasma apolipoproteins: New advances and relation to atherogenesis. In: Lenzi S, Descovich Gc, eds. Atherosclerosis and cardiovascular disease. Proceedings of the Fifth International Meeting on Atherosclerosis. Boston: MTP, 1983:269-278.
98. Gotto AM Jr, Catapano AL. [The apolipoproteins.] In: Lewis B, Paoletti R, eds. Le lipoproteine. Milan: Gruppo Lepitit, 1983:19-29.

99. Bradley WA, Karlin JA, Prasad SC, Gotto AM Jr, Gianturco SH. Immunological and biological recognition of apolipoprotein E in very low density lipoproteins. In: Lippel K, ed. Proceedings of the Workshop on Apolipoprotein Quantification, NIH Publication No. 831266. 1983:200-211.
100. Karlin JB, Prasad SC, Gotto AM Jr, Bradley WA. Immunochemical heterogeneity of human apolipoprotein E as measured by radioimmunoassay. In: Lippel K, ed. Proceedings of the Workshop on Apolipoprotein Quantification, NIH Publication No. 831266. 1983:212-222.
101. Morrisett JD, Wenkert D, Gotto AM Jr, Dahlen GH, Gianturco SH, Heideman C, Gaubatz JW. Lipoprotein[a]: Purification problems and properties. In: Lippel K, ed. Proceedings of the Workshop on Apolipoprotein Quantification, NIH Publication No. 831266. 1983:158-178.
102. Smith LC, Voyta JC, Rohde MF, Kinnunen PK, Gotto AM Jr, Sparrow JT. Lipoprotein lipase: Apolipoprotein CII interactions studied by fluorescence and monoclonal antibodies. In: Schettler FG, Gotto AM Jr, Middelhoff G, Habenicht AJR, Jurutka KR, eds. Atherosclerosis VI: Proceedings of the Sixth International Symposium. Berlin: Springer, 1983:636-639.
103. Gotto AM Jr, Pownall HJ, Ponsin G, Patsch JR, Sparrow JT. Plasma lipoproteins, apolipoproteins, and atherosclerosis. Proceedings of 16th FEBS Congress, Part A. 1985:225-232.
104. Ghiselli G, Beigel Y, Gotto AM Jr. Apolipoprotein AI and AII metabolism in subjects with coronary heart disease. In: Sirtori CR, Nichols AV, Franceschini, G, eds. NATO Advanced Research Workshop on Human Apolipoprotein Mutants: Impact on Atherosclerosis and Longevity. Plenum, 1986:
105. Chan L, Hide W, Yang Y-W, Li W-H, Gotto AM Jr, eds. Structure and evolution of the apolipoprotein and lipase. Cellular and molecular biology of atherosclerosis (Fondation Cardiologique Princesse Liliane). London: Springer, 1992:
106. Gotto AM Jr. Drug therapy in the prevention of coronary heart disease: Current agents and future directions. In: Born GVR, Schwartz CJ, eds. New horizons in coronary heart disease. London: Current Science, 1993:17.1-17.4.
107. Gotto AM Jr. William Harvey and the expansive force of research. In: Born GVR, Schwartz CJ, eds. New horizons in coronary heart disease. London: Current Science, 1993:xi-xiii.
108. Gotto AM Jr. Drugs affecting high-density lipoprotein and triglyceride metabolism. In: Catapano AL, Gotto AM Jr, Smith LC, Paoletti R, eds. [Proceedings of the XI International Symposium on] Drugs Affecting Lipid Metabolism. Dordrecht: Kluwer
109. Gotto AM Jr, Patsch W, Patsch JR. Experimental and clinical evidence for a protective role of high-density lipoprotein in coronary heart disease. In: Catapano AL, Gotto AM Jr, Smith LC, Paoletti R, eds. [Proceedings of the XI International Symposium on] Drugs Affecting Lipid Metabolism. Dordrecht: Kluwer, 1993:333-338.

110. Pownall HJ, Pace P, Knapp RD, Gotto AM Jr, Jones PH. Modulation of triglyceride metabolism by diet and drugs. In: Catapano AL, Gotto AM Jr, Smith LC, Paoletti R, eds. [Proceedings of the XI International Symposium on] Drugs Affecting Lipid Metabolism. Dordrecht: Kluwer, 1993:107-113.
111. Smith LC, Knapp RD, Faustinella F, Chan L, Gotto AM Jr. Structural features that determine the functional properties of the loop region of human lipoprotein lipase. In: Catapano AL, Gotto AM Jr, Smith LC, Paoletti R, eds. [Proceedings of the XI International Symposium on] Drugs Affecting Lipid Metabolism. Dordrecht: Kluwer, 1993:89-96.
112. Gotto AM Jr. A new appraisal of triglyceride. In: Yamamoto A, ed. [Proceedings of the] Multiple risk factors in cardiovascular disease. New York: Churchill Livingstone, 1994:137-142.
113. Gotto AM Jr. Assessment and Management of Lipid Abnormalities. In: Schlant RC, Alexander RW, eds. The Heart, arteries and veins, 8th ed. New York: McGraw-Hill, Health Professions Division, 1994.
114. Gotto AM Jr. Lipid Management. In: Fuster, RR, Topol EJ, eds. Atherosclerosis and coronary artery disease. Philadelphia: Lippincott-Raven, 1996.
115. Weis S, Clearfield M, Downs JR, Gotto AM Jr. The Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS) Primary prevention of acute major coronary events in men and women with average cholesterol. In: Grundy SM, ed. Cholesterol-lowering therapy: Evaluation of clinical trial evidence. New York: Marcel Dekker, Inc. 2000.
116. Gotto AM Jr, Farmer JA. Atherosclerosis: pathogenesis, morphology, and risk factors. In: Willerson JT, Cohn JN eds. Cardiovascular Medicine 2nd edition. Philadelphia: W.B. Saunders, 2000.
117. Gotto AM Jr, Farmer JA. In: Rosendorff C, ed. Essential Cardiology. Philadelphia: W.B. Saunders, 2000.
118. Gotto AM Jr, Farmer JA. Lipid-lowering trials. In: Braunwald E, Zipes DP, Libby P, eds. Heart Disease: A textbook of cardiovascular medicine, 6th ed. Philadelphia: W.B. Saunders, 2001.
119. Febbraio M., Gotto AM Jr., Han J, Nicholson AC, Sharma K, Podrez EA, Hoff HF, Hazen SL, Smith JD, Hajjar DP, Silverstein RL. Regulation of CD36 by PPAR-gamma: Pro- or anti-atherogenic? In: Fruchart J-C., Gotto AM Jr., Paoletti R, Staels B, Catapano AL, eds. International Symposium on PPARs: From Basic Science to Clinical Applications. Dordrecht: Kluwer, 2002; 89-94.
120. Genest J, Libby P, Gotto A. Lipoprotein disorders and cardiovascular disease. In: Zipes DP, Libby P, Bonow RO, Braunwald E, eds. Braunwald's Heart Disease: A textbook of cardiovascular medicine, 7th ed. Philadelphia: Elsevier, 2004.
121. Gotto AM Jr, Farmer JA. Clinical trials, HDL cholesterol, and Cardiovascular Risk. In: Fruchart J-C, Brewer HB, eds, HDL and Coronary Heart Disease. New York: Marcel Dekker, 2004.

122. Gotto AM Jr, Opie LH. Lipid-lowering and antiatherosclerotic drugs. In: Opie LH, Gersh B, eds. *Drugs for the Heart*, 6th ed. Elsevier: 2004.
123. Gotto AM Jr, Farmer JA. Risk factors and prevention, including hyperlipidemias. In: Rosendorff C, ed. *Essential Cardiology*, 2nd edition. Totowa: Humana Press, 2005;419-438.
124. Gotto AM Jr, Farmer JA. Atherosclerosis, morphology, and risk factors. In Willerson JT, ed, *Cardiovascular Medicine*, 3rd edition. London: Springer 2007;1593-1613.
125. Farmer JA, Gotto AM Jr. Should I treat a low serum HDL-C? What specific lifestyle changes and drugs can be used to raise a low HDL-C? In Toth PP, Sica DA, eds. *Clinical Challenges in Lipid Disorders*. Oxford: Clinical Publishing, 2008.
126. Pownall HJ, Gotto AM Jr. Human Plasma Lipoprotein Metabolism. In Ballantyne CM, ed. *Clinical Lipidology: A Companion to Braunwald's Heart Disease*. Philadelphia: Saunders, 2009:1-10.
127. Gotto AM Jr, Opie LH. Lipid-Modifying and Antiatherosclerotic Drugs. In Opie LH, Gersh BJ, eds. *Drugs for the Heart*, 7th ed. Philadelphia: Elsevier, 2009. 341-372.
128. Gotto AM Jr, Farmer JA. Dyslipidemia (Including Pathophysiology of Lipids). In Ferdinand KC, ed. *Educational Review Manual in Cardiovascular Disease*, 1st edition. Castle Connolly Graduate Medical Publishing, 2009:511-530.
129. Gotto AM Jr, Farmer JA. Lipid management and cardiovascular risk reduction. In Eckel RH, ed. *Metabolic Risk for Cardiovascular Disease*. Hoboken, NJ: Wiley-Blackwell, 2010:156-180. Antman E, ed. *AHA Clinical Series*.
130. Gotto AM, Moon J. LDL Cholesterol. In *Dyslipidemia*. Eds. Ragavendra Baliga and Christopher Cannon. New York: Oxford University Press, 2012. 1-28.
131. Gotto AM Jr, Opie LH. Lipid-Modifying and Antiatherosclerotic Drugs. In Opie LH, Gersh BJ, eds. *Drugs for the Heart*, 8th ed. Philadelphia: Elsevier, 2013. 395-435.

Books

1. Gotto AM Jr. *Metabolism of Glycollate in Microorganisms* (D.Phil. diss., University of Oxford, 1961)
2. Gotto AM Jr. *Clinical Aspects of Hyperlipidemia: Therapy of Primary Hyperlipidemia*. New York: Ayerst Laboratories Science and Medicine Press, 1973.
3. Gotto AM Jr. *Hyperlipidemia. Testing Urged As Part of the Complete Physical* (interview). Ayerst Publication No. B 3156841174, 1974.
4. Gotto AM Jr. *Clinician's Manual*. London: Science Press, 1991.
5. Gotto AM Jr, Pownall HJ. *Manual of Lipid Disorders*. Baltimore: Williams & Wilkins, 1992.

6. Gotto AM Jr. Primary Prevention of Coronary Heart Disease: Atherogenesis, Risk Factors, and Cholesterol-Lowering Trials. (Topics in Preventive Cardiology, 1.) London: Excerpta Medica, 1993.
7. Gotto AM Jr, Pownall HJ. Los Trastornos Lipidicos en la Practica Clinica. Buenos Aires: Waverly Hispanica S.A., 1995.
8. Assmann G, Carmena R, Davignon JP, Fernandez-Cruz A, Gotto AM Jr, Paoletti R. The ILIB Handbook for Clinicians. New York: Materia Medica, 1995.
9. Gotto AM Jr, Pownall HJ. Manual of Lipid Disorders. 2nd edition. Baltimore: Williams & Wilkins, 1998.
10. Gotto AM Jr. Contemporary Diagnosis and Management of Lipid Disorders. Newtown: Handbooks in Healthcare, 1998.
11. Gotto AM Jr. Contemporary Diagnosis and Management of Lipid Disorders. 2nd edition. Newtown: Handbooks in Healthcare, 2001.
12. Gotto AM Jr, Pownall HJ. Manual of Lipid Disorders. 3rd edition. Baltimore: Lippincott, Williams & Wilkins, 2003.
13. Gotto AM Jr. Contemporary Diagnosis and Management of Lipid Disorders. 4th edition. Newtown: Handbooks in Healthcare, 2008.
14. Ballantyne CB, O'Keefe JH Jr, Gotto AM Jr. Dyslipidemia and Atherosclerosis Essentials 2009. 4th ed. Sudbury, MA: Jones & Bartlett, 2009.

General Readership Books

1. DeBakey ME, Gotto AM Jr. The Living Heart. New York: David McKay, 1977.
2. DeBakey ME, Gotto AM Jr, Scott LW, Foreyt JP. The Living Heart Diet. New York: Simon & Schuster, 1984.
3. Gotto AM Jr. The Chez Eddy Living Heart Cookbook. New York: Prentice Hall, 1991.
4. DeBakey ME, Gotto AM Jr, Scott LW, Foreyt JP. The Living Heart Brand Name Shopper's Guide, 2nd edition. New York: Mastermedia, 1993.
5. DeBakey ME, Gotto AM Jr, Scott LW. The Living Heart Guide to Eating Out. New York: Mastermedia, 1993.
6. Gotto AM Jr. The Living Heart Cookbook. New York: Simon & Schuster, 1994.
7. DeBakey ME, Gotto AM Jr, Scott LW, Foreyt JP, McMann MC, Jaax S. The Living Heart Brand Name Shopper's Guide, 3rd edition. New York: MasterMedia, 1995.

8. DeBakey ME, Gotto AM Jr, Scott LW, Foreyt JP. The New Living Heart Diet. New York: Simon & Schuster, 1996.
9. DeBakey ME, Gotto AM Jr. The New Living Heart. New York: Adams Media Corporation, 1997.
10. Gotto AM Jr. A Patient's Handbook on Cholesterol Disorders. Newtown: Handbooks in Healthcare, 2000.
11. DeBakey ME, Gotto AM. The Living Heart in the 21st Century. Amherst, NY: Prometheus Books, 2012.

Books and Monographs Edited

1. Hoff HF, Titus JL, Gotto AM Jr, Meyer JS, eds. Proceedings of the Ninth International Congress of Angiology. Histochemical Ultrastructure of Human Atherosclerosis and Hyperlipoproteinemia. Rome: Minerva Press, 1974.
2. Gotto AM Jr, Miller NE, Oliver MF eds. High Density Lipoproteins and Atherosclerosis. Proceedings of the Third Argenteuil Symposium, Belgium. Amsterdam: Elsevier, 1978.
3. Gotto AM Jr, Peck EJ, Boyd AE, eds. Brain Peptides. Amsterdam: Elsevier/North Holland Biomedical Press, 1978.
4. Dietschy JM, Gotto AM Jr, Ontko JA, eds. Disturbances in Lipid and Lipoprotein Metabolism. Bethesda: American Physiological Society, 1978.
5. Gotto AM Jr, ed. Symposium on High-Density Lipoproteins and Coronary Artery Disease: Effects of Diet, Exercise, and Pharmacologic Intervention. Am J Cardiol 1983;52(4 Suppl B).
6. DeBakey ME, Gotto AM Jr, eds. Factors Influencing the Course of Myocardial Ischemia. Proceedings of the Seventh Argenteuil Symposium. Amsterdam: Elsevier Biomedical Press, 1983.
7. Schettler FG, Gotto AM Jr, Middelhoff G, Habenicht AJR, Jurutka KR, eds. Atherosclerosis VI. Proceedings of the Sixth International Symposium. Berlin: Springer-Verlag, 1983.
8. Gotto AM Jr, O'Malley BW, eds. The Role of Receptors in Biology and Medicine. Proceedings of the Ninth Argenteuil Symposium. New York: Raven Press, 1986.
9. Gotto AM Jr, ed. Plasma Lipoproteins. Amsterdam: Elsevier, 1987.
10. Gotto AM Jr, Mancini M, Scarpato N, eds. Treatment of Severe Hypercholesterolemia in the Prevention of Coronary Heart Disease. A Second International Symposium. New York: Karger, 1988.

11. Dietschy JM, Ontko JA, Gotto AM Jr. Disturbances in Lipid and Lipoprotein Metabolism. Bethesda, MD: American Physiological Society, 1988.
12. Gotto AM Jr, ed. A Symposium: The Significance of High-Density Lipoprotein Cholesterol in the Prevention of Coronary Heart Disease. Am J Cardiol 1990;666(Suppl A).
13. Gotto AM Jr, Mancini M, Richter WO, Schwandt P, eds. Treatment of Severe Hypercholesterolemia in the Prevention of Coronary Heart Disease. Second International Symposium. New York: Karger, 1990.
14. Gotto AM Jr, Smith LC, eds. Drugs Affecting Lipid Metabolism X. Proceedings of the Tenth International Symposium on Drugs Affecting Lipid Metabolism. Amsterdam: Excerpta Medica, 1990.
15. Gotto AM Jr, Paoletti R, eds. Triglycerides: The Role in Diabetes and Atherosclerosis. Atherosclerosis Reviews 1991;22.
16. Assmann G, Gotto AM Jr, Paoletti R, eds. The Hypertriglyceridemias: Risk and Management. Am J Cardiol 1991;68(Suppl).
17. Gotto AM Jr, guest ed. Cardiovascular Risk Factors 1992;2(4).
18. Gotto AM Jr, ed. Hypercholesterolemia: An Evolving Risk Factor. A Symposium. Clin Cardiol 1992;15(Suppl 3).
19. Gotto AM Jr, Lenfant C, Paoletti R, Soma M, eds. Multiple Risk Factors in Cardiovascular Disease. Medical Science Symposia Series, Vol. 1. Boston: Kluwer Academic Publishers, 1992.
20. Gotto AM Jr, Carlson LA, Illingworth DR, Thompson GR, eds. Edizione italiana: Soma MR, Paoletti R. Iperlipidemia: Manuale Clinico, 1993. Societa Internazionale dell'Aterosclerosi. London: Science Press, 1992.
21. DeBakey ME, Lawrie GM, Gotto AM Jr, eds. Atherosclerotic Occlusive Disease of the Coronary Arteries: Surgical Considerations. Atherosclerosis. Kalamazoo, Mich.: The Upjohn Company, 1992.
22. Stein Y, Gotto AM Jr, eds. A Symposium: Triglycerides as a Vascular Risk Factor: A Global Forum. Am J Cardiol 1992;70(Suppl H).
23. Gotto AM Jr, Mancini M, Richter WO, Schwandt P, eds. Treatment of Severe Dyslipoproteinemia in the Prevention of Coronary Heart Disease 4: Fourth International Symposium, Munich, October 22-23, 1992. New York: Karger, 1993.
24. Catapano AL, Gotto AM Jr, Smith LC, Paoletti R, eds. [Proceedings of the XI International Symposium on] Drugs Affecting Lipid Metabolism. Dordrecht: Kluwer Academic Publishers, 1993.
25. Gotto AM Jr. guest ed. A Symposium: Antioxidants and Lipid Metabolism. Am J Cardiol 1993;71(6).

26. Gotto AM Jr. Lipid and Lipoprotein Disorders. In: Pearson TA, Criqui MH, Luepker RV, Oberman A, Winson M, eds. Primer in Preventive Cardiology. Dallas: American Heart Association, 1994:107-129.
27. Gotto A, Grundy S, section eds. Lipid-Lowering Drugs. In: Messerli FH, ed. Cardiovascular Drug Therapy, ed. 2. Philadelphia: W. B. Saunders, 1996, pp.1061- 1135.
28. Gotto AM, Carlson LA, Illingworth DR, Thompson GR. Clinician's Manual on Hyperlipidaemia, 4th ed. London: Science Press, 1996.
29. Gotto AM Jr, ed. Drugs Affecting Lipid Metabolism. New York: Springer, 1996.
30. Gotto AM Jr, Lenfant C, Paoletti R, Catapano AL, Jackson AS, et al. Multiple Risk Factors in Cardiovascular Disease: Strategies of Prevention of Coronary Heart Disease, Cardiac Failure, and Stroke. New York: Springer, 1998.
31. Gotto AM, section ed. Dyslipoproteinemias/Atherosclerosis. In: Antman E, ed. Cardiovascular Therapeutics, 2nd ed. Philadelphia: W.B. Saunders, 2002.
32. Fruchart JC, Catapano AL, Gotto AM Jr, Paoletti R, Staels B, eds. Peroxisome Proliferator Activated Receptors: From Basic Science to Clinical Applications. New York: Springer, 2002.
33. Gotto AM, ed. The Cornell Illustrated Emergency Medicine and First Aid Guide: The Complete Family Guide. Washington, DC: Regnery Publishing, 2002.
34. Gotto AM, ed. The Cornell Illustrated Encyclopedia of Health: The Definitive Home Medical Reference. Washington, DC: Regnery Publishing, 2002.
35. Gotto AM, guest ed. Evaluation of Fluvastatin in Renal Transplant Recipients: The ALERT trial. The Cardiology Report. 2003;1(1).
36. Gotto AM Jr, Toth PP, eds. Comprehensive Management of High Risk Cardiovascular Patients. New York: Informa Healthcare, 2007.